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CHAPTER 1 
ASBESTOS 
 
1.1 Asbestos 
Asbestos are a group of naturally occurring, inert, hydrated silicate minerals. These fibres are 
interesting because of their important properties for industrial use, such as a high tensile 
strength, and resistance to thermal, chemical, and electrical degradation. Asbestos is derived 
from the Greek ‘’ and means ‘inextinguishable’. Dependent on their characteristics, 
two classes of asbestos fibres can be distinguished: serpentines and amphiboles (Figure 1, 
Table 1) [1, 2]. The only serpentine asbestos is chrysotile or white asbestos. Chrysotile 
asbestos consists of a sheet of nanosized tubular fibres with a hollow core and represents over 
95% of all asbestos produced and consumed [3]. These fibres are curlier and more bendable 
and are more prone to dissolve and be cleared in tissues. Furthermore, there are five types of 
amphibole asbestos fibres: two commercially used, i.e. crocidolite (blue asbestos or 
riebeckite) and amosite (brown asbestos or grunerite) and three non-commercially used, i.e. 
actinolite (green asbestos), anthophillite (yellow asbestos), and tremolite (grey asbestos). The 
amphibole fibres are known to be straight and sharp and more resistant to chemical and 
biological dissolution resulting in a greater durability and biopersistence of these fibres. 
 
Figure 1: General and microscopic representation of a serpentine (chrysotile, A and B) and an 
amphibole (amosite, C and D). 
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Table 1: Asbestos classes and properties 
Class Properties Name 
Serpentine Curly, bendable, short biopersistance Chrysotile (white asbestos)* 
Amphibole Straight, rigid, needle-like, strong 
with a long biopersistance 
Actinolite (green asbestos) 
Amosite (brown asbestos)* 
Anthophillite (yellow asbestos) 
Crocidolite (blue asbestos)* 
Tremolite (grey asbestos) 
*Commercially used 
 
Although chrysotile fibres are thought to be less carcinogenic, all asbestos fibres have been 
shown to be carcinogenic and are classified a group 1 human carcinogen by the International 
Agency for Research on Cancer (IARC) of the World Health Organisation (WHO) [4, 5]. 
 
1.2 Past and present consumption 
Asbestos fibres are known to exist for more than 4000 years. The Egyptians used them for 
embalming mummies and in the Roman times, asbestos fibres were used as insulating 
material and as wicks of lamps and candles. Furthermore, amphibole fibres occur naturally as 
contaminant in the minerals in rock formations [6]. Because of their interesting technical 
properties, the fibres have been used as insulation material in factories, schools, homes and 
for ship building. Besides, it was also used to make automobile brakes and clutch parts, roofing 
shingles, ceiling and floor tiles, and woven into textiles for fire and heat protection [6]. 
Industrial production of asbestos began in the late 19th century, but boomed by the World 
Wars. The first cases of asbestos-associated fibrosis were described in the early 1900s but the 
association between lung carcinoma and asbestos fibres was established half a century later 
by the mid-1950s [7], whereas the association between asbestos and malignant pleural 
mesothelioma (MPM) was recognized in the 1960 by Wagner who initiated a case-control 
study in South-African miners [8]. In the Netherlands, the first cases of mesothelioma were 
seen in the beginning of the 1970s [9, 10]. Despite these known health effects, asbestos use 
continued and peaked in the ‘70s [2]. Today, still more than 2 million tons is annually produced 
worldwide with Russia being the leading producer, followed by China, Kazakhstan, Brazil, 
Zimbabwe and Columbia, together accounting for 96% of the world production of asbestos 
[11]. Very recently, Canada was included in this list. But since April 2016, it has committed to 
Chapter 1 – Asbestos 
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move forward with a plan to ban the use of asbestos and as a first step, has banned the export 
and use of asbestos in new constructions since then.  
Asbestos use is now banned in 55 countries, including all members of the European Union 
[12]. In developing countries in need for industrial growth, where too often little or no 
protection of workers and communities exists, the asbestos cancer pandemic may be the most 
devastating. A shift in asbestos consumption is seen to Asia, with China being the largest 
consumer of asbestos in the world, followed by India, Russia, Kazakhstan, Thailand, Ukraine, 
and Uzbekistan. Belgium was one of the highest asbestos consumers in the past, which is 
reflected in the high standardized mortality for mesothelioma and asbestosis in 2004 (Figure 
2) [13]. In Belgium, the use, production or marketing of asbestos fibres is completely 
prohibited since 1998. 
 
Figure 2: Association between historical asbestos consumption and mortality from mesothelioma 
and asbestosis in men [13]. 
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CHAPTER 2 
ASBESTOS-RELATED DISEASES 
 
2.1 Introduction 
After inhalation of asbestos fibres, the fibres can act on the lung parenchyma (bronchioles, 
bronchi and lung interstitium) and on the pleura [14, 15]. The latter is a serous membrane 
covering the lungs and chest cavity, and exists of a monolayer of mesothelial cells. The part 
covering the lungs is the visceral pleura and also covers the interlobar fissures. The other part, 
the parietal pleura, covers the rest of the thoracic cavity and the diaphragm. In between the 
two pleural blades, a small virtual space is present (the pleural cavity) which is filled with 0.1-
0.2 ml/kg body weight of pleural fluid (Figure 3). 
Inhalation of asbestos fibres can cause benign (pleural plaques, asbestosis, diffuse pleural 
thickening, pleural effusions) or malignant (lung cancer, malignant mesothelioma) respiratory 
diseases [16]. This chapter discusses both types of asbestos-related diseases. 
 
 
Figure 3: Normal (left) and diseased (right) pleura [17]. 
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2.2 Benign diseases 
2.2.1 Pleural plaques 
Pleural plaques (PP) are the most common manifestation of asbestos exposure [18]. PPs are 
small areas of hyaline fibrosis which can become calcified and mostly originate on the parietal 
pleura of the chest wall and diaphragm [19]. Because of the layers of hyalinised collagen fibres, 
plaques appear white and are often multiple and bilateral [20, 21]. The plaques occur with 
lower inhaled asbestos burdens and can result from small temporally exposures. Plaques 
occur 20-30 years after asbestos exposure in approximately 50-60% of individuals with a heavy 
or prolonged asbestos exposure [18, 20]. Pleural plaques can be seen on chest X-ray, although 
a computed tomography (CT) is more sensitive. Pleural plaques are asymptomatic and do not 
undergo malignant transformation nor does their presence increases the risk for MPM [22]. 
Hence, PPs serve as a marker of asbestos-exposure. 
 
2.2.2 Asbestosis 
Asbestosis is a bilateral, diffuse interstitial fibrosis of the lung parenchyma caused by 
inhalation of asbestos fibres [19]. It is linked to high cumulative doses of asbestos exposure, 
with the presence of asbestos bodies in the alveoli [21]. There is a latency period of 20 years 
between exposure and onset of symptoms such as breathlessness and a reduced exercise 
tolerance. In contrast to the other benign asbestos-related diseases, asbestosis can be a fatal 
due to its evolution to respiratory failure [23]. 
 
2.2.3 Diffuse pleural thickening 
Diffuse pleural thickening (DPT) is essentially a plaque that extends over a wide range of the 
visceral pleura with fusion to the parietal pleura. DPT can result from multiple benign 
asbestos-related pleural effusions, but is not a pathognomic marker for asbestos exposure 
[19, 20]. In contrast to plaques, it rarely calcifies, is irregularly shaped and induces fusion of 
the pleural layers which can result in functional impairment. It occurs less frequent than 
pleural plaques and is rarely bilateral [20]. In unique cases, DPT can cause rounded atelectasis 
Chapter 2 – Asbestos-related Diseases 
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or folded lung [24], in which the fibrous tissue matures, contracts and causes the fissural 
pleura to hunch into the lung. Patients with rounded atelectasis are asymptomatic in most 
cases, but can present with dyspnoea if the atelectatic volume is large and lung function is 
compromised. An important differential diagnosis is to be made with lung cancer. 
 
2.2.4 Pleural effusions 
These are the earliest abnormality seen after asbestos exposure, usually between 10-20 years 
after exposure [19, 20]. Effusions do not contain asbestos fibres and tend to be exudative, but 
have a highly variable composition [25, 26]. Although most effusions are small to moderate, 
they can occur bilaterally in 10% of cases and effusions typically must be large enough to cause 
symptoms. When symptomatic, a pleural effusion can manifest with fever, cough, pain and 
dyspnoea [20]. A benign asbestos-related pleural effusion presents itself without 
comorbidities or a malignancy within three years. Similar to a pleural plaque, it has no 
prognostic implications for mesothelioma development, but is only a marker of past asbestos 
exposure [27]. A pleural effusion does not require specific treatment, except thoracentesis in 
symptomatic patients. Usually effusions tend to diminish slowly and spontaneously within 1-
17 months. However, recurrences are frequent (30-40%) and occur within 3 years. As 
mentioned earlier, pleural effusions can lead to DPT. 
 
2.3 Malignant diseases 
2.3.1 Lung cancer 
Although smoking is the main causal agent for lung cancer, asbestos exposure alone increases 
lung cancer mortality among non-smokers and has a synergistic effect with smoking on lung 
cancer pathogenesis, rather than additive [28]. In patients with asbestosis, asbestos fibres are 
often considered the main cause of lung cancer and the presence of asbestosis further 
increases the lung cancer risk [29]. Even without asbestosis, heavy exposure to asbestos fibres 
can cause lung cancer. However, in an individual case, the attributable risk of asbestos 
exposure is not easily separated from the risk from smoking. In a Dutch study, it was estimated 
that 11.6% of the lung cancer cases that occurred in men aged 55–73 years between 1986 and 
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1990 were related to asbestos exposure [30]. For lung cancer patients exposed to both 
smoking and asbestos, an estimated 26% (95% CI 14–38%) of lung cancer deaths were 
attributable to the interaction between asbestos and smoking [31]. In these lung cancer 
patients, there were more deaths attributable to smoking only (68%) than asbestos exposure 
only (2%) [31].  
 
2.3.2 Malignant Mesothelioma 
Mesothelioma is a lethal disease related to asbestos-exposure. It can occur on the serosal 
surfaces of the pleura, peritoneum, pericard and tunica vaginalis [32]. The most common form 
is malignant pleural mesothelioma (MPM) accounting for approximately 80% of 
mesotheliomas and originating from the lower parietal pleura and the costadiaphragmatic 
sinus [32]. It encapsulates the lung resulting in a rind of tumour that covers the lung with 
minimal penetration of the lung parenchyma. With a mean latency period of 35-40 years after 
exposure [33, 34], it occurs in a mainly elderly population.  
There are typically four major different histological subtypes of mesothelioma: epithelioid, 
sarcomatoid, desmoplastic and mixed or biphasic (Figure 4) [35]. 
 
Figure 4: Histology of A: epithelioid, B: sarcomatoid, C: biphasic/mixed, and D: desmoplastic 
mesothelioma [35]. 
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Epithelioid mesothelioma is the most common subtype and consists of polygonal, oval or 
cuboidal cells that often mimic non-neoplastic reactive mesothelial cells, and is present in 
approximately 50-60% of mesothelioma patients [20]. It often presents with a pleural effusion. 
Epithelioid mesothelioma show a wide range of morphologic patterns. The most frequent 
patterns are (tubulo)papillary, trabecular, adenomatoid (microglandular) and sheet like. Less 
frequent patterns are small cell, clear cell, pleiomorphic and deciduoid [36, 37]. Recognition 
of these patterns have no clear prognostic significance. Therefore, the international 
mesothelioma WHO pathology panel has stated that epithelioid and sarcomatoid 
mesothelioma be diagnosed without further subclassifiers [37]. 
Sarcomatoid mesothelioma comprises 10-20% of mesothelioma cases [38] and consists of 
malignant spindle cells, but can mimic malignant mesenchymal tumours (e.g. fibrosarcoma or 
leiomyosarcomas). Biphasic or mixed mesothelioma has both epithelioid and sarcomatoid 
features present in at least 10% of the sample and accounts for 20-35% of mesothelioma cases 
[36, 37]. A rare variant of sarcomatoid mesothelioma is the highly aggressive desmoplastic 
subtype. Patients with the epithelioid subtype have better outcomes than those with mixed 
or sarcomatoid histology. 
Furthermore, since the pleura is also a common site for metastatic disease and reactive 
changes in the pleura, these must not be confused with MPM. 
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CHAPTER 3 
MALIGNANT PLEURAL MESOTHELIOMA 
 
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer originating from the 
mesothelial cells from the pleural blades surrounding the lungs [14]. By light microscopy, we 
can differentiate 3 main histological types: epithelioid, sarcomatoid and a mixed form. MPM 
typically originates from the lower parietal pleura in the costodiaphragmatic sinus. Presenting 
clinical symptoms are most often dyspnoea and chest pain, each present in 60% of patients 
[15]. The global attributable proportion of MPM to asbestos exposure is >80% in males [33] 
and a dose-dependency has been shown. However, no safe threshold of asbestos exposure 
has been identified below which there is no increased risk for mesothelioma [6]. Other risk 
factors and cofactors for MPM include naturally occurring fibres (erionite), exposure to 
ionising radiation, Simian Virus (SV) 40, and a familial predisposition due to a mutation in the 
‘BRCA Associated Protein 1’ (BAP1) gene [39-47]. 
 
3.1 Oncogenesis 
The following are factors that determine the risk for MPM according to the asbestos fibre 
characteristics [48]: the type, biopersistence, dimensions and surface properties of the fibre, 
the time since first exposure and the cumulative exposure. Depending on the length-to-width 
ratio and the shape of the fibres, fibres can penetrate to the alveolar regions. There, the fibres 
are cleared by phagocytosis through alveolar macrophages [49]. Since chrysotile fibres are 
more prone to dissolve, these are more easily cleared and are considered less carcinogenic 
than amphiboles. Amphiboles are not prone to acid dissolution, resulting in a slower 
dissolution kinetic and hence, a longer presence in the body. Furthermore, asbestos fibres 
produce reactive oxidants by two known mechanisms. The first mechanism involves the iron 
content of the fibres, also known as acellular or direct oxidant formation (Figure 5) [50]. 
Asbestos fibres can be clad with up to 30% iron [49, 51] or, in the case of chrysotile, iron can 
be present as a contaminant of the attached proteins [51, 52]. Ferrous iron (Fe2+) can dissolve 
from asbestos fibres, inducing oxidative injury with the formation of reactive oxygen species 
(ROS), such as hydroxyl (HO●) and superoxide (O2●-) radicals, from hydrogen peroxide (H2O2) 
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[53] through Fenton chemistry and the Haber-Weiss cycle. The hydroxyl radical is extremely 
reactive (reaction rate constant >108 M-1s-1), immediately attacking biomolecules in its direct 
environment. These oxidants induce deoxynucleic acid (DNA) damage either by hydrogen 
abstraction or addition of HO● to the DNA [51] and oxidation of membrane lipids [54]. 
Furthermore, the asbestos fibres can physically interfere with the mitotic spindle and induce 
structural abnormalities and aneuploidy of the mesothelial cells. 
 
The second mechanism of asbestos-induced oxidant formation involves the activation of 
inflammatory cells like the alveolar macrophages and neutrophils, known as cellular or indirect 
oxidant formation (Figure 5) [22, 51, 53, 55]. Because asbestos fibres can be long, the fibres 
cannot be fully engulfed by the macrophages, inducing frustrated phagocytosis. This 
relentlessly stimulates the alveolar macrophages in generating O2-, H2O2 and HO●, sustaining 
a constant generation of oxygen species at the asbestos fibre and subsequent DNA damage in 
mesothelial cells [49-51, 56, 57]. 
 
 
 
Figure 5: Mechanisms of asbestos-induced oncogenesis. (Figure by Kevin Lamote) 
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Furthermore, asbestos fibres cause mesothelial cell necrosis instead of apoptosis, 
translocating the nuclear protein high mobility group box 1 (HMGB1) to the extracellular space 
(Figure 6). HMGB1 stimulates the “receptor for advanced glycation end products” (RAGE) on 
alveolar macrophages, triggering the Nalp3 inflammasome and subsequent IL-1β and tumour 
necrosis factor (TNF)-α secretion [55, 58]. TNF-α binds its receptor on the mesothelial cells, 
activating the nuclear factor (NF)-κB pathway and survival of the damaged mesothelial cells. 
TNF-α protects the cells from asbestos-induced cell death and results in a chronic 
inflammatory process, supporting the carcinogenic development [55, 59, 60]. 
 
 
Figure 6: Mesothelioma carcinogenesis [58]. Asbestos fibres cause necrosis of the mesothelial cells, 
leading to the release of HMGB1. This causes macrophage accumulation and the secretion of TNF-α. 
When bound to its receptor on the mesothelial cells, the NF-κB pathway is triggered, inducing cell 
survival and allowing the mesothelial cells with asbestos-induced DNA damage to survive rather than 
to die. Together with genetic alterations, mesothelioma can be developed. HMC: human mesothelial 
cell. HMGB1: high mobility group box 1. TNF-α: tumour necrosis factor-α.  
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A major pathway triggered by asbestos fibres is the mitogen-activated protein kinase (MAPK) 
cascade [61-64]. Several molecular defects have been described in malignant mesothelioma 
cells, including the cyclin-dependent kinase inhibitor 2A (CDKN2A), neurofibromin 2 (NF2) and 
BRCA-associated protein 1 (BAP1) gene, aberrant activation of the Wnt pathway and up-
regulation of several receptors including epidermal growth factor receptors (EGFR), insulin-
like growth factor (IGF)-1 receptor, vascular endothelial growth factor receptor (VEGFR)-2, 
RON (Receptor d’Origine Nantais) and c-Met [63, 65-70]. CDKN2A mutations are found in 55% 
of MPM gene mutations and is the most aberrant mutated gene in MPM [71]. It encodes 
p14ARF, a proteins that interacts with Mdm2, a negative regulator of p53 [72]. In 
mesothelioma, extensive gene copy number alterations have been reported with common 
regions of allele loss being 1p, 3p21, 6q, 9p21, 15q11-15 and 22q [59, 73]. On the other hand, 
mutations present at high frequencies on other tumours, such as the p53, rat sarcoma (Ras) 
and retinoblastoma (Rb) proteins, are very rare in MPM. Compared to other tumours like 
melanoma and non-small cell lung cancer (NSCLC), the mutational load of mesothelioma is 
lower, making it a less evident target for checkpoint inhibition therapy. 
 
3.2 Epidemiology 
Over the last decades, a shift has been observed in the exposure history of mesothelioma 
cases, from primary and secondary exposure of asbestos workers (e.g. miners handling raw 
asbestos material) over shipyard or factory workers to end-users often exposed when 
removing or handling asbestos materials that are still ubiquitously in place, e.g. construction 
workers, electricians, plumbers, carpenters, mechanics and heating workers with an 
occupational asbestos-exposure (tertiary exposure) [33]. Even if the occupations with the 
highest risk of mesothelioma belong to the first group, the number of subjects at risk of MPM 
is presently much larger in the latter group.  
Secondly, there can be para-occupational asbestos exposure in households of asbestos 
workers due to domestic exposure via work clothes.  
Lastly, a certain background exposure exists since asbestos or asbestos-like minerals (erionite) 
exists naturally in certain areas of the world as a geological component of the soil (Turkey, 
Corsica, Cyprus and New Caledonia), or can be present in construction materials that contain 
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asbestos, or occur in the neighbourhood for people living close to asbestos mines or factories 
[74, 75]. This is called the environmental asbestos exposure.  
A dose–effect relationship has been demonstrated with mesothelioma and lung cancer, but it 
is impossible to define a safe threshold of cumulative exposure below which there is no 
increased risk [6]. Therefore, all individuals who have been exposed to asbestos, even briefly 
but intensively, are considered a population at risk for mesothelioma.  
 
3.2.1 Incidence and mortality 
The mean latency period between MPM diagnosis and asbestos exposure ranges between 15-
67 years with a mean period of 40 years [14]. Due to this long latency period, MPM patients 
are mostly elderly with a median age at diagnosis in Western countries of 69 years [14]. There 
are geographical differences in MPM incidence worldwide, ranging from 7 cases per million 
inhabitants in Japan to 40 cases per million inhabitants in Australia [15, 34]. For Europe, the 
incidence is reported to be approximately 20 per million inhabitants with large intercountry 
differences [33]. Belgium had one of the highest historical asbestos consumption worldwide, 
which is reflected in the high incidence rate of MPM of 39 per million male inhabitants. Since 
the asbestos industry predominantly occupied males, there is also a gender difference in 
incidence with 10-66 cases per million in males and 1-2.5 cases per million in females, 
respectively. Furthermore, given the long latency period and the rather recent bans on 
asbestos use, the incidence of MPM is expected to increase [76], except in the United States 
(US) and Sweden, where the peak already may have been reached [33]. Persons exposed to 
asbestos fibres in the past have a lifetime risk for developing MPM of 5-10% [77]. 
Nevertheless, given the latency period and the continued mining and use of chrysotile 
asbestos, it is expected MPM will remain a global health concern for future generations. 
Besides, there remains an environmental exposure to the fibres and recent documentation of 
a genetic familial predisposition due to BAP-1 mutations [46, 78]. 
Survival for MPM patients is very poor. Within one year after diagnosis, more than half of the 
patients has already died and the relative survival at five years after diagnosis is only 5% [14]. 
As shown in Figure 2 on page 10, Belgium has a standardized mortality for MPM and asbestosis 
of respectively 20 and 8 per million people per year in 2000-2004. Worldwide, the WHO 
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estimates 107,000 people die annually of asbestos-related diseases (lung cancer, 
mesothelioma and asbestosis) of whom 43,000 from MPM [79]. Next to this, 125 million 
people are still exposed to asbestos fibres at the workplace today and are potentially at risk 
for developing MPM. 
 
3.2.2 Economic impact 
Next to the direct substantial personal and health care burden for MPM, asbestos-related 
diseases will cost a large amount on extra compensation. It is estimated that the total 
economic burden of MPM will cost up to $200 billion for the US and $80 billion for Europe in 
the next 30 years related to compensation [15]. 
In Belgium, some patients with occupational asbestos-related diseases can obtain a 
compensation for their inability to work and the related medical costs. However, their 
condition has to be recognized by the Occupational Disease Fund (ODF), now fused to Fedris 
[80, 81]. For the other patients with mesothelioma or asbestosis who are not compensated by 
the ODF, the Asbestos Fund was founded in 2007 [82]. 
 
3.3 Diagnosing MPM 
The onset of symptoms in MPM is often insidious and non-specific, shifting diagnosis to 
advanced stage disease in more elderly patients [33]. Symptoms like dyspnoea (due to pleural 
effusions) and chest pain (due to infiltration into the chest wall and its intercostal nerves) are 
the more prevalent in 88% of patients [20]. More suspicious symptoms like weight loss, 
fatigue, fever, thrombocytosis, hypo-albuminemia and anaemia do not appear at diagnosis, 
but tend to rise with advanced disease [15]. The diagnosis of MPM should be considered in 
any patient presenting with unilateral pleural effusion or thickening, especially if chest pain is 
reported [83]. For the diagnosis of MPM, several modalities can be explored. 
 
3.3.1 Imaging techniques 
The standard diagnostic work-up includes a chest X-ray to evaluate a pleural effusion or 
pleural thickening and a computed tomography (CT) scan of the chest and upper abdomen 
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[15, 33]. However, both should not be used alone for MPM diagnosis since the accuracy for 
MPM detection is hampering [14]. However, a rind-like tumour on CT along the pleural cavity 
together with diffuse or nodular pleural thickening are suggestive of the disease. Magnetic 
resonance imaging (MRI) is not yet relevant for the diagnosis of mesothelioma and is only 
recommended when tumour delineation is needed [84]. Positron emission tomography (PET) 
scanning is currently only useful for the staging of mesothelioma [33, 85, 86]. When 
radiological images are suggestive for MPM and a history of asbestos exposure is known, a 
cytological or histological analysis should be performed [87]. 
 
3.3.2 Cytology 
Since more than 80% of MPM patients present with pleural effusions, cytological examination 
is often performed [88]. However, it is not recommended to establish a diagnosis of 
mesothelioma based on cytology alone because of its important false positive and negative 
rate [14, 89] and the fact that mesothelioma cells in the pleural fluid are always of the 
epithelioid type and do not show any typical aspects. Therefore, it is hard to make a 
differential diagnosis with benign, reactive mesothelial proliferations. Besides, cytology does 
not allow for evaluation of the invasiveness of the tumour. A histopathological examination 
of a pleural biopsy specimen obtained by thoracoscopy is required to establish a definitive 
diagnosis. 
 
3.3.3 Histopathology 
The gold standard to obtain a definite MPM diagnosis is the light microscopical evaluation of 
a histopathological tissue sample with additional use of a panel of immunohistochemical 
markers [33]. Thoracoscopy is preferred, allowing a diagnosis in more than 90% of cases, 
except in cases with pleural symphysis or contraindication to thoracoscopy, when either a 
surgical or transthoracic needle biopsy can be substituted, albeit with a lower sensitivity 
(±30%) [33]. 
In order to make a definite diagnosis, we first need to define the biopsy tissue as benign or 
malignant. Next, epithelioid mesothelioma needs to be separated from metastatic 
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adenocarcinoma. This can be done by using two markers with positive diagnostic value for 
mesothelioma (e.g. the nuclear markers anticalretinin and anti-Wilms tumour (WT) antigen-1 
or the membrane markers anti-epithelial membrane antigen (EMA) for epithelioid 
mesothelioma, anti-cytokeratin(CK)5/6, antiD2-40 (podoplanin) or anti-mesothelin) and two 
markers with negative diagnostic value (e.g. a membrane marker like anti-Ber-EP4, a nuclear 
marker like antithyroid transcription factor-1, or monoclonal antigen markers like anti-
carcinoembryonic antigen, anti-B72-3, anti-MOC-31, antioestrogen/progesterone) [89-91]. 
Among the various sources of antibodies, it is mandatory to use those presenting at a 
minimum of 60–70% sensitivity. It is not recommended to use anti-CK7/anti-CK20 to make the 
diagnosis of mesothelioma. Furthermore, to separate sarcomatoid mesothelioma from 
squamous and transitional cell carcinoma, it is recommended to use two broad-spectrum anti-
cytokeratin antibodies and two markers with negative predictive value (such as anti-CD34 and 
anti-B-cell lymphoma 2 marker, anti-desmin, anti-S100) to confirm the diagnosis. 
Nevertheless, negative immunostaining with a single antibody does not exclude the diagnosis. 
With regard to atypical mesothelial hyperplasia (superficial mesothelial proliferations), there 
are currently no commercially available immunohistochemical markers that identify the 
benign or malignant nature of the cells observed. However, the discovery of inactivating 
mutations in the BAP1 gene has shown to be promising as marker to separate mesothelioma 
from reactive mesothelial proliferations [36, 92], although further confirmation is needed. 
 
3.3.4 Staging 
Staging is used to describe the anatomical extent of a tumour, correlates with prognosis and 
helps in selecting the optimal treatment strategy. The tumour stage is reported by using a 
TNM staging classification system. In this system, T (‘Tumour’) describes the extent of the 
primary tumour, N (‘Nodes’) evaluates the involvement of regional lymph nodes and M 
(‘Metastasis’) describes the presence or absence of distant metastasis. 
For MPM, the recent 8th edition of the staging system developed by the International 
Association for the Study of Lung Cancer (IASLC), is recommended for use (Table 2) and is 
approved by the Union for International Cancer Control (UICC). 
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Accurate T staging is important in determining the resectability of the tumour. In patients with 
locally advanced tumours, imaging aims at distinguishing T3 from unresectable T4 disease. 
Contrast-enhanced CT is preferred for initial staging because of its easy accessibility and cost-
effectiveness. Thoracic MRI is complementary to CT for identifying invasion of the chest wall, 
mediastinum, and diaphragm. However, PET with 2-deoxy-2-[fluorine-18]fluoro- D-glucose 
integrated with CT (18F-FDG PET/CT) remains inadequate for accurately defining locoregional 
tumour extent [84, 93]. 
 
To assess the N status, 18F-FDG PET/CT and thoracoscopy only showed moderate agreement 
for the presence of nodular lesions. Hence, CT is typically used to evaluate hilar and 
mediastinal nodal disease. However, the specificity of CT for detecting nodal disease is poor 
since occult metastases can be detected. Furthermore, 18F-FDG PET is not suitable to assess 
nodal involvement because of the false-negative results in patients with microscopic disease 
as well as the false-positive results in patients with inflammatory or infectious conditions. 
These potential pitfalls can lead to misinterpretation and have implications for management 
[84, 93].  
 
Distant metastases can be solitary or diffuse and may involve the brain, lung, bone, adrenal 
gland, peritoneum, abdominal nodes, and abdominal wall. Therefore, a whole-body 18F-FDG 
PET/CT can be used to assess the M status [84, 93].  
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Table 2: 8th edition of the TNM classification for malignant pleural mesothelioma. 
Descriptor/Stage Extent of involvement 
T T1 Tumour involving the ipsilateral parietal or visceral pleura only 
T2 Tumour involving ipsilateral pleura (parietal or visceral) with invasion 
involving at least one of the following: 
 Diaphragmatic muscle 
 Pulmonary parenchyma 
T31 Tumour involving ipsilateral pleura (parietal or visceral) with invasion 
involving at least one of the following: 
 Endothoracic fascia 
 Mediastinal fat 
 Chest wall, with or without associated rib destruction (solitary, 
resectable) 
 Pericardium (non-transmural invasion) 
T42 Tumour involving ipsilateral pleura (parietal or visceral) with invasion 
involving at least one of the following: 
 Chest wall, with or without associated rib destruction (diffuse or 
multifocal, unresectable) 
 Peritoneum (via direct transdiaphragmatic extension) 
 Contralateral pleura 
 Mediastinal organs (oesophagus, trachea, heart, great vessels) 
 Vertebra, neuroforamen, spinal cord or brachial plexus 
 Pericardium (transmural invasion with or without a pericardial 
effusion) 
N NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastases to ipsilateral intrathoracic lymph nodes (includes ipsilateral 
bronchopulmonary, hilar, subcarinal, paratracheal, aortopulmonary, 
paraoesophageal, peridiaphragmatic, pericardial, intercostal and 
internal mammary nodes) 
N2 Metastases to contralateral intrathoracic lymph nodes. Metastases to 
ipsilateral or contralateral supraclavicular lymph nodes. 
M M0 No distant metastases 
M1 Distant metastasis present 
Stage IA T1, N0, M0 
Stage IB T2/T3, N0, M0 
Stage II T1/T2, N1, M0 
Stage IIIA T3, N1, M0 
Stage IIIB 
T1/T2/T3, N2, M0 
T4, N0/N1/N2, M0 
Stage IV any T, any N, M1 
1T3 describes locally advanced, but potentially resectable tumour. 
2T4 describes locally advanced, technically unresectable tumour. 
Chapter 3 – Malignant Pleural Mesothelioma 
Part I | 27 
3.4 Therapeutic strategies 
MPM has a dismal prognosis with less than 5% five year survival [14]. When untreated, median 
survival of patients is 6-9 months. First-line treatment with standard of care chemotherapy 
provides a three month survival benefit [14] which even increases to 18 months after adding 
targeted therapy with bevacizumab, a monoclonal antibody against the VEGF receptor [94]. 
Nevertheless, MPM remains a fatal tumour despite the presence of several treatment options. 
Depending on the performance status of the patient, comorbidities, tumour stage and the 
patient’s age, different treatment options can be chosen [95]. Around 40% of MPM patients 
respond to the combination of treatments [96-98]. For patients who are unresponsive to first-
line treatment or became progressive after treatment, there is no standard second-line 
treatment. Furthermore, most of the patients present with unresectable disease, where 
palliative care to relieve the pain and dyspnoea is the only option. This includes thoracentesis, 
analgesia, pleurodesis, external beam radiation therapy and peritoneal-pleural or external 
shunting [47]. If the treatment can prolong survival and induce tumour response without 
significant toxicity, chemotherapy can also be used for palliative treatment. Next, we will 
discuss the possible treatment strategies for patients with MPM. 
 
3.4.1 Radiation therapy 
In the past, the instrument tracts following drainage or thoracoscopy were preventively 
irradiated as prophylactic radiation therapy to prevent the occurrence of metastasis in these 
tracts [99, 100]. However, its use is controversial since there is no evidence of reduced tumour 
seeding after this treatment [101, 102]. A recent randomized trial showed the lack of efficacy 
of prophylactic tract irradiation [103]. Nevertheless, in patients with painful infiltration or 
nodules, palliative radiation therapy can be used for pain relief [89]. Responses of more than 
60% have been seen, although the duration of response is often disappointing (2-3 months). 
The presence of critical organs as the lungs, heart, liver spinal cord and oesophagus limit the 
use of radiation as radical treatment [104]. 
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3.4.2 Chemotherapy 
The current standard of care first line chemotherapy exists of the combination of an antifolate 
with platinum-derivates [33, 96, 105, 106]. The antifolate pemetrexed (AlimtaTM) and 
raltitrexed (TomudexTM) are multitargeted antifolate agents that inhibit multiple enzymes in 
the folate pathway and, hence, inhibit synthesis of purines and pyrimidines resulting in a 
reduced cell growth [107]. Pemetrexed induces haematological toxicity, which can be 
countered by adding folic acid and vitamin 12 supplements to the treatment [107]. As 
platinum derivates, cisplatin and its analogue carboplatin are the most commonly used where 
cisplatin has a higher toxicity profile [108, 109]. By using platinum, DNA strands are cross-
linked and tumour cell death is induced by either apoptosis, necrosis or both [109]. A 
randomized phase III study of pemetrexed plus cisplatin versus cisplatin alone in chemo-naïve 
patients with MPM showed a response rate of 41.3% versus 16.7% and a median survival of 
12.1 versus 9.3 months, in favour of the combination arm [96]. On the basis of the high 
response rate and the improvement in overall survival, pemetrexed in combination with 
cisplatin was approved by the United States Food and Drug Administration (FDA) in 2004 for 
the treatment of MPM patients who had unresectable disease or were unfavourable for 
curative surgery. Similar approvals were also granted by European regulatory agencies. 
Another study by van Meerbeeck et al. combined cisplatin with raltitrexed versus cisplatin and 
showed a response rate of 23.6% compared to 13.6% and a median overall survival of 11.4 
months versus 8.8 months [110].  
Unfortunately, 80% of patients have recurrent disease within the first 2 years after treatment. 
For second-line therapy, no general recommendations exist and patients are encouraged to 
be enrolled in clinical trials [33, 89]. Patients who had a partial or complete response with first-
line chemotherapy may be treated again with the same regimen. If patients show progressive 
disease or experience severe toxicities, chemotherapy should be stopped. In stable or 
responding patients, up to six cycles can be given [33]. 
Several targeted therapies acting on several pathways in cancer have been investigated. The 
use of several small molecules inhibiting the tyrosine kinase activity of the epidermal growth 
factor receptor (EGFR) like erlotinib and gefitinib or monoclonal antibodies against the EGFR 
receptor like cetuximab have not showed any response [105, 111]. Furthermore, imatinib and 
dasatinib, both inhibiting the tyrosine kinase activity from the platelet-derived growth factor 
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(PDGF) receptor, have not proven useful [112]. Another growth factor is vascular endothelial 
growth factor (VEGF) which plays a role in angiogenesis. VEGF Receptor inhibition by 
sorafenib, sunitinib, vatalanib, cediranib and thalidomide did not improve the overall survival 
for MPM patients [112]. However, as mentioned before, bevacizumab, an antibody binding 
VEGF, has been tested in a phase III trial in combination with cisplatin and pemetrexed. In 
patients who were able to receive bevacizumab next to standard of care, the overall survival 
was significantly longer (18.8 months) compared to standard of care cisplatin/pemetrexed 
combination (16.1 months) [94]. Another target is mesothelin, an antigen that is expressed on 
mesothelial cells and overexpressed in epithelioid mesothelioma (see Part I, Chapter 4). 
Amatuximab is a chimeric monoclonal antibody binding to mesothelin with great affinity. In a 
single-arm phase II study, cisplatin and pemetrexed were combined with amatuximab for six 
cycles, followed by amatuximab maintenance therapy in case of response or stable disease. 
Although the primary endpoint was not met, a partial response was seen in 39% of the 
patients and 51% of the patients had stable disease, underlining an activity of amatuximab in 
mesothelioma [113].  
 
3.4.3 Surgery 
Surgery can either be palliative or radical. Before performing any form of surgery, the patient’s 
pulmonary and cardiac status needs to be properly evaluated [47].  
Palliative surgery refers to debulking pleurectomy which consists of an incomplete 
macroscopic clearance of pleural tumour. The objective of this operation is to relieve the 
entrapped lung by removing the visceral tumour cortex. Removal of the cranial parietal 
tumour cortex may relieve a restrictive ventilatory deficit and reduce chest wall pain [33]. This 
operative procedure may be performed by either open thoracotomy, but the closed video 
assisted thoracoscopic surgery (VATS) is preferred. The associated morbidity of thoracotomy 
may diminish the benefits [114], however there is limited but emerging evidence that VATS 
can provide good symptom control and may have a beneficial effect on survival. 
Radical surgery may be defined as an attempt to remove all macroscopic tumours from the 
hemithorax. These objectives are usually achieved by extrapleural pneumonectomy (EPP) with 
en bloc resection of visceral and parietal pleura, lung, pericardium and diaphragm and 
systematic nodal dissection followed by pericardial and diaphragmatic reconstruction with 
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prosthetic material [33]. Operative mortality has fallen to an acceptable level of 5% in 
experienced centres but morbidity remains high at 50% [115]. There is limited evidence for 
the efficacy of radical surgery for mesothelioma. However, EPP surgery alone for MPM is not 
curative since no free oncological resection margins can be obtained. The pleural lining, 
especially on the pericardium and mediastinum cannot be resected with a 1–2 cm margin 
[116]. Extended pleurectomy/decortication (e-P/D) is another surgical procedure, which aims 
at maximal debulking with resection and reconstruction of the diaphragm and/or pericardium 
if necessary [117]. An e-P/D can involve resection of a lobe, multiple wedges, or even a 
segment as long as it is lung sparing. There is less mortality and morbidity in comparison with 
EPP, but the procedure currently suffers from a lack of standardisation and uniformity. 
Consequently, there is a high risk for recurrence and this observation is therefore the rationale 
for combined therapy. 
 
3.4.4 Multimodality approach 
Since several studies have shown that surgical treatment alone offers dismal prognosis only 
[118, 119], multimodality approaches including chemo- and/or radiotherapy have been 
suggested in order to improve survival. The best long-term results are achieved by 
multidisciplinary strategies that include EPP together with either neo- or adjuvant 
chemotherapy [115, 116]. The particular advantage of chemotherapy before surgery 
(neoadjuvant) is a possible reduction of tumour load and downstaging, which may lead to a 
better understanding of the individual tumour biology and a more optimal patient selection. 
A median survival time of about 2 years has been reported by several studies, including some 
long-term survivors [115, 120]. Nevertheless, these trials included highly selected patients 
with the best prognosis, younger age, and most often only the epithelioid subtype. The 
Mesothelioma and Radical Surgery (MARS) trial demonstrated the feasibility of randomizing 
patients for chemotherapy alone or followed by EPP [121, 122]. The trial found no evidence 
that patients would benefit from EPP. Importantly, it must be stated that the study was 
underpowered to prove the effectiveness of EPP. The bulk of data supporting EPP are derived 
from a series of uncontrolled studies on subsets of highly selected patients. The lack of 
encouraging survival with EPP is reflected by studies on patterns of recurrence, which are 
mostly in the ipsilateral hemithorax. Furthermore, the choice between EPP and e-P/D is to be 
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elucidated. A study that compared EPP versus e-P/D demonstrated better survival associated 
with e-P/D than with EPP after controlling for histologic type, stage, multimodality treatment, 
and sex [123]. Despite potential bias due to the retrospective nature of this study, surgeon 
selection, and variations in adjuvant treatment, the surgical numbers are large enough to 
allow comparison. If EPP is to be preferred despite its higher operative risk, then huge 
differences in survival are to be expected. However, such differences were not observed. In 
practice, e-P/D preserves more lung tissue and demonstrates similar or better overall survival 
and decreased postoperative morbidity and mortality when compared with EPP, while 
patterns of recurrence remain local. E-P/D appears to provide the most benefit and the least 
harm to the patient with mesothelioma. 
Since e-P/D has been associated with similar to better outcome than EPP, and EPP 
accompanied by perioperative chemotherapy and radiotherapy was better than EPP alone, 
the question arises whether e-P/D as part of a multimodality treatment further improves 
outcome. Therefore, the role of e-P/D will be investigated in a “MARS-2” trial. In this trial, e-
P/D will be added to standard induction chemotherapy and randomly compared with 
chemotherapy only [119]. The European Organisation for Research and Treatment of Cancer 
(EORTC) is presently conducting a randomised controlled trial whereby patients are allocated 
to e-P/D preceded or followed by chemotherapy (www.clinicaltrials.gov, identifier 
NCT02436733).  
Because of its negative effects, postoperative radiotherapy (PORT) is not recommended in 
cases where the lung remains in situ after decortication. The introduction of intensity-
modulated radiotherapy (IMRT) seems to overcome most of these issues and allows the 
remaining tissue to be properly irradiated or use it as neoadjuvant therapy.  
 
3.4.5 Immunotherapy 
Based on preclinical studies and clinical trials, the role of immunotherapy in cancer treatment 
has rapidly increased. MPM has a high infiltration of lymphocytes (TILs) and macrophages and 
a significant T-cell inflammatory expression pattern [124]. The tumour escape mechanisms 
have different ways to elude immune reaction, including the expression of T cell inhibitory 
ligands, such as cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed death 1 ligand (PD-
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L1), and programmed death 1 receptor (PD-1), making these interesting as therapeutic targets 
for immunotherapy.  
PD-L1 expression in MPM was correlated with disease extension at presentation and with 
sarcomatoid subtypes. Immune checkpoint inhibitors resume T cell cytotoxic activity on 
cancer cells by blocking T cell inhibitory mechanisms. Monoclonal antibodies like ipilumumab 
and tremelimumab bind the CTLA4 receptor, whereas pembrolizumab and nivolumab bind 
PD-L1 and PD-1 receptor, respectively. Tremelimumab is a fully human IgG2 anti-CTLA-4 
antibody and was tested in a phase II study in MPM patients that progressed after first-line 
platinum-based therapy [125]. The most common side effects with tremelimumab were 
gastrointestinal toxicity (colitis and diarrhoea) and dermatological toxicity (rash and pruritus). 
The trial didn’t reach the primary end point but the disease was controlled in 31% of patients, 
with 6.2 months of progression free survival (PFS) and an overall survival (OS) of 10.2 months. 
These data suggested promising activity in MPM. Considering anti-PD-1 and anti-PDL1 
antibodies, pembrolizumab demonstrated to be safe and tolerable for patients with MPM in 
a phase Ib trial (KEYNOTE-028) that included several types of solid tumours. Preliminary 
analysis showed a 28% of patients had a partial response where 48% of patients remained 
stable. The overall disease control rate was 76%. These new developments in immunotherapy 
will open new perspectives for treatment. 
 
A relatively new field of therapy are tumour vaccines [105]. Vaccines against mesothelioma 
cells may increase immune responses against the tumour in which patients receive mature 
dendritic cells (DCs), pulsed with the patient’s own tumour lysate, after chemotherapy. In pilot 
studies, treatment was feasible and safe and in some patients anti-tumour immune responses 
were detected [126]. A study showed that the WT1 peptide vaccine gave minimal toxicity and 
induced immune responses against WT1 in a high proportion of patients (78%) [127]. 
Therefore, a study loaded DCs with mRNA encoding the WT1 protein and injected these 
intradermally in 10 patients with unresectable, epithelial MPM and non-progressive disease 
after standard of care chemotherapy [128]. Seven patients showed stable disease and 3 had 
progressive disease. Median overall survival (OS) from start of chemotherapy was 32 months; 
this compares with an OS of 22 months reported in the literature for a similar subgroup of 
patients treated with chemotherapy only. However, this should be further tested in a larger 
number of patients and a clinical phase I/II trial is currently recruiting patients to test dendritic 
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cells (DCs) loaded with the mesothelioma-associated tumour antigen WT1 in conjunction with 
conventional chemotherapy for the frontline treatment of resectable MPM (clinicaltrials.gov 
identifier NCT02649829). 
 
3.5 Screening for MPM 
As mentioned, the WHO estimates that annually 125 million individuals are still exposed to 
asbestos fibres at the workplace and are potentially at risk for mesothelioma [79]. Therefore, 
screening these asymptomatic persons at risk would be beneficial if the detection of the 
disease is possible at an earlier stage and, hence, improves the prognosis by more effective 
treatment options, assuming that therapy is more effective if given at earlier stage [33, 129]. 
By doing so, persons with a positive test could be subjected to a further more intensive 
surveillance with imaging techniques or undergo a thoracoscopy. In that way, not every 
individual at risk will be subjected to these procedures, limitating the cost and associated 
screening radiation if screening was proposed to asbestos-exposed subjects. For MPM, a 
biomarker with a positive predictive value (PPV) of 10% is considered acceptable for screening 
[129]. However, given the rather low prevalence of MPM, specificity then needs to be very 
high (>95%) since otherwise the number of false-positive subjects would be several times 
higher than true-positive subjects which would then all undergo unnecessary diagnostic 
procedures [130].  
As will be discussed in chapter 4, the available data for MPM about the performance of 
potential screening biomarkers hampers a large-scale screening program up to today. There 
are no studies that recommend the screening of persons at risk with an (occupational) history 
of asbestos exposure [89]. Considering imaging techniques, low-dose computed tomography 
(LDCT) scans have not proven to be effective for the early detection of MPM [131]. 
Furthermore, a PET scan and MRI are useful for MPM management and in the differentiation 
of malignant from benign pleural disease, but are not applicable for screening purposes. Next 
to the high cost, the associated radiation exposure also limits its further use [77, 129, 131]. 
Several blood biomarkers will be discussed in the next chapter but a recent meta-analysis 
assessed the value of serum mesothelin-related protein (SMRP) as a screening tool (chapter 
4, paragraph 4.2). Including 4,491 individuals of which 1,026 were MPM patients, the 
sensitivities and specificities of SMRP ranged from 19%-68% and 88%-100%, respectively 
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[132]. The poor sensitivity and PPV (14%-46%) of mesothelin clearly limits its value as early 
marker for MPM diagnosis and stresses the need for further biomarker research.  
Lastly, there is no proof that early discovery of MPM would cure the patient or even improve 
their survival. Therefore, prospective studies should investigate the effect of earlier treatment 
on survival.  
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CHAPTER 4 
BIOMARKERS 
 
4.1 Introduction 
In 1998, the National Institutes of Health (NIH) Biomarkers Definitions Working Group defined 
a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [133, 134]. There are different types of biomarkers depending on 
their clinical use [135]: those that assist in the care and follow-up of asymptomatic patients 
(screening biomarkers), biomarkers to identify patients in subjects suspected to have the 
disease (diagnostic biomarkers) and those that can predict the prognosis in treatment-naïve 
patients with overt disease (prognostic biomarkers). Biomarkers can also be used for 
predicting the treatment response (predictive biomarkers) or for surveillance after therapy 
(monitoring biomarkers). Fundamental for the use of biomarkers in all situations is the 
biomarker’s accuracy or the ability to correctly classify one condition and/or outcome from 
another (for instance healthy versus diseased). 
Although different kinds of biomarkers exist, blood proteins are being studied the most 
because these manage and regulate many catalytic processes and structural and signalling 
functions in living organisms [136, 137]. Furthermore, blood is considered to be the most 
comprehensive and represents all body tissues. Also, blood sampling is less invasive for the 
patient with the medical infrastructure immediately available at the hospital site [137, 138]. 
By measuring their responses, changes and malfunctions in the metabolism and disease 
progression can be explored. 
 
4.2 Blood biomarkers 
Blood exists out of 55% plasma while the remaining 45% consists of blood cells (platelets, 
white blood cells and erythrocytes) [139]. After plasma clots, serum remains, which is similar 
to plasma but has lost fibrinogen and has prothrombin cleaved to thrombin [136]. Several 
biomarkers have been studied in blood. One of the most extensively evaluated serum 
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biomarkers is soluble mesothelin-related protein (SMRP). Several studies have shown SMRP 
levels to be significantly increased in MPM patients, making this biomarker interesting to 
investigate as a screening tool. Ferro et al. studied SMRP levels in both serum (S-SMRP) and 
pleural effusions (PE-SMRP) [140]. They found that PE-SMRP had a better diagnostic 
performance in differentiating MPM from other malignancies and asbestos-related benign 
diseases. Despite of the high specificity, S-SMRP shows a lack of sensitivity. Therefore, further 
research has focussed on the combination of serum mesothelin with several other biomarkers 
in order to improve the diagnostic accuracy. Creaney et al. combined SMRP with cancer 
antigen 125 (CA125) but this did not improve sensitivity for detecting MPM over SMRP alone 
[141].  
Osteopontin (OPN) and megakaryocyte potentiating factor (MPF) are also biomarkers that 
show increased levels in MPM patients. The diagnostic performance of these markers was 
assessed in multiple studies but both glycoproteins lack sensitivity to be used as stand-alone 
diagnostic biomarkers [142-147]. However, combining SMRP and OPN improved the 
diagnostic accuracy [145] opposed to a previous study where the combination of SMRP with 
OPN did not improve the diagnostic performance compared to SMRP alone [142]. The same 
has been observed for the combination of SMRP and MPF [142].  
It has been shown that SMRP levels correlate with the histological subtype of the tumour since 
it is only expressed in epithelial mesothelioma. The same correlation has been observed for 
MPF [148]. This is due to the fact that SMRP and MPF both originate from the same mesothelin 
gene [91]. Mesothelin encodes a 69 kilodalton (kDa) precursor protein which is bound to the 
cell membrane by a glycosylphosphatidylinositol (GPI) anchor [149]. After glycosylation, this 
precursor is cleaved into the 40 kDa membrane-bound mesothelin and the 31 kDa 
glycoprotein MPF. When the GPI anchor is cleaved, mesothelin enters the bloodstream as 
‘soluble mesothelin-related protein’ (SMRP). Membrane-bound mesothelin is normally 
expressed on normal mesothelial cells, and highly expressed in cancers like pancreatic cancer, 
ovarian cancer and epithelioid mesothelioma. Asbestos-exposed individuals seem to have 
higher SMRP concentrations than normal control individuals, regardless of the presence of 
pleural disease. Therefore, serum SMRP levels also can be a marker of asbestos exposure 
[150]. 
Other interesting biomarkers are C-C motif chemokine ligand 2 (CCL2) and galectin-3, both 
measured in pleural effusions [151]. CCL2 levels were found increased in MPM patients, where 
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galectin-3 concentrations were found to be decreased in case of MPM [151]. Furthermore, 
the combination of SMRP, CCL2 and galectin-3 had better diagnostic accuracy for MPM 
compared to SMRP alone [152]. 
Another potential diagnostic marker is thioredoxin-1 (TRX), which was found elevated in MPM 
patients in comparison with asymptomatic asbestos-exposed individuals [153]. Research also 
focussed on fibulin-3 as a potential diagnostic biomarker. Fibulin-3 levels in plasma and pleural 
effusions were able to distinguish MPM patients from controls [154]. Although this was on 
retrospective data and the marker had a similar diagnostic performance as SMRP [155, 156], 
SMRP was later shown to outperform fibulin-3 [157].  
Very recently, it was shown that the levels of total HMGB1 in serum discriminated 
asymptomatic asbestos-exposed individuals from non-asbestos-exposed healthy subjects 
[158]. A specific HMGB1 isoform (hyper-acetylated HMGB1) even outperforms previously 
described biomarkers and discriminated between MPM from asbestos-exposed or non-
exposed individuals with 100% sensitivity and specificity [158]. Combining fibulin-3 with either 
total or hyper-acetylated HMGB-1 improved both sensitivity and specificity for differentiating 
MPM patients from individuals with non-MPM pleural effusions [158]. Although some of the 
abovementioned biomarkers show diagnostic potential, none of these are validated and 
therefore cannot be used in clinical practice to screen potential individuals at risk for MPM. 
This stresses an urgent need to continue the search for an accurate diagnostic biomarker to 
enable early stage diagnosis of MPM. Therefore, the field of breath analysis can be explored.  
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CHAPTER 5 
BREATHOMICS FOR ASBESTOS-RELATED DISEASES 
 
Breath contains volatile organic compounds (VOCs) which arise from the (patho)physiological 
processes of the body [159, 160]. The generation of VOCs is linked to oxidative stress and 
increased metabolism which releases VOCs from the tissues into the blood stream and which 
are transported through the circulation to the lungs [161-164]. Volatile compounds will 
undergo the gas-exchange mechanisms in the alveolar region of the lungs and, hence, enter 
the breath. In that way, breath can be a non-invasive source of biomarkers for disease and is 
a less complex mixture than blood. Chapter 5 focusses on the different aspects of human 
breath, the different techniques used for breath analysis and current state-of-the-art 
discussing breath analysis for the spectrum of asbestos-related diseases. 
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ABSTRACT 
Past and present asbestos use will reflect in increasing numbers of mesothelioma cases in the 
next decades, diagnosed at a late stage and with a dismal prognosis. This stresses the need 
for early detection tools which could improve patient’s survival. Recently, breath analysis as a 
non-invasive and fast diagnostic tool has found its way into biomedical research. High-
throughput breathomics uses spectrometric, chromatographic and sensor techniques to 
diagnose asbestos-related pulmonary diseases based upon volatile organic compounds (VOCs) 
in breath. This article reviews the state-of-the-art available breath analysing techniques and 
provides the insight in the current use of VOCs as early diagnostic or prognostic biomarkers of 
mesothelioma in order to stimulate further research in this field. 
  
Chapter 5 – Breathomics for Asbestos-related Diseases 
42 | Part I 
Introduction 
Asbestos fibres cause malignant pleural mesothelioma (MPM), an aggressive tumour from the 
serosal surface lining the pleural cavity [14]. Because of the large asbestos consumption in the 
past, MPM incidence rates will further increase the next decade [2, 13], although with large 
intercountry differences [15, 132], and peak between 2015-2020 [14, 33]. This MPM epidemic 
will cost the United States and the European Union $200 billion and $80 billion respectively in 
compensation, urging the need for an early detection [77].  
The ‘Holy Grail’ in MPM diagnosis would be a non-invasive, accurate test in asbestos-exposed 
persons at risk for developing MPM which makes early stage detection possible, reduces the 
economic burden of wild screening and improves MPM management. Present research efforts 
have however, not yet revealed a validated diagnostic blood biomarker [132, 154].  
Breathomics is an innovative, non-invasive tool that uses high-throughput technologies to 
identify organic molecules as biomarkers that reflect the patient’s metabolic status. The aim 
of this manuscript is to critically review the current state of the art concerning different 
techniques used for gaseous breath analysis, focused on their diagnostic yield in various 
asbestos-related diseases and MPM specifically in order to stimulate future MPM biomarker 
research using breathomics and improve MPM management. 
 
Search strategy and literature selection 
MEDLINE (PubMed) and Web of Science were searched for studies concerning exhaled breath 
research in asbestos-related pulmonary diseases until December 2013. Following keywords 
were selected as MeSH terms and used as search terms in PubMed and Web of Science: 
“asbestos”, “asbestosis”, “mesothelioma”, “lung neoplasms” and “breath tests”. Other 
additional search terms included “breath analysis”, “pleural plaques”, “pleural thickening”, 
“pleural effusion”, “volatile organic compounds” and “lung cancer”. After a first inspection of 
the literature “electronic nose”, “ion mobility spectrometry”, “GC-MS”, “exhaled breath 
condensate” and “dog” were added as additional terms for specific search combinations. Only 
literature published in English on human material was considered. References of the 131 
selected publications were searched manually for additional relevant literature concerning 
breath analysing techniques in asbestos-related diseases. This delivered another 21 
publications. 
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The spectrum of asbestos-related diseases 
Asbestos fibres are hydrated silicate minerals containing a high tensile strength and resistance 
to chemical and thermal degradation, making these ‘magic minerals’ interesting for insulation 
in (ship) building [165]. Hence, many people were professionally exposed to the fibres. 
Inhaling asbestos fibres damages the lung parenchyma and the pleura, leading to benign 
conditions like pleural effusions, pleural plaques, diffuse pleural thickening (DPT) and 
asbestosis but also to malignant diseases like lung cancer (although in association with 
tobacco) and MPM (Figure 7). The World Health Organization estimates that annually 125,000 
new persons are confronted with an occupational asbestos exposure [79] and worldwide, 
there are approximately 25,000 patients diagnosed with mesothelioma per year [166]. The 
lifetime MPM risk after occupational asbestos exposure is 10% [77] with a mean latency period 
between exposure and diagnosis of 40 years (range 15-67 years) [33]. A non-specific 
symptomatology and a lack of imaging accuracy delay its diagnosis so that patients present in 
an advanced stage which jeopardizes potential curative management [14]. Despite that 
current guidelines dissuade screening for MPM [77], asbestos-exposed individuals are wildly 
and widely subjected to non-specific investigations (lung function testing, chest X-rays and 
computed tomography scans) at an unknown cost [33]. 
Asbestos exposure also increases the likelihood for lung cancer development through a 
synergistic effect with smoking and via the mechanism of fibrosis [167, 168]. Any biomarker 
of asbestos-induced lung cancer is hence likely to be confounded by smoking. Happily, a low-
dose spiral CT scan has recently been advocated an effective technique for the early diagnosis 
of lung cancer [169, 170] but not of mesothelioma [171, 172], urging the need to search for 
other early detection tools for the latter disease. 
 
Breath analysis: techniques and applications 
Exhaled breath is easily and non-invasively retrievable, resembles the arterial concentrations 
of biological substances and can be monitored in real-time. It consists of a liquid phase 
containing water and proteins and a gaseous phase containing oxygen, nitrogen, carbon 
dioxide, water, inert gases, volatile organic compounds (VOCs) and non-VOCs [173-175]. Since 
their first discovery, more than 3000 VOCs have been detected in breath [176], arising from 
exogenous sources (via inhalation or skin adsorption) or from endogenous biochemical 
processes (via oxidative stress, fat metabolism) and are catabolized through cytochrome P450 
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enzymes. Independent of their origin, VOCs are transported through the blood to the lungs 
where they enter the breath by the alveolar gas exchange mechanisms. Hence, changes in the 
VOC metabolism result in different VOC profiles in breath [177].  
Oxidative stress plays a key role in endogenous VOC production: acetone is linked to lipolysis 
via decarboxylation of excess acetyl-CoA after oxidation of fatty acids, isoprene is liberated 
during the mevalonic pathway of cholesterol synthesis and hydrocarbons are formed through 
lipid peroxidation of polyunsaturated fatty acids in the cellular membranes [178]. Since 
asbestos-related diseases are driven by oxidative stress and inflammation, markers of 
oxidative damage, such as VOCs, are hence likely to be altered. Asbestos fibres have indeed a 
high iron content which directly induces oxidative stress generating reactive oxygen species 
(ROS) and nitrogen species (RNS) [51, 179]. Because of the asbestos fibre’s high length/width 
ratio, alveolar macrophages fail to engulf them, leading to a ‘frustrated phagocytosis’ [180] 
(Figure 7). In this way, asbestos indirectly induces the release of oxidants, cytokines and 
growth factors by the macrophages (and to a lesser extent by the mesothelial cells). This 
sustains the relentless generation of ROS and RNS which leads to (i) lipid peroxidation 
generating saturated hydrocarbons and aldehydes, (ii) protein oxidation and (iii) mutagenic 
DNA lesions through the generation of 8-oxo-7,8-dihydro-2’-deoxyguanosine and 8-
nitroguanine [181, 182]. In addition, asbestos-induced mesothelial cell death is also linked to 
the inflammatory reaction associated with asbestos carcinogenesis [55] and hence could play 
a role in VOC production. When asbestos damages the mesothelial cells, High Mobility Group 
Box-1 (HMGB1) is released, inducing the accumulation of macrophages, inflammation and the 
release of tumour necrosis factor-α (TNF-α) [183, 184], which binds its induced receptor on 
the mesothelial cells. This activates the NF-κB pathway, increasing the survival of damaged 
mesothelial cells and aiding MPM pathogenesis [55].  
Several very sensitive breath analysing techniques are now available for the liquid or gaseous 
phase of the breath and measure one of the different (non-)volatile breath compounds or 
recognize VOC patterns. 
 
A) Analysis of the liquid phase 
Exhaled breath forms a condensate with water representing over 99% of the exhaled breath 
condensate (EBC) sample and contains different molecules ranging from simple ions to DNA 
[185, 186]. Although not the scope of this review, diagnostic markers of asbestosis, pleural 
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plaques and diffuse pleural thickening in EBC have been investigated (Table 3). The non-
volatile oxidative markers H2O2, 8-isoprostane, 4-hydroxy-trans-2-nonenal, 8-OHdG and the 
leukotrienes (LT) B4, D4 and E4 were found increased in the breath of asbestos-exposed 
individuals or patients with asbestos-related diseases compared to healthy controls [187-194]. 
However, no EBC measurements have been performed for MPM specifically. LTB4 is a potent 
chemotactic factor for neutrophils and asbestos exposure has been shown to provoke LTB4 
secretion in alveolar macrophages in vivo [195, 196]. These findings suggest that the LTB4 level 
in EBC reflects the inflammatory response to asbestos and is attractive for further research in 
MPM. The EBC-level of 8-isoprostane is related to the degree of oxidative stress, tissue 
damage and fibrosis and hence, could also be used as a marker for lung cancer or could be 
confounded by smoking.  
 
B) Analysis of the gaseous phase 
Endogenous volatile metabolic products derived from the tumour or its environment and 
present in the gaseous phase of breath are of interest because they reflect tumour-specific 
biomarkers that are linked to their pathogenesis.  
Nitric oxide (NO) serves as a signalling molecule maintaining physiological control of airway 
function [197]. Asbestos induces chronic lung inflammation in which an inducible form of NO-
synthase (iNOS) is upregulated and the pulmonary gas diffusion capacity is decreased. Hence, 
the fractional exhaled NO (FeNO) in the gaseous phase of the breath of asbestos-exposed 
individuals increases. This was seen in asbestosis patients compared to those with pleural 
plaques, DPT and healthy controls [198] (Table 3). When flow rates over 250 ml/min are 
achieved, alveolar NO tends to be higher in asbestosis patients [187, 189] and in asbestos-
exposed persons with borderline high-resolution CT (HRCT) parenchymal changes [194]. This 
reflects the ongoing lower respiratory tract inflammation and it seems that alveolar NO is 
related to the degree of pulmonary fibrosis rather than to the asbestos exposure per se. 
Hence, the increased production of NO is not tumour-specific, is attributed to tumour-
associated non-specific immunologic and (asbestos-related) inflammatory mechanisms and 
correlates with the intensity of NO-Synthase 2 expression in alveolar macrophages [199].  
Although NO levels are dependent of age, sex and lung function, FeNO determination in early 
MPM diagnosis can have a role which has not been investigated until today. The most popular 
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technique in determining FeNO is chemiluminescence, although handheld devices with 
electrochemical sensors are available, such as NIOX MINO® (AeroCrine AB, Solna, Sweden). 
Advances in detection systems resulted in (i) combinations of mass spectrometers and fast 
flow tubes such as proton-transfer-reaction mass spectrometry and selected ion flow tube 
MS, (ii) spectroscopic methods for identification and quantification of small molecules such as 
ion mobility spectrometry (IMS) and (iii) non-specific electronic noses (eNoses) that ‘smell’ gas 
combinations. All these methods provide the capability of easily gathering repeated samples 
and obtaining results immediately in a relatively short period of time. 
 
Gas Chromatography (GC)-Mass Spectrometry (MS)  
GC-MS detects and quantifies gases from 100 parts per million to 1 part per billion by 
separating compounds based upon their elution times from the GC-column and characteristic 
fragmentation pattern obtained by MS (Figure 8A). Today, only one reported GC-MS analysis 
of the breath of respectively 13 MPM patients, 13 healthy asbestos-exposed individuals and 
13 healthy controls [200]. Table 4 summarizes the 18 VOCs identified as being able to 
discriminate MPM breath from controls with most of them being alkanes. The authors found 
higher cyclohexane concentrations in the breath of MPM patients compared to the other 
control groups in which a model they have built distinguished these groups with 97% accuracy. 
However, cyclohexane and several other VOCs were also found in the breath or urine of lung 
cancer patients and in in vitro studies with sensitivities and specificities ranging respectively 
from 71-86% and 66-100% [201-211] (Table 4). This indicates that these VOCs originate from 
oxidative stress in the inflamed stroma and hence, lack specificity for MPM since they are also 
seen in other cancers like lung cancer. Since asbestos can also induce lung cancer [29], non-
specific inflammation-related VOCs in lung cancer patients can be of great interest to 
investigate in MPM and vice-versa. Two reports identified 2-methylpentane as a potential 
marker for lung cancer [210, 211] which was also found in in vitro tests [212]. Increased 
concentrations of C4-C24 hydrocarbons [213, 214] and C3-C9 aldehydes [215] reflecting 
oxidative stress and lipid peroxidation, were also found in lung cancer patients and represent 
also promising markers as inflammation-related VOCs in MPM. 
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Ion Mobility Spectrometry (IMS) 
IMS allows separation of VOCs in the breath by their ion mobilities (size, mass, shape, charge) 
[216, 217]. Gaseous metabolites are firstly ionized in an ionization chamber by a low energetic 
63Ni β-radioactive source, although other sources exist such as UV-light, lasers, electrical 
discharges or electrospray, followed by a separation in a drift tube under influence of a 
counter gas (Figure 8B). Conventional IMS is based on absolute ion mobilities measured at low 
electrical fields while other IMS-based methods, as differential IMS or field asymmetric 
waveform IMS, use the mobility difference at high and low electrical field, eliciting a periodic 
asymmetric waveform [218]. Combining IMS with multicapillary GC-columns (MCC) permits 
an effective preseparation of VOCs based upon their chemical characteristics before entering 
the ionization chamber and drift tube (Figure 8B). A direct online measurement using 10 mL 
of human breath and a total analysis time of 10-15 min makes MCC/IMS utterly suitable for 
clinical applications.  
Data from MCC/IMS in patients with MPM or asbestos-related disease have presently not 
been reported, except one where 25 male patients with asbestosis or diffuse pleural 
thickening were discriminated from healthy controls with 96% sensitivity, 50% specificity and 
a respective positive (PPV) and negative (NPV) predictive value of 80% and 86% based upon 
alpha-pinene and 4-ethyltoluol [219]. Furthermore, its potential is demonstrated in 3 studies 
reporting breath analysis in lung cancer patients. Westhoff et al. identified 23 peak regions 
discriminating lung cancer patients from healthy controls with zero percent error rate and PPV 
and NPV of 100%, independently of smoking status, TNM-stage and histology [217]. However, 
their lung cancer patients were older and at an advanced stage and the healthy controls were 
not age-matched. Another study compared bronchoscopically obtained tumour-side air with 
non-tumour side air wherein n-dodecane discriminated lung adenocarcinoma patients from 
controls with 100% sensitivity, 75% specificity, 80% PPV and 100% NPV [220]. 2-butanol or 2-
methylfuran and nonanal discriminated squamous cell carcinoma from healthy controls with 
sensitivities of 78-79%, specificities of 67-78%, PPV’s of 70-80% and NPV’s of 75-88%, which 
was confirmed more recently [221]. Although to minimize confounding, each patient with a 
tumour was its own control and healthy subjects were not included, 2-butanol and nonanal 
had a higher value in the tumour-bearing lung but no correlation of the VOCs with the location 
or the stage of the tumour was found.  
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Electronic noses (eNoses)  
Electronic noses are based upon the change in surface conductivity of non-selective sensors 
when exposed to a bulk of different volatile breath compounds. These detectors recognize 
breath patterns without identifying and quantifying these compounds. VOCs induce a physical 
or chemical sensor change that sends a signal to a computer which then makes a classification. 
By analysing the breath of several patient groups and building a model based upon several 
data mining techniques, eNoses can be trained to identify a mixture of VOCs as a ‘smellprint’ 
(Figure 8C). By generating a database of breath signatures, identification of subjects with 
similar breath chemical characteristics becomes possible. Different sensors can be used as 
eNose sensors [222]. The most frequently used eNose, the Cyranose 320 (Intelligent Optical 
Systems, Inc., CA, USA), is a commercial and portable system whose detection capacity 
consists of an array of 32 individual polymer sensors blended with carbon black composite. 
Dragonieri et al. [223] were the first to describe the use of an eNose in diagnosing MPM. They 
distinguished 13 MPM patients from 13 asbestos-exposed individuals and 13 healthy controls 
with respectively 92% sensitivity and 86% and 69% specificity. This study was repeated, now 
distinguishing 20 MPM patients from 18 asbestos-exposed and 42 healthy individuals with 
90% sensitivity and 88% specificity [224].  
An in vitro study used an eNose to compare the headspace air between cell lines for 
mesothelioma, non-small cell lung cancer, metastatic squamous cell carcinoma and healthy 
controls [225]. eNoses separated the different malignant cell lines and discriminated 
malignant from non-malignant cell lines. These two studies underline the potential of eNose 
analysis, next to GC-MS analysis, for detecting and diagnosing MPM.  
 
Canines 
Since eNose pattern recognition is based upon natural olfactory perception, dogs have been 
used to discriminate different breath patterns. Due to their sensitive smelling ability and 
learning capacity, several dog stocks were trained to recognize and discriminate different 
breath samples. Although no studies using canine scent for asbestosis or mesothelioma are 
available, lung cancer patients have been distinguished from controls with a 71-83% sensitivity 
and 82-93% specificity [226, 227]. However, bias in these studies result from confounding 
smoking, drugs or the use of different dog stocks. 
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Properties of breath analysing techniques 
An ideal breath analysing method should be cheap, user-friendly, non-invasive and easy 
accessible without patient discomfort or traveling. The above described techniques developed 
for gaseous breath analysis, all have their specific advantages and disadvantages as 
summarized in Table 5. 
Dogs, eNoses and IMS have a high sensitivity and are transportable but do not identify the 
individual compounds. Offline sampling methods (like GC-MS or eNoses) use different bags 
and tubing material for breath sampling, are not in real-time and induce a risk of sample 
contamination which leads to potential biases for data comparison between research groups. 
The water content of breath samples is also pernicious for sensor analysis, as it causes sensor 
drift and leads to possible loss of information by dilution. The sampling technique must handle 
this by removing the water vapour before the analysis by preconcentration, increasing the risk 
of contamination and losing some of the VOCs. When offline methods are used, mixed breath 
is stored in bags or tubes which can furthermore induce errors. 
GC-MS analysis remains the gold standard, as it is very sensitive and allows VOC identification 
and quantification, albeit very expensive, time-consuming and laborious and it requires a large 
vacuum-containing set-up and qualified technicians. Furthermore, in conventional mass 
spectrometers, the impact of electrons on polyatomic molecules and complex gas mixtures as 
breath induces large fragmentation of the molecules. This complicates the mass spectra 
interpretation and makes it practically impossible to carry out accurate quantitative analyses.  
A more desirable technique is one in which the patient breathes directly (online) into the 
analytical equipment without any preconcentration steps and achieves the ionization of these 
gases with minimal fragmentation of the molecules which simplifies the outcome. This gives 
fast, real-time information about the breath composition, allows for instantaneous feedback 
and decreases the chance of contamination. IMS coupled to an MCC has these features (Table 
3) and subjects breathe directly into a CO2-controlled end-tidal breath collecting device 
collecting alveolar air in a sample loop followed by a fast analysis. A VOC database comprising 
correlated GC-MS with IMS spectra, allows immediate VOC identification and the effective 
separation of humidity is an advantage. 
 
 
Chapter 5 – Breathomics for Asbestos-related Diseases 
50 | Part I 
Conclusion and future directions 
Past and current asbestos consumption will lead to more cases of mesothelioma in the coming 
decade. Breath analysis as a non-invasive diagnostic tool provides a fast, user-friendly and 
cost-effective system which is not subjected to laboratory conditions. Hence, breathomics can 
become the missing link to screen for early cases in professional or environmental asbestos-
exposed persons i) to rule out diagnosis, requiring a high NPV, ii) to rule in diagnosis, 
necessitating a high PPV and iii) as a step-up diagnostic tool in order to enrich the fraction of 
screenees for further testing, requiring a low false negative rate.  
Although they are not tumour-specific, one of the most abundant detected molecular groups 
in the breath of asbestos-exposed individuals are alkanes representing the oxidative stress 
level (Table 4). Even though published studies were able to discriminate asbestos-related 
diseases from healthy controls, there is a lot of variation in sample size, study design, control 
groups, techniques, sampling procedures, the kind of sampled breath (mixed/alveolar), 
preconcentration techniques and data-mining techniques. This makes it hard to compare the 
studies or draw clinically relevant conclusions at the present time.  
Nevertheless, breath analysis will eventually become a useful tool for the diagnosis of 
asbestos-related diseases but the way to a validated and clinical implemented model is still 
harsh and cumbersome. A large, prospective, case-control study is to be performed using 
control groups with comparable characteristics that cover the possible confounding factors 
for asbestos-related diseases in order to strengthen the diagnostic tool’s discriminative 
power. Therefore, healthy, non-smoking and smoking controls should be included as well as 
healthy asymptomatic asbestos-exposed individuals and participants with benign asbestos-
related diseases. Lung cancer and mesothelioma patients should also be included, preferable 
treatment-naive and their VOCs should be analysed by disease stage. Standardization of the 
sampling techniques is necessary to allow comparison with results obtained in the field. 
Models should be built based upon a training set and internally validated in a separate 
validation set accounting for ambient air, gender, smoking behaviour and age. External 
validation should be performed in an independent test set estimating the general error. 
Different data mining techniques (classification trees, discriminant analysis, support vector 
machines, random forests, principle component analysis) should be investigated in 
cooperation with (bio-)statisticians [228]. In order to select appropriate VOCs representing 
MPM, comparisons with cell lines or xenografts and pre- and postoperative VOC analysis 
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should be performed. However, the importance of identifying different compounds is 
debatable: from pathophysiological view, VOCs should be identified with MCC/IMS or GC-MS 
to link MPM-related VOCs to their specific pathogenesis and hence allow to investigate 
therapeutic targets. On the other hand, recognizing breath patterns with dogs or eNoses 
allows for a clinical diagnostic assessment and monitoring.  
Finally, an international consortium, discussing and optimizing each technique in large-scaled 
validation studies is needed and therefore an International Association for Breath Research 
(IABR) Task Force for breath sampling was recently founded. This could increase the speed of 
developing good diagnostic methods in asbestos-related diseases in a cost-effective way. 
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Table 3: Overview of FeNO and of breath biomarkers measured in EBC in asbestos-related diseases. 
Marker Disease (n) Control subjects (n) Method Result Ref. 
Oxidative stress 
Hydrogen peroxide (H2O2) 
Asbestosis (18) 
Pleural plaques (26) 
DPT (16) 
Healthy (26) EcoScreen + EIA Asbestosis > HC [187] 
8-isoprostane 
Asbestos-exposed (92) Healthy (46) SPE + LC-ESI-MS/MS Asbestos-exposed > HC [191] 
Asbestos-exposed (44) NA SPE + LC-ESI-MS/MS Asbestos-exposed > HC [193] 
Asbestos-exposed (45) Healthy (29) SPE + LC-ESI-MS/MS Asbestos-exposed > HC [192] 
Asbestosis (15) Healthy (15) EcoScreen + EIA Asbestosis > HC [189] 
Asbestosis (18) 
Pleural plaques (26) 
DPT (16) 
Healthy (26) EcoScreen + EIA Asbestosis > HC [187] 
Asbestos-exposed (66) Healthy, non-exposed (41) Chemiluminescence NO analyser Asbestos-exposed > HC [194] 
HNE Asbestos-exposed (45) Healthy (29) SPE + LC-ESI-MS/MS Asbestos-exposed > HC [192] 
8-OHdG Asbestosis (10) Healthy (10) Lyophilisation + LC-ESI-MS/MS Asbestosis > HC [188] 
FeNO 
Asbestosis (12) 
Pleural plaques (32) 
DPT (12) 
Healthy (35) Chemiluminescence NO analyser 
Asbestosis > HC 
Pleural plaques > HC 
[198] 
Asbestosis (15) Healthy (15) Chemiluminescence NO analyser No differences [189] 
Asbestos-exposed (66) Healthy, non-exposed (41) Chemiluminescence NO analyser Asbestos-exposed > HC [194] 
Lipid peroxidation 
Leukotriene B4 
Asbestosis (45) 
Silicosis (37) 
Healthy (27) SPE + LC-ESI-MS/MS 
Asbestosis > HC 
Asbestosis > Silicosis 
[190] 
Asbestosis (15) Healthy (15) EcoScreen + EIA Asbestosis > HC [189] 
Asbestos-exposed (66) Healthy, non-exposed (41) EcoScreen + EIA Asbestos-exposed > HC [194] 
Leukotrienes C4, D4, E4 
Asbestosis (45) 
Silicosis (37) 
Healthy (27) SPE + LC-ESI-MS/MS 
LTD4+LTE4: 
Asbestosis > HC 
Silicosis > HC 
LTC4: no differences 
[190] 
8-isoprostane = 8-iso-prostaglandine F2α. 8-OHdG = 8-Hydroxy-2’-Deoxyguanosin. DPT = Diffuse Pleural Thickening. EIA = Enzyme Immunoassay. FeNO = Fractional 
Exhaled Nitric Oxide. HC = Healthy control. HNE = 4-Hydroxy-trans-2-Nonenal. NA = Not Applicable.
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Table 4: Volatile breath biomarkers measured with GC-MS in patients with MPM and lung cancer. 
VOC Controls (n) MPM (n) Lung Cancer (n) Method Sample Ref. 
Acetophenone 
13 13  TD-GC-MS Breath [200] 
NA  NA SPME + GC-TOF-MS Urine (Mice) + in vitro [201] 
31  65 SPME-GC-MS Breath [209] 
31  65 SPME-GC-MS Breath [211] 
Benzene, trimethyl- 
13 13  TD-GC-MS Breath [200] 
26 COPD/85 Healthy  36 SPME-GC-MS Breath [210] 
50  36 SPME-GC-MS Breath [203] 
Cyclohexane 
48 (NH)  60 TD-GC-MS Breath [207] 
13 13  TD-GC-MS Breath [200] 
Cyclohexane, methyl- 13 13  TD-GC-MS Breath [200] 
Cyclopentane 13 13  TD-GC-MS Breath [200] 
Decane 
48 (NH)  60 TD-GC-MS Breath [207] 
13 13  TD-GC-MS Breath [200] 
26 COPD/85 Healthy  36 SPME-GC-MS Breath [210] 
31  65 SPME-GC-MS Breath [211] 
13  29 SPME-GC-MS Breath + in vitro [208] 
Dodecane 
13 13  TD-GC-MS Breath [200] 
50   TD-GC-MS Breath [176] 
22  30 SPME-GC-MS Breath [204] 
Heptane 
13 13  TD-GC-MS Breath [200] 
26 COPD/85 Healthy  36 SPME-GC-MS Breath [210] 
31  65 SPME-GC-MS Breath [211] 
50  36 SPME-GC-MS Breath [203] 
Heptane, 2,4-dimethyl- 
48 (NH)  60 TD-GC-MS Breath [207] 
13 13  TD-GC-MS Breath [200] 
31  65 SPME-GC-MS Breath [211] 
NA  NA TD-GC-MS In vitro [205] 
1-Hexanol, 2-ethyl- 
13 13  TD-GC-MS Breath [200] 
20  20 SPME + GC-TOF-MS Urine [202] 
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Limonene 
13 13  TD-GC-MS Breath [200] 
50   TD-GC-MS Breath [176] 
31  65 SPME-GC-MS Breath [211] 
Nonane, dimethyl- 13 13  TD-GC-MS Breath [200] 
Octane, 3-methyl- 
48 (NH)  60 TD-GC-MS Breath [207] 
13 13  TD-GC-MS Breath [200] 
1,2-Pentadiene 13 13  TD-GC-MS Breath [200] 
α-Pinene 13 13  TD-GC-MS Breath [200] 
Styrene 
48 (NH)  60 TD-GC-MS Breath [207] 
13 13  TD-GC-MS Breath [200] 
50   TD-GC-MS Breath [176] 
26 COPD/85 Healthy  36 SPME-GC-MS Breath [210] 
31  65 SPME-GC-MS Breath [211] 
13  29 SPME-GC-MS Breath + in vitro [208] 
50  36 SPME-GC-MS Breath [203] 
Toluene 
13 13  TD-GC-MS Breath [200] 
26 COPD/85 Healthy  36 SPME-GC-MS Breath [210] 
31  65 SPME-GC-MS Breath [211] 
22  30 SPME-GC-MS Breath [204] 
50  36 SPME-GC-MS Breath [203] 
67  115 SPME-GC-MS Breath + in vitro [206] 
Xylene 
13 13  TD-GC-MS Breath [200] 
26 COPD/85 Healthy  36 SPME-GC-MS Breath [210] 
31  65 SPME-GC-MS Breath [211] 
50  36 SPME-GC-MS Breath [203] 
67  115 SPME-GC-MS Breath + in vitro [206] 
COPD: Chronic Obstructive Pulmonary Disease. GC-MS: Gas Chromatography-Mass Spectrometry. MCC/IMS: Multicapillary Column/Ion Mobility Spectrometry. MPM: 
Malignant Pleural Mesothelioma. NA: Not Applicable. NH: Non-Healthy. SPME: Solid Phase Micro Extraction. TD: Thermal Desorption. TOF: Time-of-flight. VOC: 
Volatile Organic Compound. 
  
  
 
P
art I | 55
    
C
h
ap
ter 5
 – B
reath
o
m
ics fo
r A
sb
esto
s-related
 D
iseases 
Table 5: Overview of breath analysing techniques for volatile compounds. 
Gas Chromatography –  
Mass Spectrometry 
(GC-MS) 
Electronic Nose 
(eNose) 
Ion Mobility Spectrometry 
(IMS) 
Canine Scent 
 Sensitive (ppm-ppt) 
 Identification, Detection, 
Quantification of VOCs 
 Vacuum Conditions 
 Slow 
 Offline Sampling 
 Large, Immovable Set-Up 
 Very Expensive 
 Specific Technician Training 
 Gold Standard 
 No Specific VOC 
Identification 
 Blackbox 
 Ambient Conditions 
 Fast, Easy 
 Offline Sampling 
 Transportable 
 Cheap 
 No Specific Operator 
Training 
 Sensitive (ppb-ppt) 
 VOC Identification 
possible with MCC 
column 
 Ambient Conditions 
 Fast, Easy 
 Online Sampling 
 Transportable 
 Cheap 
 No Specific Operator 
Training 
 Time Consuming (Dog 
Training) 
 No 
Quantification/Identification 
of VOCs 
 Ambient Conditions 
 Fast, Easy  
 Online Sampling 
 Transportable 
 Expensive 
 No Specific Operator Training 
MCC: Multicapillary Column. ppb: parts per billion by volume. ppm: parts per million by volume. ppt: parts per trillion by volume. VOC: Volatile Organic 
Compound. 
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FIGURES 
 
Figure 7: Pathogenesis of asbestos-related diseases. When asbestos fibres are inhaled, they penetrate 
the lung parenchyma and irritate the pleura. The iron content from asbestos fibres forms oxidants 
through the Haber-Weiss and Fenton chemistry and depletes antioxidants. Normally, fibres are cleared 
by macrophages but fibres which are too long are not fully engulfed by them, leading to frustrated 
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phagocytosis and impaired clearance of the fibres at the bronchial epithelium, mesothelium and 
fibroblasts. In its turn, this leads to oxidant and HMGB1 release and a chronic inflammatory response 
due to TNF-α release and the activation of the NF-κB pathway. Asbestos fibres also mechanically 
interfere with DNA leading to damage, breaks and chromosomal aberrations and induce the TNF-α 
receptor on mesothelial cells. Binding of TNF-α to its receptor will induce survival and proliferation of 
the damaged mesothelial cells and an upregulation of signalling pathways which leads to a cancerous 
pathogenesis. GSH: glutathione. IL-1β: interleukin 1β. MΦ: macrophages. 
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Figure 8: A. General principle of GC-MS. The breath is collected into bags (Tedlar, Mylar, 
Polytetrafluoroethylene) and subsequently concentrated by adsorbing them onto a cold surface (via 
EBC devices, cryofocussing or lyophilisation) or onto some adsorbents (Tenax columns) from which 
they are released into the sample inlet of the GC-MS via solid phase micro-extraction or thermal 
desorption. A carrier flow gas takes the sample over a heated GC column to separate the VOCs based 
upon their chemical characteristics. When entering the MS, samples are ionized, accelerated and led 
to a detector through time-of-flight or quadrupole analysis.  
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B. Principles of IMS. Breath samples are thermally desorbed or enter the IMS through direct sampling 
via a multicapillary column (MCC) to separate the different chemicals based upon their chemical 
characteristics and from the water content of the breath. In general, nitrogen or synthetic air is used 
as a carrier gas of which the molecules are directly ionized by the β-particles of a 63Ni radioactive 
source. Positive carrier gas ions (reactant ions) and free electrons will become available and undergo 
different chemical reactions with the breath analyte ions to form product ions. After the ionization 
phase, a short opening of an ion shutter (e.g. Bradbury-Nielsen gate) every 100-300 ms for 300 µs 
allows the ionized breath compounds to enter a drift tube (10-15 cm) which separates the VOCs based 
upon their ion mobilities (charge, mass, size and shape). In the drift tube, VOCs move to a detector 
(e.g. Faraday plate) under the influence of a low electric field and a counter gas which generates a 
small electric current. The time after opening of the grid and the arrival at the detector (the drift time) 
is measured to characterize the ions.  
C. Example of a smellprint. Subjects need to breath normally for 5 min through a three-way non-
rebreathing valve with a VOC and a silica filter. After a maximal deep inspiration, subjects exhale a 
single vital capacity volume into a 10 L Tedlar bag connected to the expiratory port and silica reservoir, 
sampling all of the breath. Next, the Tedlar bag is connected to the eNose for analysis or the sample is 
first brought onto Tenax columns within 10 min and thermally desorbed and subsequently sampled in 
the eNose. The bulk of the VOCs change the resistance of the 32 polymer carbon sensors of the 
Cyranose 320. The change in relative resistance (ΔR/R) for 32 carbon polymer sensors is known as a 
smellprint. 
  
 60 | Part I 
 
Chapter 6 – Biomarkers: From Bench to Bedside 
Part I | 61 
CHAPTER 6 
BIOMARKERS: FROM BENCH TO BEDSIDE 
 
6.1 Introduction 
Before a biomarker can be used in the standard-of-care diagnostic work-up, it must undergo 
a large number of steps, ranging from its discovery to clinical utility (Figures 9 & 10). It is 
essential that such tests are accurate and reliable (analytical validity; ‘is it true’), that they are 
associated with the disease or the outcome of interest (clinical validity, ‘is it meaningful’), and 
finally lead to its clinical utility (‘is it useful’) which is defined as the evidence that the use of 
the test results in an improved measurable clinical outcome of value to clinical decision making 
compared to the routine management without the use of the test [229-233]. Clinical utility 
can be proven by performing clinical trials that allow improval of favourable outcomes such 
as survival or quality of life, improval of the clinical decision making leading to avoidance of 
unnecessary therapy and cost savings or that allow a decrease of the harms such as 
symptomatology or toxicity. These outcomes can vary with the cancer type, stage, and 
treatment intention [229]. The clinical utility strongly depends on the analytical and clinical 
validity of the biomarker and is a dynamic construct that can change over time as the evidence 
accumulates, clinical practice changes and new biomarkers enter the market [229, 230]. Once 
a biomarker have been proven useful in several clinical trials, it can be approved by the US 
Food and Drug Administration (FDA) for clinical use [234]. 
 
 
Figure 9: Biomarker development: from bench to bedside. (Figure by Kevin Lamote) 
 
Chapter 6 – Biomarkers: From Bench to Bedside 
62 | Part I 
6.2 Steps for clinical implementation of breath biomarkers 
Previous general work-flow for biomarker development can be applied to the development of 
breath biomarkers (Figure 10). This includes a number of steps ranging from the discovery of 
biomarkers to the analytical validation of the method which includes the assessment of 
repeatability, reliability and reproducibility, over finding biological evidence for the biomarker 
in its specific application, and the improvement of technology and miniaturisation [233]. 
Afterwards the clinical validity can be assessed and clinical utility proven by performing 
prospective, case-control, cohort studies before the biomarkers can be approved for clinical 
implementation [229, 233]. These steps will be discussed in more detail. As mentioned, 
biomarkers may be used to help increase the certainty of presence or absence of disease 
(diagnosis/screening), support clinical management, assess the prognosis or monitor 
treatment and, hence, the biomarker test must be evaluated in accordance with its objectives. 
For diagnostic or screening purposes, the accuracy of the biomarker test is an important issue 
and reflects the ability to distinguish between patients and controls. The sensitivity with the 
negative predictive value (NPV) and specificity with the positive predictive value (PPV) jointly 
determine the accuracy of a diagnostic test [233, 235]. When dealing with a lethal disease as 
mesothelioma, a test should have high sensitivity to ensure that no patients will be missed. 
Furthermore, when used for screening, a high NPV allows to rule out disease in patients 
without the disease and subsequently decrease morbidity from diagnostic delay or 
mistreatment. Maximizing sensitivity and NPV should be key for breathomics research 
regarding diagnosing mesothelioma. On the other hand, for chronic diseases like asthma, 
COPD or sarcoidosis, the focus lies upon specificity rather than sensitivity where one wants to 
correctly identify patients among the intention-to-diagnose population. 
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Figure 10: Steps involved for clinical implementation of a breath biomarker [159]. Step 1 involves the 
discovery of VOCs indicative for disease. Step 2 involves resampling in clinical situations with analysis 
of the VOCs observed in Step 1 for validation purposes and indicates the search for biological evidence 
by analysing VOCs in cell lines, animal models, and clinical situations. Step 3 is a possible miniaturization 
phase where we move from a large analytical setup to small hand-held devices. Step 4 depicts the same 
process as step 2, a clinical validation, using the hand-held device instead of the gold standard. Step 5 
states that, ultimately, breath analysis should be used to make a decision in clinical situations with 
respect to either diagnosis or treatment. 
 
6.2.1 Discovery 
Chemical identification of VOCs aims to discover pathophysiological mechanisms related to 
disease. The current gold standard within breathomics to perform breath analysis is GC-MS. 
This technique allows to separate VOCs based upon their specific interaction with the 
stationary phase of the applied chromatography column, after which they are ionized and 
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identified based on their mass-to-charge (m/z) ratio [236, 237] (Chapter 5, page 52). Since 
these characteristics are specific for every VOC, identification becomes possible by 
comparison with a mass spectral library. This allows to theoretically identify every VOC and 
gain insights in the underlying biological mechanisms [238]. As already discussed, this 
technique is time-consuming, and requires special technical issues, limiting its direct clinical 
use. Next to GC-MS, MCC-IMS can also be used. It contains a multicapillary (MCC) column 
which allows a preseparation of VOCs based upon their interaction with the stationary phases 
of the MCC, generating a specific retention time to traverse the MCC. Afterwards, the VOCs 
are ionized and separated based upon their ion mobility characteristics [239]. The 
combination of both characteristics are specific for every VOC and hence, again a theoretical 
identification is possible by comparison with the ion mobility libraries. Next to these technical 
issues, unsupervised and supervised statistical analyses are required for selecting 
discriminatory VOCs in relation to the disease but one has to be careful for the risk of 
overfitting and false discoveries [240]. In order to identify interesting compounds, the first 
step is to perform cross-sectional studies wherein the patients and controls are clearly 
characterized so no heterogeneity would occur that could impede biomarker discovery. 
Although this induces a highly selection of patients and controls, it will ultimately allow us to 
seek for those key compounds that differ between the two extremes [235]. 
 
6.2.2 Internal validation 
Before biologically and externally validating the findings, the methods for breath analysis have 
to demonstrate an adequate reproducibility and transferability. After potential discriminatory 
compounds have been identified, the results have to be repeated [159] in order to assess the 
analytical validity. This is done preferably by repeating the study, including more patients and 
following the same protocol or by using a test set and validation set or by performing k-fold 
cross-validation. 
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6.2.3 Biological translation 
As stated in Koch’s postulates, a biomarker should be linked to the disease of interest. Despite 
progress over the past years, the biochemical origin of most VOCs is still largely unknown [159] 
and underlines the importance to understand the biochemical pathways that give rise to the 
VOCs and link the VOCs with the biological presence of disease. Although intuitively the 
biological mechanisms that induce VOCs in breath are not of primary interest for diagnostic 
purposes, VOC identification is of key importance in the initial evaluation of a diagnostic 
problem because the identity of the VOCs can aid to develop more targeted disease-specific 
sensor-based bedside tests in future phases of biomarker development [241].  
In order to elucidate biological pathways that link VOCs to a specific disease, a translational 
approach is advocated, including analysis of in vitro cell cultures and/or experimental animal 
studies and should focus on explaining the variance instead of diagnosing the disease. In vitro 
studies will help to understand the origin and kinetics of VOCs and expanding research to 
animal models will help gain insights related to the VOC metabolism in vivo. This translational 
bridge is necessary since it will aid in determining the clinical validity and improve the 
diagnostic accuracy once the factors influencing the biological levels are known. 
 
6.2.4 Technology Miniaturisation 
When clinical application at regular point-of-care is required, the optimal approach is to create 
a hand-held, easy-to-use, device for physicians by either miniaturizing GC-MS devices or by 
developing small hand-held sensors arrays capable of detecting sets of the identified 
discriminating VOCs. 
 
6.2.5 Clinical validation 
The validation of the diagnostic performance of a biomarker in human clinical trials is crucial. 
Therefore, the diagnostic performance of the miniaturised diagnostic device should be tested 
again, preferably in a blinded, prospective, case-control cohort study, following persons at risk 
over time and to assess the clinical utility and the final place in the diagnostic work-up for 
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MPM. There are guidelines regarding the analytical steps required in the design of such trials 
for biomarker validation in clinical diagnosis [242] following the recommendations for 
diagnostic studies [243, 244]. 
 
6.2.6 Regulatory approval for clinical use 
After the biomarker test has have been proven clinically useful, it can claim regulatory 
approval, for instance from the FDA, after complying with a stringent set of rules and 
regulations before getting entered on the market [234, 245]. The specific approval process 
will depend on the classification of the breath test which in turn is based upon its risks and the 
complexity of the technology. Depending on the level of regulatory control that is necessary 
to assure safety and effectiveness, breath tests can be classified into different device classes 
[234]. Class I devices induce the least risk to public health and are subject to the least 
regulatory control. Class II devices have moderate risk and include any device for which there 
is a reasonable guarantee of safety and effectiveness. Examples of class II devices are 
biomarkers for prognosis and monitoring in patients already diagnosed with the disease. Most 
class I or II devices that are not exempt from pre-market review requirements are ‘cleared’ for 
commercial distribution by the 510(k) process, taking about 100 days to be reviewed and costs 
about $5,228 on user fees [246]. This requires a manufacturer to demonstrate that a new 
product is as safe and as effective or equivalent to a product that is already being legally 
marketed. Traditionally, new products that are not similar to products already on the market 
are automatically classified as Class III, the most stringent regulatory category with the most 
risk to public health. These devices require the Pre-Market Approval (PMA) process which 
takes about 180 days to 1 year and costs $261,388 on user fees [246]. Although Class III devices 
include life sustaining devices and other devices that pose a potential direct risk to the patient, 
new in vitro devices (blood tests) are included in Class III since use of the device could result 
in harm if it leads to inappropriate interventions, for instance markers for diagnosing or 
screening for cancer. Since breath analysis will be used for screening, and help enrich people 
at risk for future monitoring, it is expected to be classified as class III.  
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AIMS OF THE THESIS 
 
This research works aims to explore the role of breath analysis as screening and diagnostic 
tool for malignant pleural mesothelioma. Therefore, we aimed to provide the first steps in 
breath biomarker development and used three different breath sampling methods: 
multicapillary column/ion mobility spectrometry (MCC/IMS), gas chromatography – mass 
spectrometry (GC-MS) and sensor technology (electronic nose; eNose).  
 
Although the incidence of MPM is increasing, it still remains a rare disease with Belgium having 
only 273 new incident cases in 2013. In order to obtain a sufficient number of patients and 
participants, we initiated a cross-sectional, case-control series (called the MesoBreath series), 
wherein a collaboration with the departments of Respiratory Medicine of the University 
Hospitals of Ghent, Leuven and Antwerp was established. Furthermore, we collaborated with 
a company that had used asbestos in their products until 1997 in order to include a 
representative control population of asymptomatic persons at risk for MPM.  
 
In total, we aim to include 300 participants, divided over six different patient and control 
groups, in a timespan of three years (Table 4). These include (a) healthy controls without 
known historical occupational asbestos-exposure, (b) asymptomatic persons with a known 
historical occupational asbestos exposure, (c) patients with benign asbestos-related diseases 
(Part I, Chapter 2), (d) patients with benign non-asbestos related respiratory diseases, (e) 
primary lung cancer patients and (f) mesothelioma patients who were all treatment-naïve. 
 
Table 4: Participant groups of the MesoBreath series 
Group Aim (N) Included (N) 
Healthy controls 50 52 
Healthy asymptomatic asbestos-exposed individuals 50 59 
Patients with benign asbestos-related diseases 50 41 
Patients with benign non-asbestos related respiratory diseases 50 70 
Lung cancer patients 50 56 
Mesothelioma patients 50 52 
TOTAL 300 330 
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In Part III – Chapter 1, we aim to establish a good sampling protocol that allows to discriminate 
mesothelioma patients from asymptomatic controls with historical asbestos exposure (AEx) 
and without this exposure (HC) with an acceptable accuracy. Therefore, a multicentre, cross-
sectional study was initiated including a limited number of patients and controls. By doing so, 
we initiate the first step in biomarker development and explore the analytical validity (Figure 
11). Furthermore, we want to discover important volatile breath biomarkers that allowed the 
discrimination. 
 
In Part III – Chapter 2, we aim to confirm the analytical validity by repeating the study using 
the same protocol and including more patients and different patient groups (Figure 11). 
Together with the previous study, this allows us to pinpoint interesting discriminatory VOCs 
and to assess the discriminatory capacity to differentiate mesothelioma patients from 
confounding groups. 
 
In Part III – Chapter 3, we want to technically validate the findings by comparing the breath 
sampling method with the gold standard, GC-MS. By performing GC-MS analysis in several 
patients and controls, we will ultimately be able to identify discriminatory VOCs. Furthermore, 
in preparation for the miniaturisation phase and to investigate the possibility to detect MPM 
with hand-held sensor technology, we validated the GC-MS findings by performing parallel 
eNose analysis (Figure 11). 
 
 
Figure 11: Overview of the research aims. MCC/IMS: multicapillary column/ion mobility spectrometry. 
GC-MS: gas chromatography-mass spectrometry. eNose: electronic nose. 
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In summary, this thesis aims to fulfil the following goals: 
1) Set up a cross-sectional, case-control series of studies (the MesoBreath series) to 
evaluate the role of VOCs in screening for MPM and its diagnosis. 
2) To determine the diagnostic and screening value in discriminating MPM from at risk 
control groups. 
3) To identify discriminatory compounds and determine the analytical validity of the 
biomarker test. 
4) To validate the findings by using essentially different technologies for molecular 
assessment in exhaled breath. 
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CHAPTER 1 
 
 
 
 
 
 
 
Detection of malignant pleural mesothelioma in exhaled 
breath by multicapillary column/ion mobility 
spectrometry (MCC/IMS). 
 
 
Lamote K, Vynck M, Van Cleemput J, Thas O, Nackaerts K, van Meerbeeck JP. Journal of Breath 
Research. 2016:10(4):046001.  
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ABSTRACT 
Background: Malignant Pleural Mesothelioma (MPM) is predominantly caused by previous 
asbestos exposure. Diagnosis often happens in advanced stages restricting any therapeutic 
perspectives. Early stage detection via breath analysis was explored using multicapillary 
column/ion mobility spectrometry (MCC/IMS) to detect volatile organic compounds (VOCs) in 
the exhaled breath of MPM patients in comparison to former occupational asbestos-exposed 
and non-exposed controls. 
Methods: Breath and background samples of 23 MPM patients, 22 asymptomatic former 
asbestos (AEx) workers and 21 healthy non-asbestos exposed persons were taken for analysis. 
After background correction, we performed a logistic least absolute shrinkage and selection 
operator (lasso) regression to select the most important VOCs, followed by receiver operating 
characteristic (ROC) analysis. 
Results: MPM patients were discriminated from both controls with 87% sensitivity, 70% 
specificity and respective positive and negative predictive values of 61% and 91%. The overall 
accuracy was 76% and the area under the ROC-curve was 0.81. AEx individuals could be 
discriminated from MPM patients with 87% sensitivity, 86% specificity and respective positive 
and negative predictive values of 87% and 86%. The overall accuracy was 87% with an area 
under the ROC-curve of 0.86. 
Conclusion: Breath analysis by MCC/IMS allows MPM patients to be discriminated from 
controls and holds promise for further investigation as a screening tool for former asbestos-
exposed persons at risk of developing MPM. 
 
Belgian registration number B670201111954  
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INTRODUCTION 
Malignant pleural mesothelioma (MPM) is a tumour predominantly caused by asbestos 
exposure [1, 2]. Most West-European countries banned the use of asbestos in the 1990s and 
regulations banning the use of asbestos became effective in the entire European Union in 
2005. However, the continued asbestos usage in low-income regions and communities, 
Russia, China and India remains worrisome. Most countries faced increasing numbers of 
occupational exposures up to the 1970s. In studies with adequately long follow-up, an average 
latency of 40-50 years since first exposure [3, 4] explains the observed increase in 
mesothelioma incidence and why substantial decreases are not expected before 2025.  
A formal tissue diagnosis obtained by thoracoscopy is essential for MPM management [2]. 
With a median survival of less than one year and a five-year survival rate below 5%, prognosis 
is poor [1]. Therefore, research has focused on early detection by using several blood 
biomarkers. Despite promising trials, soluble mesothelin-related protein, osteopontin and 
megakaryocyte potentiating factor were not suitable as early detection tools [5, 6], whereas 
fibulin-3 and connective tissue growth factor need further prospective validation [7, 8], urging 
the need for other non-invasive screening biomarkers. 
Recently, breath analysis emerged as a high-throughput breathomics research field [9]. 
Exhaled breath is easily accessible without patient discomfort and contains trace elements 
known as volatile organic compounds (VOCs) [10-13] which arise from the 
(patho)physiological processes in the body. For instance, acetone is linked to lipolysis via 
decarboxylation of excess acetyl-CoA, the mevalonic pathway in cholesterol synthesis 
liberates isoprene and lipid peroxidation of (poly)unsaturated fatty acids by oxidative stress in 
cellular membranes induces the formation of several hydrocarbons [11, 13, 14]. These VOCs 
enter the bloodstream, are transported to the lungs where they enter the alveoli through gas 
exchange mechanisms and are subsequently released in the exhaled breath. Until today, de 
Gennaro et al. found cyclohexane to discriminate breath samples of 13 MPM patients, 13 
occupational asbestos-exposed persons and 13 healthy non-exposed controls using gas 
chromatography-mass spectrometry (GC-MS) with 97.4% accuracy [15]. Furthermore, 
Dragonieri et al. [16] used an electronic nose (e-Nose) to compare breath samples of the same 
three groups and distinguished MPM patients from controls with 92.3% sensitivity. Chapman 
et al. repeated this e-Nose study and distinguished MPM patients with 90% sensitivity and 
88% specificity [17]. Since asbestos causes oxidative stress of the mesothelium [18, 19], 
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tumours upregulate their metabolism and these small-sized studies suggest that MPM 
patients can be distinguished from controls based upon breath patterns [16, 17]; we 
hypothesize that the VOC composition in the breath of MPM patients differs from those in the 
breath of controls and that breath analysis can be used to screen for MPM in an at risk 
population. 
 
  
Chapter 1 – Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS) 
Part III | 95 
MATERIALS AND METHODS 
Design, participants and settings 
This is a multicentre, cross-sectional, case-control study. MPM patients and healthy non-
asbestos exposed controls (HC) were recruited from the University Hospitals of Ghent, Leuven 
and Antwerp (Belgium). Asymptomatic former asbestos workers (AEx) were recruited via the 
occupational health service of a fibre-cement factory that used asbestos until 1997. MPM 
diagnosis was verified by the Belgian Mesothelioma Pathology Panel. Exclusion criteria were 
(1) the start of any anti-tumour treatment before breath sampling in MPM patients and (2) 
the presence of other asbestos-related diseases in the control groups (a recent CT-scan or chest 
X-ray <12 months was mandatory to confirm the medical condition). Participants had to refrain 
from eating, drinking and smoking at least two hours before breath sampling. Two 
questionnaires were taken at inclusion: one to check whether participants met the inclusion 
criteria and one to collect demographical and past occupational asbestos exposure data. A 
detailed patient record with all details of the patient’s medical condition was available.  
The study was approved by the Institutional Review Board of Ghent University Hospital (LONG 
11-01; Belgian registration number B670201111954) and was conducted according to the 
Helsinki Convention. Participants had to give their written informed consent before inclusion.  
 
Technical information ion mobility spectrometer (IMS) 
A BioScout breath analysing device was used operating on VOCan v2.4 software (B&S Analytik, 
Dortmund, Germany). It consists of a BreathDiscovery ion mobility spectrometer (IMS) 
coupled to a multicapillary column (MCC), which is connected to a SpiroScout ultrasound-
controlled breath sampler (Ganshorn Medizin Electronic, Niederlauer, Germany) by a sample 
loop. By capno-volumetry, the SpiroScout detects the CO2-levels in exhaled breath and starts 
the breath sampling when a plateau in CO2-levels is reached, indicating alveolar air is sampled. 
Table 1 summarizes the MCC/IMS characteristics and its principles are previously described 
[13, 20].  
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Table 1: Characteristics of the BreathDiscovery ion mobility spectrometer. 
Parameter  
Ionisation source 63Ni (95 MBq) 
Electrical field strength 320 V/cm 
Length of the drift region 12 cm 
Diameter of the drift region 15 mm 
Length of the ionisation chamber 15 mm 
Shutter opening time 300 µs 
Shutter impulse time 100 ms 
Drift gas α1-nitrogen gas (99.999% pure, CAS-n°: 7727-37-9) 
Drift gas flow 100 ml/min 
Carrier gas flow 100 ml/min 
Working temperature Ambient temperature 
Pressure Ambient pressure (101 kPa) 
MCC OV-5, non-polar, 1000 packed columns, 3 mm diameter, 20 cm length 
Column temperature 40°C, isothermal, adjusted 
Polarity Positive mode 
 
Briefly, the MCC/IMS uses a 95MBq 63Ni β-radiation source for the ionisation of the carrier gas 
(α1-nitrogen gas, Air Liquide Medical, 99.999% pure, CAS-n°: 7727-37-9, Schelle, Belgium). 
After breath sampling, the gaseous breath analytes enter a non-polar OV-5 MCC column 
(Multichrom Ltd, Novosibirsk, Russia) for pre-separation based upon the analytes’ chemical 
characteristics. After passing the MCC column, the pre-separated volatiles enter the ionization 
chamber of the IMS with a certain retention time. In this ionization chamber, the breath 
volatiles become positively charged through secondary ionization and charge transfer 
reactions by colliding with the ionized carrier gas. Subsequently, the ionized breath 
compounds enter a drift tube where a second separation takes place based upon their ion 
mobility characteristics (size, charge, mass and shape) under the influence of an electrical field 
and a counter gas. Finally, the VOCs collide on a Faraday plate detector where they evoke an 
electrical current, which results in a VOC peak intensity (Volt, V) which correlates to its 
concentration. The drift time from entering the drift tube until collision at the Faraday 
detector is also measured. 
 
Exhaled breath sampling 
Breath samples were taken between January, 1st 2012 and December, 20th 2014. All 
participants were asked to first rinse their mouth with distilled water and put on rubber gloves 
and a nose clip. Next, while sitting in an upright position at rest and without performing forced 
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breathing manoeuvres, they were asked to breathe calmly through the SpiroScout’s 
mouthpiece, connected to a bacteria filter and the MCC/IMS sample loop. After three minutes 
of calm breathing, 10 ml of alveolar air was sampled and sent to the MCC/IMS for immediate 
analysis. After breath analysis, 10 ml of ambient air was sampled as background reference for 
every participant using an internal pump. In order to rule out external contamination or 
sampling artefacts as much as possible, we used disposable mouthpieces and filters. 
Furthermore, the unheated sample lines are made of inert Teflon (PTFE) [21], and in between 
the breath sampling of different participants, the MCC/IMS was flushed at least 10 times with 
humid air to remove contaminants and to make sure that the MCC/IMS spectra were clean. 
 
Statistics 
VOC analysis was done with VisualNow v3.7 software (B&S Analytik, Dortmund, Germany). 
The raw data consists of 2D-chromatograms with individual VOCs separated by retention time 
(s; from the MCC column) on the y-axis and their inverse reduced ion mobility (Vs/cm²; linked 
to the drift time in the IMS) on the x-axis (Figure 1(a)). Next, the chromatograms were pre-
processed (Figure 1(b)) by aligning all chromatograms and denoising through baseline 
correction using a 5x3 low pass filter (Figure S1(b)) [22]. The data was subsequently 
normalized to the reactant ion peak (RIP), which is the output from the ionized carrier gas, by 
estimating its shape and subtracting it from the measured spectra. (Figure S1(c)) and 
compensated for RIP-tailing by subtracting a median spectrum form each spectrum within the 
data set [22] (Figure S1(d)). Next, the data was smoothed (Figure S1(e)). After a visual 
inspection of all breath and background samples, 89 VOCs were manually selected (Figure 
1(c)) and subsequently analysed resulting in a list of VOC-peak intensities (maximum peak 
height in the selected peak area) (Figure 1(d)).  
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Figure 1: Data analysis scheme. A: Raw data. B: Data after pre-processing by denoising and 
smoothening. C: Manual selection of 89 volatile compounds in breath and background samples. D: 
Optimization of peak selection and analysis of the maximum peak intensity.  
 
To remove the impact of environmental chemical confounders, the alveolar gradient was 
calculated for every VOC by subtracting the standardized peak intensity in the background 
samples from the standardized peak intensity in the corresponding breath samples [23]. These 
alveolar gradient intensities (Volt, V) were then processed as predictors together with the 
patient characteristics and clinical data using R software (version 3.2.4) [24].  
The high number of variables and the rather low number of samples requires an approach like 
penalized logistic regression using the least absolute shrinkage and selection operator (lasso) 
to search for peaks that have the most discriminative power for distinguishing MPM patients 
from asymptomatic former asbestos workers (AEx) and healthy controls (HC). We used the 
glmnet R-package (version 2.0-2) for fitting a binomial lasso logistic model [25]. Advantages of 
this approach include the ease of model interpretability and variable selection (i.e. removal of 
non-informative peaks). Fitting these models involves the selection of a tuning parameter (λ) 
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that determines the number of selected peaks. The optimal λ is selected by fitting the model 
for a sequence of λ-values, and for each of the λ-values the fitted model is evaluated by 
estimating the misclassification error rate by leave-one-out cross-validation (LOOCV). The λ-
value minimizing this error rate was selected and used to fit the final model. Using the 
predicted outcomes of all of the patients, we then constructed an ROC curve (using the ROCR 
R-package (version 1.0-7) [26]) and estimated sensitivity, specificity, positive (PPV) and 
negative predictive value (NPV) and the diagnostic accuracy of the final model and their 95% 
confidence intervals. We furthermore had a look at the number of times (the number of folds) 
a VOC was selected by the lasso regressions. Variables selected in a large proportion of folds 
(>50%) were considered important. We performed binary lasso regressions using the same 
approach to compare MPM patients to HC controls, MPM patients to AEx controls and AEx to 
HC controls. For discriminating MPM patients from pooled AEx and HC controls with only 
gender and smoking status as predictors, a generalized linear model was fitted, again using 
LOOCV to assess classifier performance. 
Summary statistics of the continuous variables were calculated. A chi-squared test or Fisher’s 
exact test was used to test whether the categorical outcomes were equally likely. For 
continuous variables, a Kolmogorov-Smirnov test was performed to assess normality and 
subsequently a t-test or analysis of variance (ANOVA) was performed to assess differences of 
means for the normally distributed variables. For continuous variables showing deviation from 
normality, differences in their distribution were assessed using the Wilcoxon-Mann-Whitney 
test or Kruskal-Wallis test. A significance level of 5% was used throughout the analyses. 
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RESULTS 
Patient characteristics 
Sixty-six participants were included from which a breath sample was taken: 23 treatment-
naïve MPM patients, 22 AEx persons and 21 HC individuals, all without comorbidities (Table 
2).  
 
Table 2: Patient characteristics. 
 MPM AEx HC p-value 
N 23 22 21  
% males 91 96 91 0.863a 
Age (years)# 66 (59 – 73) 56 (55 – 57) 56 (40 – 58) <0.001b 
BMI (kg/m²)§ 24.31 (2.69) 26.76 (3.09) 25.35 (3.37) 0.032c 
Smoke status (never/current/ex) 9/5/9 5/5/12 13/0/8 0.032a 
Pack years#,∆ 2.0 (0 – 26) 7.0 (1 – 22) 0 (0 – 2) 0.009b 
% occupational asbestos exposure 61 100 0 <0.001a 
aFisher’s Exact-test.  
bKruskal-Wallis test.  
cOne-way ANOVA test. 
#Median (Q1 – Q3). 
§Mean (SD). 
∆Self-reported. 
AEx: Asymptomatic former asbestos workers. HC: Healthy non-asbestos exposed control persons. MPM: 
Malignant pleural mesothelioma patients. 
 
MPM patients were significantly older (median 66 years) than AEx persons (median 56 years; 
p-value<0.001) and HC controls (median 56 years; p-value<0.001). There were more current 
and ex-smokers in the MPM (14/23) and AEx (17/22) group compared to healthy controls 
(8/21) and MPM patients had a lower BMI (mean 24.3 kg/m²) compared to AEx persons (mean 
26.8 kg/m²; p-value=0.027). All AEx and none of the HC persons had an occupational asbestos 
exposure while 61% of MPM patients had occupational asbestos exposure. 
 
Modelling 
Using LOOCV for discriminating MPM patients from pooled AEx and HC controls, 66 models 
were evaluated.  
With only gender and smoking status as clinical variables in the model selection, ROC analysis 
showed a diagnostic accuracy of 62% (50%-73%) with a sensitivity of 17% (6%-37%), a 
specificity of 86% (73%-94%) and a respective PPV and NPV of 40% (14%-71%) and 66% (53%-
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78%). The area under the ROC-curve (AUCROC) was 0.17 (0.04-0.32) (Table 3, Figure 2(a)). 
Although we expect a classifier with no predictive quality to have an AUC of 0.5, this may be 
negatively biased in small samples resulting in an AUC<0.3 [27]. Gender and smoking status 
were close to balanced across the outcome groups, thus little predictive quality can be 
expected.  
When allowing the 89 VOCs in the lasso procedure, the final selected model improved to 87% 
sensitivity (69%-97%), 61% (43%-76%) PPV and 91% (77%-98%) NPV, with a specificity of 70% 
(55%-82%). The overall accuracy was 76% (64%-98%) in differentiating MPM patients from 
AEx and HC controls with an AUCROC of 0.81 (0.69-0.91) (Table 3, Figure 2(a)). For this 
discrimination, the VOCs P3, P5, P50 and P71 were selected most often (Table 4).  
 
 
Figure 2: ROC-analysis. A: Model comparing the effect of clinical variables and VOCs in differentiating 
MPM patients from pooled AEx and HC controls (solid (orange) line = with VOCs; dotdash (blue) line = 
clinical variables without VOCs). B: Model comparing the groups separately (dotdash (blue) line = AEx 
vs. HC; solid (orange) line = MPM vs. AEx; dash (red) line = MPM vs. HC). The diagonal dashed line 
represents an uninformative test corresponding to a random chance diagnosis. AEx: asymptomatic 
former asbestos workers. HC: healthy controls. MPM: malignant pleural mesothelioma patients. 
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Table 3: Model characteristics. 
 Clinical characteristicsb Clinical characteristicsb + VOCs 
Model characteristicsa MPM vs. HC+AEx MPM vs. HC+AEx MPM vs. AEx AEx vs. HC MPM vs. HC 
Sensitivity 0.17 (0.06 – 0.37) 0.87 (0.69 – 0.97) 0.87 (0.69 – 0.97) 0.95 (0.80 – 1.00) 0.96 (0.80 – 1.00) 
Specificity 0.86 (0.73 – 0.94) 0.70 (0.55 – 0.82) 0.86 (0.67 – 0.96) 0.86 (0.66 – 0.96) 0.67 (0.45 – 0.84) 
PPV 0.40 (0.14 – 0.71) 0.61 (0.43 – 0.76) 0.87 (0.69 – 0.97) 0.88 (0.70 – 0.97) 0.76 (0.58 – 0.89) 
NPV 0.66 (0.53 – 0.78) 0.91 (0.77 – 0.98) 0.86 (0.67 – 0.96) 0.95 (0.77 – 1.00) 0.93 (0.71 – 1.00) 
Accuracy 0.62 (0.50 – 0.73) 0.76 (0.64 – 0.85) 0.87 (0.74 – 0.94) 0.91 (0.79 – 0.97) 0.82 (0.68 – 0.91) 
AUCROC 0.17 (0.04 – 0.32) 0.81 (0.69 – 0.91) 0.86 (0.73 – 0.97) 0.94 (0.84 – 1.00) 0.73 (0.55 – 0.89) 
awith 95%CI.  
bgender + smoking status. 
AEx: Asymptomatic former asbestos workers. AUCROC: Area under the receiver operator characteristics curve. HC: Healthy non-asbestos exposed 
control persons. MPM: Malignant pleural mesothelioma patients. NPV: Negative predictive value. PPV: Positive predictive value.  
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Table 4: VOC characteristics. 
Peak 
RT  
(s) 
1/K0  
(V/cm²) 
Times selected (%) and direction Alveolar gradient (V)a 
p-valueb MPM vs.  
AEx+HC 
MPM vs.  
AEx 
MPM vs.  
HC 
AEx vs.  
HC 
MPM AEx HC 
P1 27.4 0.576 82  80  - - -0.0420 (-0.0526; -0.0232) -0.0222 (-0.0315; -0.0170) -0.0250 (-0.0450; 0.0006) 0.042 
P3 6.3 0.586 100  96  - 12  0.1304 (0.0452; 0.2098) 0.0156 (0.0104; 0.0300) 0.0822 (0.0045; 0.2079) 0.001 
P5 4.9 0.515 100  100  - 100  -0.0570 (-0.1198; -0.0331) 0.0257 (0.0073; 0.0650) -0.0245 (-0.0636; -0.0069) <0.001 
P8 7.6 0.502 20  9  - 100  0.0356 (0.0249; 0.0602) 0.0801 (0.0561; 0.1272) 0.0336 (0.0033; 0.0636) <0.001 
P13 21.5 0.717 - 2  - 100  0.0002 (-0.0047; 0.0012) -0.0138 (-0.0212; -0.0041) -0.0010 (-0.0033; 0.0016) <0.001 
P25 9.1 0.516 - 11  - 100  0.0014 (-0.0375; 0.0181) 0.0480 (0.0278; 0.0722) -0.0026 (-0.0227; 0.0030) <0.001 
P30 17.2 0.694 21  98  - - -0.0023 (-0.0043; 0.0001) -0.0133 (-0.0243; -0.0039) -0.0011 (-0.0061; 0.0008) <0.001 
P33 7.5 0.529 79  - - - -0.0088 (-0.0125; -0.0005) 0.0011 (-0.0039; 0.0047) -0.0042 (-0.0096; 0.0012) 0.023 
P35 68.7 0.598 61  - - - -0.0024 (-0.0047; 0.0005) -0.0040 (-0.0075; -0.0015) -0.0020 (-0.0041; 0.0008) 0.177 
P45 11.1 0.577 89  91  -  -0.0047 (-0.0259; 0.0031) 0.0076 (0.0018; 0.0173) 0.0049 (-0.0106; 0.0178) 0.006 
P50 78.1 0.730 100  93  100  - -0.0003 (-0.0014; 0.0011) -0.0067 (-0.0155; -0.0006) -0.0070 (-0.0142; -0.0019) <0.001 
P54 9.3 0.833 17  93  - - -0.0010 (-0.0024; -0.0002) -0.0004 (-0.0014; 0.0008) 0.0006 (-0.0012; 0.0029) 0.042 
P57 25.6 0.824 67  - 16  - -0.0015 (-0.0031; 0.0000) -0.0017 (-0.0034; 0.0000) -0.0008 (-0.0013; 0.0007) 0.101 
P65 14.5 0.626 - - - 53  -0.0106 (-0.0328; -0.0019) -0.2267 (-0.4511; -0.0309) -0.0167 (-0.0382; -0.0043) 0.001 
P68 7.3 0.632 67  53  - 2  0.0003 (-0.0018; 0.0035) 0.0043 (0.0022; 0.0062) -0.0003 (-0.0026; 0.0031) 0.004 
P71 9.5 0.729 97  96  16  - -0.0070 (-0.0106; -0.0019) -0.0009 (-0.0057; 0.0039) 0.0035 (-0.0024; 0.0702) <0.001 
P84 31.8 0.637 2  - 100  - -0.0051 (-0.0108; -0.0019) -0.0004 (-0.0041; 0.0045) 0.0010 (-0.0018; 0.0099) <0.001 
aMedian (Q1; Q3). bKruskal-Wallis test.  
: an increase in signal will result in a lower odds to be classified in the MPM group (first 3 columns) or AEx group (4th column). : an increase in signal will result in a higher odds to be 
classified in the MPM group (first 3 columns) or AEx group (4th column). 1/K0: inverse reduced ion mobility. AEx: Asymptomatic former asbestos workers. HC: Healthy non-asbestos 
exposed control persons. MPM: Malignant pleural mesothelioma patients. RT: Retention time. V: Volt. 
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Occupationally asbestos-exposed workers can have a mesothelioma lifetime risk as high as 
10% [28]. Therefore, we examined whether breath analysis could be used to discriminate 
former asbestos-exposed workers from MPM patients and hence, as a potential screening 
tool. This discrimination had 87% (74%-94%) accuracy, 87% (69%-97%) sensitivity, 86% (67%-
96%) specificity, 87% (69%-97%) PPV and 86% (67%-96%) NPV with an AUCROC of 0.86 (0.74-
0.94) (Table 3, Figure 2(b)). The VOCs P3, P5, P30, P50, P54 and P71 were selected most often 
(Table 4). 
With 91% (79%-97%) accuracy, AEx persons could be discriminated from HC controls using the 
same variables, yielding 95% (80%-100%) sensitivity, 86% (66%-96%) specificity, 88% (70%-
98%) PPV and 95% (77%-100%) NPV. The AUCROC was 0.94 (0.84-1.00) (Table 3, Figure 2(b)). 
The VOCs P5, P8, P13 and P25 were found to be important in discriminating HC from AEx 
individuals (Table 4). 
HC persons were discriminated from MPM patients with an accuracy of 82% (68%-91%) and 
an AUCROC of 0.74 (0.55-0.89), 96% (80%-100%) sensitivity, 67% (45%-84%) specificity and the 
PPV and NPV were respectively 76% (58%-89%) and 93% (71%-100%) (Table 3, Figure 2(b)). 
Next to P50, the VOC selected as being the most important feature for the discrimination was 
P84 (Table 4), which was found to be important only in this discrimination. 
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DISCUSSION 
Using breath analysis by MCC/IMS, we improved the accuracy of discriminating MPM patients 
from AEx and HC persons. We identified VOCs P3, P5, P50 and P71 as the most important 
discriminating features between MPM patients and both the control groups, with 87% 
sensitivity, 70% specificity and a respective PPV and NPV of 61% and 91%.  
Considering that asbestos-exposed individuals have an increased risk of developing MPM, 
early-stage MPM detection is important to explore new perspectives for treatment and 
improve prognosis. We discriminated AEx persons from MPM patients with 87% accuracy and 
found some of the same VOCs (P3, P5, P50 and P71) to be the most important features for this 
discrimination, strengthening their importance for MPM detection. We found other VOCs 
important in discriminating HC from AEx persons (P8, P13 and P25), suggesting a link of these 
with asbestos-exposure. The VOC P50 was also found to be important for discriminating MPM 
patients from healthy controls and, together with the VOC P3, from AEx persons, suggesting 
a link of the VOCs P3 and P50 with mesothelioma development.  
Our results are in line with what has been previously described concerning breathomics for 
detecting asbestos-related diseases [15-17, 29]. The group of de Gennaro compared breath 
samples of 13 MPM patients, 13 former asbestos workers and 13 healthy non-exposed 
controls using gas chromatography-mass spectrometry (GC-MS) [15] and distinguished these 
three groups with 97.4% accuracy. They found cyclohexane to be the only compound that 
discriminated MPM from the other groups and cyclopentane to be a marker for long-term 
asbestos exposure. Since we do not know the inverse reduced ion mobility and retention time 
for both compounds, we cannot exclude them from our selected VOCs and, hence, it is 
possible these compounds were also selected in our lasso regression models. Furthermore, 
Dragonieri et al. [16] used an electronic nose (e-Nose) to compare breath samples of the same 
three groups and distinguished MPM patients from AEx individuals with 92.3% sensitivity and 
85.7% specificity and from healthy controls with 92.3% sensitivity and 69.2% specificity. 
Chapman et al. repeated this e-Nose study in 20 MPM patients, 42 healthy controls and 18 
persons with asbestos-related diseases and distinguished MPM patients with 90% sensitivity 
and 88% specificity [17].  
These studies show that breath analysis is promising for MPM detection. However, although 
GC-MS is the gold standard which allows VOCs to be identified with a high sensitivity, it is an 
expensive, time-consuming and offline technique requiring specific operator training and 
Chapter 1 – Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS) 
106 | Part III 
laboratory conditions and involves different analytical steps. Furthermore, e-Noses are not 
specifically built for medical diagnostics and recognize the bulk of the breath as a smellprint 
but do not identify the individual VOCs, despite their ease for analysis.  
We used MCC/IMS as an analysing tool which allows an online sampling where the patients 
breathe directly into the device and is relatively cheap and user-friendly. It contains a built-in 
library where the inverse reduced ion mobility and retention time characteristics have been 
allocated to a specific VOC due to GC-MS crosschecking and MCC/IMS analysis of a VOC 
standard. This library thus allows to identify VOCs, if validated. This database is constantly 
being updated with new VOC allocations by GC-MS crosschecking and hence, gives the 
opportunity to detect biochemical pathways that mark MPM pathogenesis [13]. 
Cakir et al. used MCC/IMS to discriminate 25 patients with either asbestosis and/or asbestos-
related pleural thickening from 12 healthy controls based upon exhaled breath [29]. They 
found a higher alpha-pinene concentration in the diseased group than in the control group 
and discriminated these groups with 96% sensitivity, 50% specificity, 80% PPV and 86% NPV. 
They linked alpha-pinene to the asbestos-induced chronic inflammation. However, the 
authors did not include MPM patients. To our knowledge, we are the first to show that 
MCC/IMS can be used to discriminate MPM patients from controls.  
In contrast, alpha-pinene was not identified as being important in our study. This could be 
explained by several interstudy differences. First, Cakir et al. used an MCC/IMS with a 550 
MBq radioactive source for ionization whereas we used a 95 MBq source, meaning they have 
a larger linear range for VOC ionization and are potentially able to ionize more VOCs. Secondly, 
they did not include MPM patients, females, (ex-)smokers or asymptomatic former asbestos 
workers. Their patients with asbestos-related diseases are slightly older than our MPM 
patients (73 vs. 66 years) and our AEx persons (73 vs. 56 years). Also, their healthy controls 
were more than half the age of their group with asbestos-related diseases (73 vs. 36 years).  
Furthermore, they did not correct for possible exogenous contamination. It is known that 
hospital air is contaminated with ethanol and acetone and that exogenous VOCs from smoking 
can influence the breath composition [30], suggesting the need to correct for these 
contaminants. We tried to counteract environmental contamination by calculating the 
alveolar gradient [23] and used background-corrected values for analysis. Nevertheless, 
background correction by calculating the alveolar gradient may not be sufficient to completely 
remove environmental VOCs. Long-term exposure to exogenous VOCs could lead to storage 
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in muscle or fat tissue depending on the VOCs’ concentration, exposure duration, 
physicochemical properties and the blood:gas and blood:fat partition coefficient [31], 
indicating that VOCs can take a long time to be eliminated from the body. Since alpha-pinene 
is also known to be emitted from several aromatic plants and trees [32], to be present in 
several teas and pine nuts [33] and to be used as an aromatic in different essential oils and 
healthcare products [34], it could be that patients were exogenously exposed to alpha-pinene 
by using these products and hence, alpha-pinene is more likely to be a contaminant from an 
exogenous source rather than endogenously linked to asbestos exposure. Lastly, the fact that 
we discriminated MPM from AEx and HC or that we have performed lasso regression instead 
of a rank sum test and decision tree can be incriminated. 
 
Even though our results are promising to use breath analysis for screening, our study has 
limitations. The participant numbers are too low to extrapolate the results to the whole at-
risk population. Therefore, external validation of our results is mandatory in an independent 
validation set also including patients with lung cancer and benign asbestos-related diseases. 
Furthermore, the groups were not age-matched and we found differences in smoking status 
between the groups. This age difference can be explained by the fact that MPM is a disease 
with a long asymptomatic latency period leading to a diagnosis at advanced age and that it is 
hard to find healthy controls without comorbidities at matched age. Although some studies 
suggest that aging has an effect on human metabolism and VOCs [35, 36], and thus may be a 
confounding variable, several other groups found VOCs not to be influenced by age [37-39]. 
We decided not to include age as a predictor in our models, because the significant age 
difference between the groups is a consequence of the patient selection process. Including 
age as a predictor would likely make age turn up as an important predictor without any 
guarantee that it is associated with MPM. Consequently, the obtained predictive quality of a 
model including age would be overly optimistic. The difference in smoking status is also 
reflected by differences in pack years. Former asbestos workers and MPM patients are 
individuals who worked as blue-collar labourers at asbestos-processing factories where the 
incidence of smoking is known to be higher than in other industries [40-42]. As smoking status 
was never selected in the lasso model, it is likely that smoking is not predictive for 
mesothelioma. However, the effect of smoking should be further investigated because 
smoking can induce the CYP450 enzymes to degrade the VOCs and hydroxylate alkanes to 
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alcohols which can be further metabolized to aldehydes [43]. Next, since our Teflon transfer 
line was not heated, it is possible some VOCs were retained at the surface of the tubing and 
lost for analysis. Finally, although MCC/IMS allows identification of VOCs, we were not yet able 
to identify our VOCs P3, P5, P50 and P71 by cross-checking with the existing MCC/IMS 
database and the participant numbers are too low to be certain to identify the molecular 
discriminators or to say something about the kinetics of these compounds. Furthermore, since 
we do not have GC-MS supporting data, it could be that the compounds we found are co-
eluting compounds or that the compounds are monomers, dimers or trimers of the same 
molecular compound. So our results must be interpreted carefully. To rule out these technical 
issues, GC-MS supporting data are needed. 
Therefore, future research should take breath samples for gas chromatography-mass 
spectrometry analysis taken in parallel which will allow us to ultimately identify these VOCs 
and to find links to the underlying MPM pathogenesis. 
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CONCLUSION 
In conclusion, we demonstrated the feasibility of an easy to perform breath test to 
discriminate MPM patients from patients with and without occupational asbestos exposure 
using MCC/IMS. This allows an easy, non-invasive, large-scale enrichment of former asbestos 
workers at risk for developing MPM for follow-up with repeated imaging. Hence, the 
acceptable specificity and NPV of our results could hold promise to use this breath test for 
screening of asbestos-exposed asymptomatic seniors. Results should be further validated in a 
larger patient population and be compared to other lung diseases before clinical 
implementation.  
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Supplementary Figure 1:  
 
Figure S1: Detailed data analysis scheme. A: Raw data. B: Data after baseline correction. C: Data after 
normalizing to the reactant ion peak (RIP). D: Compensating for RIP-tailing. E: smoothening of the data. 
F: Manual selection of 89 volatile compounds in breath and background samples. G: Optimization of 
peak selection and analysis of the maximum peak intensity. H: Output file with the maximum 
intensities per VOC per sample. 
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ABSTRACT 
Background: Malignant Pleural Mesothelioma (MPM) is predominantly caused by previous 
asbestos exposure. It is often diagnosed in advanced stages restricting any therapeutic 
options. Breath analysis can be explored as early detection tool since breath contains volatile 
organic compounds (VOCs). Using multi-capillary column-ion mobility spectrometry 
(MCC/IMS) as analysing tool, we previously were able to discriminate MPM patients from 
asymptomatic persons previously exposed to asbestos fibres and aim to validate our findings 
and determine the specificity of the model for MPM by comparing with the breath of lung 
cancer patients. 
Methods: Breath and background samples of 52 MPM patients, 59 asymptomatic former 
asbestos (AEx) workers, 52 healthy non-asbestos exposed persons, 41 patients with benign 
asbestos-related diseases (ARD), 70 patients with benign non-asbestos-related lung diseases 
(BLD) and 56 lung cancer (LC) patients were taken for analysis. After background correction, 
we performed a logistic lasso regression to select the most important VOCs, followed by ROC 
analysis. 
Results: MPM patients could be discriminated from HC, AEx, ARD, BLD and LC patients with 
65%, 88%, 82%, 80% and 72%, respectively. When AEx and ARD patients were combined, the 
discriminating accuracy was 85%. The VOCs selected as most important were P1, P3, P7, P9, 
P21, P15 and P26. 
Conclusion: We discriminated pleural mesothelioma patients from at risk subjects with great 
accuracy. The high sensitivity and negative predictive value allows to use breath analysis as 
screening tool for MPM. 
 
Belgian registration number B670201111954  
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INTRODUCTION 
Malignant pleural mesothelioma (MPM) is a tumour from the serosal linings of the thorax, 
predominantly caused by previous asbestos exposure [1, 2]. Despite the ban on the use of 
asbestos in Europe in 2005, asbestos is still being mined and consumed by countries in need 
for industrial growth, remaining an important health issue. Together with the large amount 
consumed in the past and the long latency period between first exposure and diagnosis of 40-
50 years, its incidence is expected to further increase in the future. MPM is usually diagnosed 
in an advanced stage from a tissue sample often to be obtained through an invasive and costly 
biopsy, limiting curative treatment options [3]. This results in low survival rates with a median 
overall survival of up to 18 months with standard of care platinum-based chemotherapy in 
combination with bevacizumab [4, 5]. Together, this stresses the urgent need for screening 
tools for early detection, which is believed to improve the patients’ outcome.  
Breathomics can be used to analyse volatile organic compounds (VOCs) in breath which can 
serve as markers for MPM [6]. Proof-of-principle studies have identified cyclohexane to 
discriminate breath samples of 13 MPM patients, 13 occupational asbestos-exposed persons 
and 13 healthy non-exposed controls using gas chromatography-mass spectrometry (GC-MS) 
with 97.4% accuracy [7] or used pattern recognition with cross-reactive sensor technology 
(electronic nose) [8, 9] to discriminate MPM patients from asymptomatic persons with 
previous occupational asbestos-exposure (AEx) with acceptable accuracy. Using ion mobility 
spectrometry (IMS), Cakir et al. separated patients with benign asbestos-related diseases 
(ARD) from healthy controls with 99.9% accuracy [10]. Using the same technique, our research 
group was able to discriminate 23 MPM patients from 21 healthy controls (HC) and 22 AEx 
patients with 82% and 87% accuracy, respectively [11]. The goal of this study was to validate 
our findings in a larger study and determine how specific breath analysis is for MPM compared 
to lung cancer.  
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MATERIALS AND METHODS 
Study design and participants 
This study is a multicentre, cross-sectional, case-control study. The study was approved by the 
Institutional Review Board of Ghent University Hospital (LONG 11-01; Belgian registration 
number B670201111954) and was conducted in accordance with the Helsinki Convention. 
Before inclusion, participants had to give their written informed consent. Healthy controls 
(HC), patients with benign asbestos-related diseases (ARD), patients with benign lung diseases 
(BLD) unrelated to asbestos exposure, primary lung cancer (LC) patients and pleural 
mesothelioma (MPM) patients were recruited via the University Hospitals of Ghent, Leuven 
and Antwerp (Belgium). Other ARD patients and asymptomatic persons formerly exposed to 
asbestos fibres (AEx) were recruited via the occupational health service of a company that 
produced asbestos until 1997. MPM diagnosis must be confirmed by the Belgian 
Mesothelioma Pathology Panel. If any anti-tumour treatment was started before the breath 
sampling in MPM or lung cancer patients, patients were excluded. Furthermore, other 
asbestos-related diseases must not be present in any of the control groups except for the ARD 
patients. A recent CT-scan or chest X-ray (<12 months) was mandatory to confirm the medical 
condition. Participants were asked to refrain from eating, drinking and smoking at least for 2 
hours before the breath sampling. Participants had to fill in 2 questionnaires: one to check if 
the inclusion criteria were met and one to collect demographical data and previous asbestos 
exposure data. For patients, a detailed patient record had to be available with all details about 
the patient’s medical condition. 
 
Breath Sampling and Analysis 
As breath analysis device, a BioScout multicapillary column-ion mobility spectrometer (MCC-
IMS) was used (B&S Analytik, Dortmund, Germany). For breath sampling, a SpiroScout 
ultrasound-controlled breath sampler (Ganshorn Medizin Electronic, Niederlauer, Germany) 
was connected to the sample loop of the MCC-IMS. This detects the CO2-levels in breath and 
takes a sample when a plateau in CO2-levels is reached, sampling breath from the alveolar 
region.  
The MCC-IMS characteristics and characteristics are previously described [6, 11]. In short, 
breath samples were taken between January, 1st 2012 and December, 20th 2014. All 
participants were asked to first rinse their mouth with distilled water and put on rubber gloves 
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and a nose clip. Next, while sitting in an upright position at rest and without performing forced 
breathing manoeuvres, they were asked to breathe normal for 3 minutes through the 
SpiroScout’s mouthpiece, connected to a bacteria filter and the MCC/IMS sample loop. After 
3 minutes, 10 ml of alveolar air is sampled in the sample loop using an internal pump and 
subsequently sent to the MCC-IMS for analysis. The breath analytes first pass a non-polar OV-
5 MCC column (Multichrom Ltd, Novosibirsk, Russia) for pre-separation based upon the 
analytes’ chemical characteristics. After passing the MCC column, the pre-separated volatiles 
enter the ionization chamber of the IMS with a certain retention time. For ionisation of the 
VOCs, the MCC-IMS uses a 95MBq 63Ni β-radiation source. This ionises a carrier gas (α1-
nitrogen gas, Air Liquide Medical, 99.999% pure, CAS-n°: 7727-37-9, Schelle, Belgium) which 
will ionise and positively charge the VOCs through secondary ionization and charge transfer 
reactions. Subsequently, the ionised breath compounds enter a drift tube where a second 
separation takes place based upon their ion mobility characteristics (size, charge, mass and 
shape) under the influence of an electrical field and the same α1-nitrogen gas as counter gas. 
Finally, the VOCs collide on a Faraday plate detector, evoking an electrical current, which 
results in a VOC peak intensity (Volt, V) that correlates to its concentration. The drift time from 
entering the drift tube until collision at the Faraday detector is also measured. After taking a 
breath sample, a background sample was taken using the same materials and conditions. In 
order to rule out external contamination or sampling artefacts, we used disposable 
mouthpieces and filters. All the sample lines are made of Teflon (PTFE), an inert material 
known not to retain compounds [12]. Between the breath sampling of different participants, 
the MCC/IMS was flushed at least 10 times with humid air to remove contaminants and to 
make sure that MCC/IMS spectra were clean. 
 
Statistics 
VOC analysis was done as with VisualNow v3.7 software (B&S Analytik, Dortmund, Germany) 
as previously described [11]. The raw data consists of IMS-chromatograms which separates 
VOCs by retention time from the MCC column (s) and their inverse reduced ion mobility linked 
to the drift time in the IMS (Vs/cm²). Next, the chromatograms were pre-processed by aligning 
all chromatograms and denoising the data through baseline correction using a 5x3 low pass 
filter [13]. The data is subsequently normalized to the reactant ion peak (RIP), which is the 
output from the ionised carrier gas, by estimating its shape and subtracting it from the 
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measured spectra. We compensated for RIP-tailing by subtracting a median spectrum form 
each spectrum within the data set [13]. Next, the data is smoothed. After a visual inspection 
of all breath and background samples, 250 VOCs were manually selected and subsequently 
analysed resulting in a list of VOC-peak intensities (maximum peak height in the selected peak 
area).  
To remove an effect of environmental chemical confounders, the alveolar gradient was 
calculated for every VOC by subtracting the standardized peak intensity in the background 
samples from the standardized peak intensity in the corresponding breath samples [14]. These 
alveolar gradient intensities (Volt, V) are then used in R (version 3.3.1) [15] as predictors 
together with the patient characteristics and clinical data. Because of the high dimensionality 
setting (large number of variables and low number of samples), penalized logistic regression 
(lasso) was used to discriminate MPM patients from asymptomatic former asbestos workers 
(AEx) and healthy controls (HC) as described earlier [11]. We used the glmnet R-package 
(version 2.0-2) for fitting a binomial lasso logistic model [16]. Using the predicted outcomes of 
all of the patients, we then constructed a ROC curve and estimated sensitivity, specificity, 
positive (PPV) and negative predictive value (NPV) and the diagnostic accuracy of the final 
model and their 95% confidence intervals. We furthermore had a look at the number of times 
(the number of folds) a VOC was selected by the lasso regressions. Variables selected in a large 
proportion of folds (>50%) were considered important. Furthermore, we compared MPM 
patients to HC, AEx, ARD, BLD and LC controls.  
 
Summary statistics of the continuous variables were calculated. A Fisher’s exact test was used 
to test whether the categorical outcomes were equally likely. For continuous variables, a 
Kolmogorov-Smirnov test was performed to assess normality and subsequently an ANOVA 
was performed to assess differences of means in case there was no evidence for deviation 
from normality. For continuous variables showing deviation from normality, differences in 
their distribution were assessed using a Kruskal-Wallis test. A p-value below 5% was 
considered statistically significant after adjustment using the Bonferroni procedure. 
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RESULTS 
Patient characteristics 
In total, 330 participants were included in the study: 52 healthy controls (HC), 59 
asymptomatic persons with a past occupational asbestos-exposure (AEx), 41 patients with 
benign asbestos-related diseases (ARD), 70 patients with benign lung diseases independent of 
asbestos-exposure (BLD), 56 primary lung cancer (LC) patients and 52 mesothelioma (MPM) 
patients (Table 1). There were significantly more males in the groups related to asbestos-
related diseases (MPM, AEx, ARD) compared to the other groups and the patient groups were 
significantly older than the HC and AEx group. There were more current smokers in the AEx, 
ARD, BLD and LC groups.  
 
Table 1: Baseline patient characteristics. 
 
 
HC AEx ARD BLD LC MPM p-value 
N 52 59 41 70 56 52  
Gender 
Male  
Female 
 
34 (65%) 
18 (35%) 
 
58 (98%) 
1 (2%) 
 
40 (98%) 
1 (2%) 
 
47 (67%) 
23 (33%) 
 
37 (66%) 
19 (34%) 
 
43 (83%) 
9 (17%) 
<0.001 
Age (years) 
Median 
(Q1-Q3) 
 
51.2 
(34.5-56.7) 
 
53.2 
(50.2-55.3) 
 
58.3 
(55.3-62.2) 
 
58.8 
(40.6-68.0) 
 
69.9 
(64.3-72.7) 
 
67.3  
(61.6-72.9) 
<0.001 
Weight (kg) 
Mean 
SD 
 
78.3 
17.1 
 
85.6 
11.4 
 
84.5 
14.6 
 
71.3 
15.1 
 
70.7 
14.4 
 
74.5 
10.3 
<0.001 
Length (m) 
Mean 
SD 
 
1.76 
0.09 
 
1.77 
0.06 
 
1.74 
0.05 
 
1.71 
0.09 
 
1.68 
0.08 
 
1.72 
0.08 
<0.001 
BMI (kg/m²) 
Median 
(Q1-Q3) 
 
25.2 
(22.2-27.7) 
 
26.9 
(24.9-28.9) 
 
26.8 
(24.5-31.5) 
 
24.4 
(20.8-25.9) 
 
24.0 
(21.6-27.8) 
 
25.4 
(23.6-27.2) 
<0.001 
Smoke status 
Never 
Current 
Ex 
 
35 (67%) 
1 (2%) 
16 (31%) 
 
19 (32%) 
14 (24%) 
26 (44%) 
 
15 (37%) 
8 (20%) 
18 (43%) 
 
24 (35%) 
14 (20%) 
31 (45%) 
 
6 (10%) 
25 (45%) 
25 (45%) 
 
19 (37%) 
5 (9%) 
28 (54%) 
 
<0.001 
Pack years 
Median 
(Q1-Q3) 
 
0.0 
(0.0-1.61) 
 
6.0 
(0.0-21.5) 
 
5.3 
(0.0-24.8) 
 
7.5 
(0.0-36.0) 
 
30.0 
(14.4-45.0) 
 
2.65 
(0.0-14.7) 
<0.001 
AEx: asymptomatic former asbestos-exposed individual. ARD: patients with benign asbestos-related diseases. BLD: 
patients with benign non-asbestos related lung diseases. HC: Healthy control. LC: primary lung cancer patients. 
MPM: malignant pleural mesothelioma patients. 
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Breath analysis 
MPM patients could be discriminated from HC controls with 65% accuracy (Table 2, Figure 1). 
Since asbestos is causally linked to MPM pathogenesis and, hence, persons exposed to these 
fibres are at risk for MPM, we examined if MPM patients could be discriminated from AEx and 
ARD participants and use it as a screening tool. We discriminated MPM from AEx patients with 
88% accuracy, 87% sensitivity, 90% specificity and a PPV and NPV of 88% and 88%, 
respectively. The AUCROC was 0.879. MPM patients could be discriminated from ARD patients 
with 82% accuracy. The sensitivity, specificity, PPV and NPV were 89%, 73%, 81% and 83%, 
respectively with an AUCROC of 0.850. Furthermore, pooling both groups allowed to 
discriminate MPM patients with 85% accuracy, 94% sensitivity, 80% specificity, 71% PPV and 
96% NPV. The AUCROC was 0.890 (Table 2, Figure 1). The large sensitivity and NPV make it an 
excellent clinical tool for screening and ruling out disease. MPM patients were also nicely 
discriminated from patients with benign lung diseases with 80% accuracy. The sensitivity, 
specificity, PPV, NPV and AUCROC were 71%, 87%, 80%, 80% and 0.837, respectively. However, 
the discrimination between MPM and LC patients was less clear, showing 72% accuracy, 73% 
sensitivity, 71% specificity, 70% PPV and 74% NPV. The AUCROC was 0.770 (Table 2, Figure 1). 
 
Furthermore, with an AUCROC of 0.522 and accuracy of 55%, we were not able to discriminate 
AEx from ARD controls, even when a lot of VOCs were included in the models (Table 3, Figure 
2). Nevertheless, BLD patients could be nicely discriminated from AEx en ARD patients with 
90% and 85% accuracy, respectively. 
Lung cancer patients were discriminated from HC controls with 71% accuracy, 87% sensitivity, 
65% specificity, 71% PPV and 72% NPV, respectively. Furthermore, AEx participants were also 
nicely discriminated from LC patients with 90% accuracy. The sensitivity, specificity, PPV and 
NPV were 89%, 90% 89% and 90%, respectively (Table 3, Figure 2). LC patients were 
discriminated from BLD patients showing 71% accuracy, 64% sensitivity and 77% specificity. 
The AUCROC was 0.724. 
By the lasso regression, the most important VOCs selected to discriminate MPM from the at 
risk groups and BLD patients are P1, P7, P9, P15, P21, and P26. These were not selected when 
discriminating MPM from HC controls (Table 2). These were also selected to discriminate MPM 
from LC patients, but this did not generate a large accuracy. Peaks P1, P3, P21 and P26 were 
also found important to discriminate LC from AEx participants and AEx from BLD patients. 
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Figure 1: ROC Curves for MPM discrimination. AEx: asymptomatic persons with past asbestos 
exposure. ARD: patients with benign asbestos-related diseases. BLD: patients with benign non-
asbestos-related lung diseases. HC: healthy controls without occupational asbestos exposure. LC: lung 
cancer patients. MPM: malignant pleural mesothelioma patients. 
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Table 2: Model characteristics for discriminating mesothelioma. 
 MPM vs. HC MPM vs AEx MPM vs ARD MPM vs AEx+ARD MPM vs BLD MPM vs LC 
N 54 vs 52 54 vs 59 54 vs 41 54 vs 100 54 vs 70 54 vs 54 
Sensitivity 88.5% (77.6%-95.2%) 86.5% (75.2%-93.9%) 88.5% (77.6%-95.2%) 94.2% (85.1%-98.5%) 71.2% (57.8%-82.2%) 73.1% (59.9%-83.8%) 
Specificity 42.3% (29.5%-56.0%) 89.8% (80.1%-95.8%) 73.2% (58.2%-85.0%) 80.0% (71.3%-87.0%) 87.1% (77.8%-93.5%) 71.4% (58.7%-82.1%) 
PPV 60.5% (49.3%-71.0%) 88.2% (77.2%-95.1%) 80.7% (69.0%-89.4%) 71.0% (59.6%-80.8%) 80.4% (67.2%-90.0%) 70.4% (57.3%-81.4%) 
NPV 78.7% (60.7%-90.8%) 88.3% (78.3%-94.7%) 83.3% (68.6%-92.9%) 96.4% (90.5%-99.1%) 80.3% (70.2%-88.1%) 74.1% (61.2%-84.4%) 
Accuracy 65.4% (55.9%-74.0%) 88.3% (81.3%-93.3%) 81.7% (72.9%-88.6%) 84.9% (78.5%-89.9%) 80.3% (72.6%-86.7%) 72.2% (63.3%-80.0%) 
AUCROC 0.612 (0.502-0.724)# 0.879 (0.799-0.948)# 0.850 (0.764-0.927)# 0.890 (0.832-0.942)# 0.837 (0.759-0.907)# 0.770 (0.678-0.855)# 
VOCs (>50% of 
times selected) 
P0, P4, P10, P15, P66, 
P85, P88, P92, P99, 
P103, P104, P108, 
P114, P119, P170, 
P189, P192, P196, 
P203, P207, P208, 
P212, P218, P223 
P1, P3, P7, P9, P15, 
P21, P22, P26, P65, 
P66, P73, P75, P84, 
P99, P101, P110, P112, 
P114, P118,  P120, 
P126, P132, P133, 
P137, P176, P177, 
P184, P186, P195, 
P210, P212, P221, 
P223, P225, P229, 
P231, P237, P243, 
P244, P248 
P1, P9, P15, P21, P26, 
P34, P83, P88, P92, 
P94, P102, P108,  
P114, P119, P127, 
P176, P181, P185, 
P187, P195, P201, 
P207, P212, P220 
P1, P7, P9, P15, P21, 
P26, P70, P83, P84, 
P88, P101, P110, P118, 
P122, P123, P142, 
P151, P153, P159, 
P161, P167, P173, 
P178, P222, P235, 
P236, P240 
P1, P8, P9, P15, P42, 
P98, P115, P121, P123, 
P130, P131, P137, 
P164, P220, P237, 
P243, P245 
P0, P7, P8, P9, P15, 
P21, P28, P37, P42, 
P43, P48, P64, P73, 
P78, P107, P108, P115, 
P116, P117, P123, 
P129, P136, P145, 
P150, P151, P156, 
P172, P181, P186,  
P215, P216, P223, 
P224, P225, P231, 
P237, P244 
#AUCROC significantly different from 0.50. 
AEx: asymptomatic former asbestos-exposed controls. ARD: patients with benign asbestos related diseases. AUCROC: area under the receiver operator characteristic curve. HC: 
healthy controls. MPM: malignant pleural mesothelioma. NPV: negative predictive value. PPV: positive predictive value. VOC: volatile organic compound. VOCs in bold are 
selected in >80% of folds. 
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Figure 2: ROC Curves for lung cancer discrimination. AEx: asymptomatic persons with past 
asbestos exposure. ARD: patients with benign asbestos-related diseases. BLD: patients with 
benign non-asbestos-related lung diseases. HC: healthy controls without occupational 
asbestos exposure. LC: lung cancer patients. MPM: malignant pleural mesothelioma patients. 
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Table 3: Model characteristics for discriminating lung cancer. 
 LC vs. HC LC vs AEx LC vs BLD AEx vs ARD AEx vs BLD ARD vs BLD 
N 54 vs 52 54 vs 59 54 vs 70 59 vs 41 59 vs 70 41 vs 70 
Sensitivity 76.8% (64.5%-86.4%) 89.3% (79.1%-95.5%) 64.3% (51.2%-76.0%) 82.9% (69.2%-92.2%) 88.6% (79.5%-94.5%) 88.6% (79.5%-94.5%) 
Specificity 65.4% (51.8%-77.3%) 89.8% (80.1%-95.8%) 77.1% (66.3%-85.8%) 35.6% (24.2%-48.4%) 91.5% (82.3%-96.8%) 78.0% (63.6%-88.7%) 
PPV 70.5% (58.2%-80.9%) 89.3% (79.1%-95.5%) 69.2% (55.8%-80.6%) 47.2% (36.0%-58.7%) 92.5% (84.3%-97.2%) 87.3% (78.1%-93.6%) 
NPV 72.3% (58.4%-83.7%) 89.8% (80.1%-95.8%) 73.0% (62.1%-82.1%) 75.0% (56.7%-88.3%) 87.1% (77.0%-93.8%) 80.0% (65.6%-90.2%) 
Accuracy 71.3% (62.3%-79.2%) 89.6% (83.0%-94.2%) 71.4% (63.1%-78.8%) 55.0% (45.2%-64.5%) 89.9% (83.8%-94.3%) 84.7% (77.1%-90.5%) 
AUCROC 0.752 (0.659-0.839)# 0.936 (0.884-0.976)# 0.724 (0.630-0.813)# 0.522 (0.366-0.591) 0.957 (0.917-0.988)# 0.855 (0.766-0.930)# 
VOCs (>50% of 
times selected) 
P4, P7, P8, P10, P23, 
P28, P43, P55, P59, 
P76, P83, P107, P112, 
P115, P116, P118, 
P131, P136, P151, 
P163, P167, P184, 
P191, P215, P220, 
P223, P224, P226, 
P239, P244 
P0, P1, P3, P14, P21, 
P26, P43, P61, P65, 
P66, P72, P84, P88, 
P90, P101, P112, P114, 
P115, P116, P118, 
P129, P136, P141, 
P158, P176, P180, 
P181, P187, P199, 
P203, P205, P216, 
P227, P229, P230, 
P231, P233, P244 
P0, P1, P42, P44, P107, 
P125, P126, P127, 
P168, P170, P233 
 
P1, P3, P20, P23, P26, 
P34, P37, P44, P66, 
P69, P70, P80, P83, 
P84, P90, P92, P99, 
P101, P103, P120, 
P123, P126, P134, 
P137, P144, P166, 
P169, P170, P180, 
P183, P184, P190, 
P192, P199, P201, 
P203, P223, P226, 
P234, P237, P244 
P1, P3, P21, P42, P50, 
P84, P87, P88, P97, 
P101, P104, P128, 
P130, P132, P150, 
P171, P179, P213, 
P216, P217, P226, 
P230, P233 
 
P21, P25, P42, P87, 
P88, P101, P110, P132, 
P136, P153, P198, 
P199, P212, P221, 
P243, P247 
#AUCROC significantly different from 0.50. 
AEx: asymptomatic former asbestos-exposed controls. ARD: patients with benign asbestos related diseases. AUCROC: area under the receiver operator characteristic curve. HC: 
healthy controls. MPM: malignant pleural mesothelioma. NPV: negative predictive value. PPV: positive predictive value. VOC: volatile organic compound. VOCs in bold are 
selected in >80% of folds. 
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DISCUSSION 
In this multicentre, cross-sectional, case-control study, we showed that breath analysis by 
MCC-IMS discriminated MPM patients with clinical importance from healthy controls, AEx 
persons, ARD patients, BLD patients, and LC patients with clinically important accuracy. We 
are the first to perform such a study including a large number of patients and control groups. 
Persons previously exposed to asbestos fibres have a lifetime increased risk of developing 
MPM. Together with the poor prognosis, it is of utmost importance to detect the disease in 
its early stages by screening, which is believed to improve the patient’s outcome. Therefore, 
we examined if MPM patients could be discriminated from asymptomatic persons with past 
occupational asbestos-exposure and from patients with benign asbestos-related diseases. 
MPM patients were discriminated from AEx and ARD patients with 88% and 82% accuracy, 
respectively. When both groups were combined, the accuracy was 85%, with a sensitivity, 
specificity, PPV and NPV of 94%, 80%, 71% and 96%, respectively. The high sensitivity and NPV 
from discriminating MPM from these at risk control groups stresses the screening capability. 
The most important VOCs found in these discriminations are the VOCs P1, P3, P7, P9, P15, 
P21, and P26 of which P3 was also found in our previous proof-of-principle study [11].  
 
Our results confirm and extend previous studies. The group of de Gennaro et al. discriminated 
13 MPM patients from 13 AEx and 13 HC persons with 97.4% accuracy [7]. They identified 
cyclopentane as marker for long-term asbestos-exposure and cyclohexane as marker for 
MPM. Using pattern recognition, Dragonieri et al. distinguished 13 MPM patients from 13 AEx 
and 13 HC controls with 80.8% and 84.6% accuracy, respectively [8]. The group of Chapman 
et al. repeated this last study and discriminated 10 MPM patients from 32 HC subjects and 18 
ARD patients with 88% accuracy, respectively [9]. Using MCC-IMS, Cakir et al. discriminated 
25 ARD patients from 12 HC with 96% sensitivity and 50% specificity and identified alpha-
pinene and 4-ethyltoluol as markers for asbestos-related diseases [10]. 
Our group used MCC-IMS and discriminated 23 MPM patients from 22 AEx and 21 HC subjects 
with 87% and 82% accuracy, respectively. We found P3, P5, P50 and P71 as most important 
VOCs in the discriminations [11].  
However, with 72% accuracy, we were not able to fully discriminate MPM patients from LC 
patients. This could be due to the fact that VOCs are induced by inflammation. Since 
inflammation is one of the hallmarks in cancer [17], these VOCs could be more general 
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markers for cancer rather than tumour-specific. However, since we obtained a modest 
discrimination between MPM and LC and the VOCs used for this discrimination are mostly 
different from those used to discriminate MPM from the at risk groups, this indicates the 
possibility that some VOCs are able to discriminate between the different tumour types. 
The strength of our study lies within the inclusion and comparison of multiple control groups 
and the large number of participants included in each group. To our knowledge, we are the 
first to report the use of breath analysis for MPM including a large number of patients and 
control groups. Our study serves as the final proof-of-principle and validates all previous 
research. Despite these satisfying results, we acknowledge our study has some limitations. 
First, since this is no randomised study, the groups were not matched for gender, age, BMI 
and smoking status. MPM and LC patients were significantly older and could be explained by 
the latency period between first exposure to the causal agent and the diagnosis of the 
diseases. This is further explained by the fact that healthy controls without significant 
comorbidities or medication use are hard to find at matched age. And although some studies 
suggest that aging has an effect on human metabolism and VOCs [18, 19], several other groups 
found VOCs not to be influenced by age [20-22]. Furthermore, a higher incidence of males was 
seen in the groups with asbestos exposure (AEx, ARD and MPM). This can be explained by the 
fact that the asbestos-industry is known to have a male predominance. This industry also 
explains the difference in smoking status: asbestos-workers are operational in the blue-collar 
industry, which is also known to have a higher incidence of current smokers. Furthermore, 
since smoking is the main causal agent of lung cancer, it is expected to have the highest 
incidence of current smokers in our study. However, we do not believe smoking had any 
impact on the modelling considering MPM pathogenesis is independent of smoking. This is 
further strengthened by the fact we could not discriminate MPM patients from LC patients. 
Secondly, although we took background samples for correction, we cannot fully exclude the 
possibility that external VOCs could have influenced the breath samples. Dependent on their 
kinetics, VOCs can be inhaled and stored in the body’s fat compartments and slowly released 
over time [23, 24]. Although we have tried to counteract environmental contamination as 
much as possible by using inert sampling materials and by calculating the alveolar gradients 
of the VOCs as stated by Phillips et al. [14], it is only one way to cope with background effects 
and may not be sufficient to completely remove the impact of environmental confounders. 
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However, since the patients were randomly sampled and, hence, also the background 
samples, the effects of contamination were excluded as much as possible.  
Lastly, our selected VOCs have not been identified and are not included in the MCC-IMS VOC 
library. This has no impact on the discriminating accuracy but identification of the VOCs should 
allow us to biologically link the VOCs to MPM pathogenesis and serve as additional proof. 
 
In summary, we can say that MPM patients were discriminated from at risk groups with a 
great clinically relevant accuracy. The large sensitivity and negative predictive value allow 
breath analysis to be used as step-up screening tool in the diagnostic workflow for MPM. 
Future research should now focus on the next step in biomarker validation: the external 
validation in a prospective, case-control, series in independent patient cohorts, with blinding 
of the investigator for the underlying pathology, and follow at risk subjects over time. This will 
ultimately lead to assess the clinical utility of the breath test compared to the current imaging 
screening. 
 
CONCLUSION 
Using MCC-IMS, we discriminated pleural mesothelioma patients from healthy controls, 
subjects previously exposed to asbestos, with benign asbestos-related and non-related lung 
diseases and lung cancer patients with great accuracy. The high sensitivity and negative 
predictive value allows to use breath analysis as screening tool for MPM. Validating these 
results in an independent, blinded prospective study should allow us to assess the clinical 
utility of breath analysis for MPM screening in persons previously exposed to asbestos fibres. 
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ABSTRACT 
Rationale: Malignant pleural mesothelioma (MPM) is mainly caused by previous exposure to 
asbestos fibres and has a poor prognosis. Due to a long latency period between exposure and 
diagnosis, MPM incidence is expected to peak between 2020-2025. Screening of asbestos-
exposed individuals is believed to improve early detection and hence, MPM management. 
Recent developments focus on breath analysis for screening since breath contains volatile 
organic compounds (VOCs) which reflect the cell’s metabolism.  
Objectives: The goal of this cross-sectional, case-control study is to identify VOCs in exhaled 
breath of MPM patients with gas chromatography-mass spectrometry (GC-MS) and to validate 
these VOCs to screen for MPM using an electronic nose (eNose). 
Methods: Breath and background samples were taken from 64 subjects: 16 healthy controls 
(HC), 19 asymptomatic former asbestos-exposed (AEx) individuals, 15 patients with benign 
asbestos-related diseases (ARD) and 14 MPM patients. Samples were analysed with both GC-
MS and eNose. 
Results: Using GC-MS, AEx individuals were discriminated from MPM patients with 97% 
accuracy, with diethyl ether, limonene, nonanal, methylcyclopentane and cyclohexane as 
important VOCs. This was validated by eNose analysis. MPM patients were discriminated from 
AEx+ARD participants by GC-MS and eNose with 94% and 74% accuracy, respectively. The 
sensitivity, specificity, positive and negative predictive values were 100%, 91%, 82%, 100% for 
GC-MS and 82%, 55%, 82%, 55% for eNose, respectively. 
Conclusion: This study shows accurate discrimination of patients with MPM from 
asymptomatic asbestos-exposed persons at risk by GC-MS and eNose analysis of exhaled VOCs 
and provides proof-of-principle of breath analysis for MPM screening. 
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INTRODUCTION 
Malignant pleural mesothelioma (MPM) is an aggressive tumour originating from the pleural 
lining of the thorax and is causally associated with previous asbestos exposure [1, 2]. Despite 
a ban on asbestos use in the entire European Union in 2005, asbestos is still being produced 
and consumed in several countries in need for industrial growth. Together with a long average 
latency period of 40-50 years between first asbestos exposure and MPM diagnosis, this 
indicates that MPM incidence will further increase [3]. With a 5-year survival rate below 5%, 
prognosis remains poor, stressing the need for an earlier diagnosis by screening. Serum 
biomarkers have not proven to be useful for the screening and diagnosis of MPM [4, 5]. 
Therefore, recent research focused on breath analysis [6]. Breath contains volatile organic 
compounds (VOCs) which arise from the body’s (patho)physiological processes and have 
demonstrated to be useful in the detection of asthma, COPD, and tumours [7-12].  
Asbestos fibres are known to initiate oxidative stress at the mesothelium [13], inducing lipid 
peroxidation of the mesothelial cell wall, releasing VOCs, and mutagenic DNA lesions. 
Furthermore, asbestos fibres activate the NF-κB pathway and promote cell survival which 
contributes to MPM development [14]. VOCs enter the bloodstream, are transported to the 
lungs where they enter the alveoli through the gas exchange mechanisms and finally are 
exhaled. Few studies have addressed the use of VOCs for MPM detection. One study analysed 
breath samples from 13 MPM patients, 13 occupationally asbestos-exposed persons, and 13 
healthy non-exposed controls using gas chromatography-mass spectrometry (GC-MS) [15]. 
Cyclohexane allowed to discriminate MPM patients with 97.4% accuracy. Two studies used 
pattern recognition of exhaled VOCs by cross-reactive sensor technology (electronic nose: e-
Nose) to compare breath samples of the same 3 groups. Dragonieri et al. [16] and Chapman 
et al. [17] distinguished MPM patients from controls with 92.3% and 90% sensitivity, 
respectively. Recently, our research group was able to discriminate 23 MPM patients from 22 
asymptomatic occupationally asbestos-exposed persons and 21 healthy non-exposed controls 
with 87% sensitivity and 70% specificity using multicapillary column-ion mobility spectrometry 
(MCC/IMS) [18]. Nevertheless, these studies have not been replicated nor has GC-MS been 
directly validated against eNose.  
Since MPM is linked to asbestos exposure and oxidative stress, we hypothesize that VOCs and 
VOC patterns will differ between MPM patients, persons occupationally exposed to asbestos, 
and those unexposed. To that end, we aimed to identify discriminating VOCs by GC-MS and 
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validate the between-group comparisons with eNose in order to provide the proof-of-
principle of screening for MPM by breath analysis.  
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MATERIALS AND METHODS 
Study design and participants 
We performed a multicentre, cross-sectional, case-control study in 64 subjects. Fourteen 
MPM patients, fifteen patients with well-defined benign asbestos-related diseases (ARD), and 
sixteen healthy non-asbestos exposed (HC) controls were recruited in the three participating 
university hospitals. Nineteen asymptomatic former asbestos-exposed individuals with well-
documented asbestos exposure, were recruited via the occupational health service of a 
Belgian fibre-cement factory that processed asbestos until 1997. Treatment-naïve MPM 
patients were included after diagnosis, confirmed by the Belgian Mesothelioma Pathology 
Panel. Exclusion criteria were the start of any anti-tumour treatment before breath sampling, 
and the presence of non-asbestos-related diseases in the control groups. Before inclusion, a 
recent CT scan or chest X-ray (<12 months) had to be present to confirm the medical condition. 
The study was approved by the Institutional Review Board of Ghent University Hospital (LONG 
11-01; Belgian registration number B670201111954) and was conducted in accordance with 
the Helsinki Convention. Participants had to give their written informed consent and two 
questionnaires had to be completed: one to check if the participants met the inclusion criteria 
and one to collect data about demographics and past occupational asbestos exposure. For all 
patients, a detailed medical record had to be available. 
 
Breath sampling 
Breath was sampled using a previously validated method [8, 12]. In short, participants 
breathed tidally with a nose clip into a 2-way non-rebreathing valve (Hans Rudolph 2700, Hans 
Rudolph, Kansas City, USA) with an inspiratory VOC-filter (A2, North Safety, Middelburg, NL) 
at the inlet side. After 5 minutes of tidal breathing, the participants inhaled maximally and the 
expiratory port was connected to a 10 L Tedlar bag (SKC Inc., Eighty Four, PA, USA). 
Subsequently, the subjects exhaled a full vital capacity volume into the Tedlar bag which was 
closed afterwards. Within 10 minutes, the bag was connected to an external pump and 500 
ml of the breath sample was loaded onto a sorbent tube (3.5” long, 0.25” outer diameter) 
filled with 200 mg Tenax®GR (35/60 mesh; Markes International Ltd., Llantrisant, UK) for GC-
MS analysis at a flow rate of 100 ml.min-1 for 5 minutes. Immediately afterwards, 500 ml of 
the breath sample was loaded onto another Tenax®GR tube (Tenax®GR SS 6 mm x 7” (CAMSCO, 
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Houston, Texas, USA)) for eNose analysis at a flow rate of 250 ml.min-1 for 2 minutes. The 
sampling tubes were tightened, packed in a glass jar, and sent out for central analysis. 
 
Gas chromatography – mass spectrometry (GC-MS) analysis 
Prior to use, the Tenax®GR-tubes were conditioned for 1 hour at 300°C while being flushed 
with helium (50 ml.min-1). After conditioning but before sampling, the tubes were loaded with 
10.7 ng toluene-d8 internal standard, by making a two-phase system and using a home-made 
injector system. After sampling, breath analytes were desorbed from the Tenax®GR-column 
using a Unity series 2 Thermal Desorption system (Markes, Llantrisant, UK) by heating the tube 
to 260°C (10 min at 20 ml.min-1). Prior to desorption, tubes were dry purged for 4 minutes at 
20 ml.min-1. Next, analytes were refocused on a microtrap filled with Tenax®TA, cooled at -
10°C. After flash-heating the microtrap at 280°C for 3 min, analytes were carried by a He-flow 
(constant pressure: 50 kPa) and injected with a split-flow of 5 ml.min-1 onto a 30 m FactorFour 
VF-1ms low-bleed bounded-phase capillary GC-column (Varian, Sint-Katelijne-Waver, 
Belgium; 100% polydimethylsiloxane, internal diameter 0·25 mm, film thickness 1 mm). The 
flow path was heated to 130°C. The GC (Focus GC, Thermo Finnigan, Milan, Italy) oven 
temperature was initially set at 35°C for and kept for 10 minutes, then heated to 60°C at a rate 
of 2°C.min-1. Afterwards the temperature was increased to 170°C at 8°C.min-1 and finally to 
240°C (at 15°C.min-1), maintained for 10 min. The MS transfer line was heated to 240°C. The 
ion source was put at 220°C. Masses with m/z 29 to 300 were recorded in full scan mode (200 
ms/scan) on a DSQII Single Quadrupole MS (Thermo Finnigan, Austin, TX, USA), hyphenated 
to the GC, and operating at an electron impact energy of 70 eV. Chromatograms and mass 
spectra were processed using XCalibur software (Thermo Finnigan, v2.2) and the NIST 
database. For unidentified compounds, the Kováts retention index (IK) was calculated. 
 
Electronic nose (eNose) analysis 
Exhaled VOCs were thermally desorbed from Tenax®GR tubes using nitrogen as carrier gas. 
Next, samples were analysed by an assembly of four different eNoses, based on deviant sensor 
technologies: Cyranose C320 [19], Tor Vergata eNose [20], Common Invent eNose [21], and 
Owlstone Lonestar [22]. When exposed to a gas mixture, the sensors swell, resulting in a 
change of electrical resistances (∆R). The ∆R/R-values are stored as raw data, producing a 
breathprint that describes the VOC mixture which can be used for pattern-recognition 
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algorithms [23, 24]. The final eNose-based breath profiles were established by merging the 
sensor defections of all four devices.  
 
Statistics 
R (v3.3.1) using the R studio interface was used for data analysis. Categorical variables are 
compared using a Pearson Chi²-test and reported as ratios. For continuous variables, normality 
was checked by a Shapiro-Wilk test. Dependent on the outcome, variables are given as mean 
(standard deviation) or median (quartile 1-quartile 3).  
The raw eNose data were reduced by principle components analysis into principle 
components (PC). PCs explaining at least 70% of variance were retained and subsequently 
used as independent variables for linear discriminant analysis. The leave-one-out cross-
validated (LOOCV) accuracy was reported in order to limit false discoveries. Receiver operating 
characteristic (ROC) curves were constructed.  
For GC-MS data, the high number of variables and the rather low number of samples requires 
penalized logistic regression using the least absolute shrinkage and selection operator (lasso) 
to search for VOCs that have the most discriminative power for distinguishing MPM patients 
from controls. We used the glmnet R-package (v2.0-2) for fitting binomial lasso logistic 
models. This involves the selection of a tuning parameter (λ) that determines the number of 
selected VOCs. The optimal λ is selected by fitting the model for a sequence of λ-values, and 
for each of the λ-values the fitted model is evaluated by estimating the misclassification error 
rate by LOOCV. The λ-value minimizing this error rate was selected and used to fit the final 
model. Using the predicted outcomes of all of the patients, we then constructed a ROC curve 
(using the ROCR R-package (v1.0-7)) and estimated sensitivity, specificity, positive (PPV) and 
negative predictive value (NPV), the diagnostic accuracy of the final model, and the area under 
the curve (AUCROC) with their 95% confidence intervals. We furthermore examined the 
number of times a VOC was selected by the lasso regressions. Variables selected in >50% of 
folds were considered important. 
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RESULTS 
Patient characteristics 
Sixty-four participants were included: 14 treatment-naïve MPM patients, 15 patients with 
benign asbestos-related diseases (ARD), 19 AEx persons, and 16 HC individuals (Table 1). 
MPM patients were significantly older than the other groups; AEx persons were the youngest. 
No significant differences were found in smoking status, pack years or BMI between the 
groups although we observed a trend with AEx persons having have more current smokers. 
Among the ARD patients, 14 (93%) had pleural plaques and 1 (7%) had asbestosis. 
 
Table 1: Patient characteristics 
 HC AEx ARD MPM p-value 
N 16 19 15 14  
Gender 
Male 
Female 
 
15 (93.8%) 
1 (6.3%) 
 
19 (100%) 
0 (0.0%) 
 
14 (93.3%) 
1 (6.7%) 
 
11 (78.6%) 
3 (22.4%) 
0.173a 
Age 56 (52.5 – 59.4) 50 (49.6 – 53.2) 60 (58.3 – 63.8) 69 (65.7 – 73.6) <0.001b 
Smoke status 
Current 
Ex 
Never 
 
0 (0.0%) 
8 (50.0%) 
8 (50.0%) 
 
6 (31.6%) 
7 (36.8%) 
6 (31.6%) 
 
1 (6.7%) 
5 (33.3%) 
9 (60.0%) 
 
1 (7.1%) 
9 (64.3%) 
4 (28.6%) 
 
0.079a 
Pack years 0.3 (0.0 - 6.1) 9.0 (0.0 - 36.0) 0 (0.0 – 10.5) 7 (0.0 – 30.0) 0.106b 
BMI (kg/m²) 27 (23.4 – 29.3) 27 (25.4 – 28.4) 27 (24.5 – 32.8) 26 (23.9 – 27.1) 0.529b 
aFisher’s Exact test. 
bnon-parametric Kruskal-Wallis test. 
AEx: asymptomatic former asbestos-exposed controls. ARD: patients with benign asbestos related diseases. 
BMI: body mass index. HC: healthy controls. MPM: malignant pleural mesothelioma. 
 
GC-MS analysis 
In total, 14 MPM patients, 19 AEx subjects, 15 ARD patients and 14 HC controls gave a breath 
sample for GC-MS analysis. We analysed 5 different models (Table 2, Figure 1): MPM vs. HC 
(model 1), MPM vs. AEx (model 2), MPM vs. ARD (model 3), MPM vs. AEx+ARD (model 4) and 
ARD vs. AEx (model 5). Model 1 showed a diagnostic accuracy of 71% (52.9%-85.7%). The 
AUCROC was 0.770.  
 
  
Chapter 3 – Validating breath analysis to screen for pleural mesothelioma: a cross-sectional, case-control study 
Part III | 141 
 
Figure 1: ROC curves of the different models based upon GC-MS analysis. 
 
Since asbestos-exposed individuals can have a lifetime risk of MPM up to 10%,[13] we 
examined if it was possible to discriminate AEx and ARD participants from MPM patients in 
view of using it as screening tool (models 2-4). Discriminating MPM from AEx persons was 
possible with 97% accuracy (86.0%-99.8%), 93% sensitivity, 100% specificity, 100% PPV, and 
95% NPV. The AUCROC was 0.989. Discriminating MPM from ARD patients was possible with 
79% accuracy (61.9%-91.2%), 79% sensitivity, 80% specificity, 79% PPV, and 80% NPV. The 
AUCROC was 0.838. By pooling ARD and AEx persons, we could discriminate MPM patients with 
94% accuracy (84.0%-98.4%), 100% sensitivity, 91% specificity, 82% PPV, and 100% NPV. The 
AUCROC was 0.943.  
The most frequently selected VOCs in these discriminations were diethyl ether, limonene, 
cyclohexane, nonanal, VOC IK 1287 and isothiocyanatocyclohexane (Table 2, Figure S1-S2).  
As negative control analysis, we tried to discriminate ARD patients from AEx persons (model 
5). This was not possible, showing 50% accuracy (33.6%-66.4%) and an AUCROC of 0.365, even 
when important discriminators from the other models were included.  
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Table 2: Model characteristics from GC-MS data.  
 MODEL 1 MODEL 2 MODEL 3 MODEL 4 MODEL 5 
Cases vs 
Controls 
MPM vs HC MPM vs AEx MPM vs ARD MPM vs AEx+ARD AEx vs ARD 
N 14 vs 14 14 vs 19 14 vs 15 14 vs 34 19 vs 15 
Sensitivity 64.3% (37.6%-85.6%) 92.9% (69.5%-99.6%) 78.6% (52.1%-94.2%) 100% (80.7%-100%) 60.0% (34.6%-81.9%) 
Specificity 78.6% (52.1%-94.2%) 100% (85.4%-100%) 80.0% (54.7%-94.6%) 91.2% (77.9%-97.7%) 42.1% (21.9%-64.6%) 
PPV 75.0% (45.9%-93.2%) 100% (79.4%-100%) 78.6% (52.1%-94.2%) 82.4% (59.2%-95.3%) 45.0% (24.7%-66.7%) 
NPV 68.8% (43.7%-87.5%) 95.0% (77.8%-99.7%) 80.0% (54.7%-94.6%) 100% (90.8%-100%) 57.1% (31.2%-80.4%) 
Accuracy 71.4% (52.9%-85.7%) 97.0% (86.0%-99.8%) 79.3% (61.9%-91.2%) 93.8% (84.0%-98.4%) 50.0% (33.6%-66.4%) 
AUCROC 0.770 (0.577-0.923) 0.989 (0.955 – 1.000) 0.838 (0.671-0.962) 0.943 (0.866-1.000) 0.365 (0.435-0.818) 
VOCs  
(≥50% of 
times 
selected) 
Nonane 
VOC IK 1349 
Propylbenzene 
Benzonitrile 
Isoprene 
Limonene 
3-methylpentane 
1,3-dichlorobenzene 
 
Ethanol 
Diethyl ether 
2-ethyl-1-hexanol 
Limonene 
Nonanal 
2-methyl-1-propanol 
Methylcyclopentane 
Cyclohexane 
1,2,4-trichlorobenzene 
Naphtalene 
VOC IK 679 
Phenol 
Chloroform 
Linalool 
Furfural 
VOC IK 1287 
Bromobenzene  
VOC IK 931 
VOC IK 1493 
Beta-pinene 
Diethyl ether 
Limonene 
Hexane 
1,2-dichlorobenzene 
 
Ethanol 
Diethyl ether 
Isothiocyanatocyclohexane 
VOC IK 1233 
VOC IK 1287 
VOC IK 1309 
1,2-dichlorobenzene 
n-Butylbenzene 
Methylbenzoate 
1,2,3-trichlorobenzene 
Limonene 
Bromobenzene 
VOC IK 1100 
Tert-butylbenzene 
m/p-xylene 
2,2,4-trimethylpentane 
Hexamethyldisiloxane 
VOC IK 1493 
VOC IK 720 
 
Limonene 
Isopropyl acetate 
1,3,5-triisopropylbenzene 
Diethyl ether 
3,7-dimethyl-3-octanol 
Trichloroethylene 
Dimethyldisulfide 
Ethanol 
Phenol 
Acetophenone 
2-methyl-1-propanol 
1-butanol 
Naphtalene 
VOC IK 615 
1-methylthio-1-propene 
Isothiocyanatocyclohexane 
Isopropylbenzene 
VOC IK 566 
VOC IK 1111 
Hexanal 
VOC IK 767 
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Ethylbenzene 
VOC IK 1349 
1,3-dichlorobenzene 
Dimethylsulfide 
VOC IK 1105 
2-hexanone 
VOC IK 732 
Nonane 
3-methylpentane 
n-Butylbenzene 
AEx: asymptomatic former asbestos-exposed controls. ARD: patients with benign asbestos related diseases. AUCROC: area under the receiver operator 
characteristic curve. HC: healthy controls. IK: Kováts retention index. MPM: malignant pleural mesothelioma. NPV: negative predictive value. PPV: positive 
predictive value. VOC: volatile organic compound. 
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eNose analysis 
In total, 11 MPM patients, 15 AEx subjects, 12 ARD patients and 12 HC controls gave a breath 
sample for eNose analysis. We analysed the same 5 models as with GC-MS analysis (Table 3, 
Figure 2). We were able to discriminate MPM patients from HC controls (model 1) with 65% 
accuracy (44.5%-82.3%). The AUCROC was 0.667. Discriminating MPM from AEx persons was 
possible with 73% accuracy (53.9%-87.4%), 80% sensitivity, 64% specificity, 75% PPV, and 70% 
NPV. The AUCROC was 0.655. 
MPM patients could be discriminated from ARD patients with 70% accuracy (48.9%-85.6%), 
75% sensitivity, 64% specificity, 69% PPV, and 70% NPV. The AUCROC was 0.758. When ARD 
and AEx persons were pooled, we could discriminate MPM patients with 74% accuracy (58.1%-
85.8%), 82% sensitivity, 55% specificity, 82% PPV, and 55% NPV. The AUCROC was 0.747.  
Again, it was not possible to discriminate AEx persons from ARD patients, showing 52% 
accuracy (33.4%-70.0%) and an AUCROC of 0.550. 
 
 
Figure 2: ROC curves of the different models based upon eNose analysis. 
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Table 3: Model characteristics from eNose data. 
 MODEL 1 MODEL 2 MODEL 3 MODEL 4 MODEL 5 
Cases vs Controls MPM vs HC MPM vs AEx MPM vs ARD MPM vs AEx+ARD AEx vs ARD 
N 11 vs 12 11 vs 15 11 vs 12 11 vs 27 15 vs 12 
Sensitivity 66.7% (37.7%-88.4%) 80.0% (54.7%-94.6%) 75.0% (45.9%-93.2%) 81.5% (63.7%-92.9%) 58.3% (30.3%-82.8%) 
Specificity 63.6% (33.7%-87.2%) 63.6% (33.7%-87.2%) 63.6% (33.7%-87.2%) 54.5% (26.0%-81.0%) 46.7% (23.2%-71.3%) 
PPV 66.7% (37.7%-88.4%) 75.0% (50.1%-91.5%) 69.2% (41.3%-89.4%) 81.5% (63.7%-92.9%) 46.7% (23.2%-71.3%) 
NPV 63.6% (33.7%-87.2%) 70.0% (38.0%-91.7%) 70.0% (38.0%-91.7%) 54.5% (26.0%-81.0%) 58.3% (30.3%-82.8%) 
Accuracy 65.2% (44.5%-82.3%) 73.1% (53.9%-87.4%) 69.6% (48.9%-85.6%) 73.7% (58.1%-85.8%) 51.9% (33.4%-70.0%) 
AUCROC 0.667 (0.434-0.900) 0.655 (0.416-0.893) 0.758 (0.548-0.967) 0.747 (0.582-0.913) 0.550 (0.322-0.778) 
AEx: asymptomatic former asbestos-exposed controls. ARD: patients with benign asbestos related diseases. AUCROC: area under the receiver operator 
characteristic curve. HC: healthy controls. MPM: malignant pleural mesothelioma. NA: not applicable. NPV: negative predictive value. PPV: positive predictive 
value.  
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DISCUSSION 
In this cross-sectional study, breath analysis by GC-MS allows to discriminate with great 
accuracy mesothelioma patients from healthy controls, patients with benign asbestos-related 
diseases, and asymptomatic individuals occupationally exposed to asbestos fibres in the past. 
This was replicated with an eNose. To our knowledge, this is the first time these 
discriminations are shown using multiple control groups and taking samples in parallel for GC-
MS analysis and eNose replication by using previously validated methods [12]. Considering 
that occupationally asbestos-exposed persons have a lifetime increased risk for MPM and the 
latter is a lethal condition with a late-onset development, early detection is of utter 
importance to improve the disease’s management. Therefore, we examined whether it was 
possible to discriminate MPM patients from AEx and ARD persons. By GC-MS, we 
discriminated MPM from AEx and ARD persons with 97% and 79% accuracy, respectively. 
When both groups were pooled, the accuracy was 94%. Given the large sensitivity and NPV of 
these findings, the present study underlines the capacity of breath analysis as screening tool 
for persons at risk for MPM.  
The most important VOCs selected in all of these GC-MS discriminations are nonanal, diethyl 
ether, limonene, methylcyclopentane, cyclohexane, a VOC with IK 1287, and 
isothiocyanatocyclohexane. Furthermore, AEx persons were not easily discriminated from 
ARD patients, even when including the VOCs that discriminated MPM from the at risk groups, 
serving as negative controls. This underlines their importance as breath biomarkers for the 
presence of MPM.  
Our results confirm and extend the findings from previous studies [15-18, 25]. Using GC-MS, 
de Gennaro et al. discriminated 13 MPM patients from 13 HC controls and 13 AEx persons 
with 97.4% accuracy using cyclopentane, cyclohexane, dodecane, dimethyl nonane, limonene 
and β-pinene [15]. The group showed cyclohexane to be an important MPM marker and 
cyclopentane as marker for asbestos-exposure. We also found cyclohexane and limonene to 
be important in the discrimination of MPM from AEx patients and β-pinene to discriminate 
ARD from MPM patients. Furthermore, we found diethyl ether and nonanal important 
discriminators of MPM from AEx and/or ARD patients. These compounds are also found 
discriminative for lung cancer and are likely to be associated with tumorigenesis [26-28]. This 
adds to the plausibility of the discriminating capacity of these compounds of MPM. 
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Furthermore, Cakir et al. discriminated ARD patients and HC controls using ion mobility 
spectrometry with 99.9% accuracy, 96% sensitivity, and 50% specificity based upon α-pinene 
and 4-ethyltoluol [25]. We did not find these compounds as important discriminators in our 
models, weakening their importance as markers for ARD. 
The GC-MS findings were replicated by pattern recognition of VOCs obtained by the cross-
reactive sensors from the eNose. We discriminated MPM patients from HC controls, AEx 
persons and ARD patients with 65%, 73%, and 70% accuracy, 67%, 80%, and 75% sensitivity 
and 64%, 64%, and 64% specificity, respectively. When AEx and ARD patients were pooled, 
MPM patients were discriminated with 74% accuracy, 82% sensitivity and 55% specificity. The 
finding that the discriminative capacity by the present eNose were somewhat lower as 
compared to the GC-MS results is due to the smaller number of patients who gave a sample 
for eNose analysis.  
Although we are reaching the same conclusions, our results slightly differ from those 
previously reported. Using the Cyranose, Dragonieri et al. discriminated 13 MPM patients 
from 13 AEx controls with 92% sensitivity and 86% specificity and from 13 HC controls with 
92% sensitivity and 69% specificity [16]. Furthermore, Chapman et al. discriminated 10 MPM 
patients from 32 HC controls with 90% sensitivity and 91% specificity and from 18 ARD patients 
with 90% sensitivity and 83% specificity [17]. This may not be unexpected because of the lower 
number of patients and the fact we merged the sensor defections of 4 devices as final eNose 
profile.  
Again, we could not discriminate ARD patients from AEx controls, which confirms our GC-MS 
findings. This could be due to the fact that 93% of the ARD patients had pleural plaques: the 
most common benign asbestos-related disease with collagen deposits in the mesothelium. 
Since there is no inflammatory aspect which can induce VOCs, no substantial VOC differences 
with AEx persons are to be expected. This allowed us to pool both groups which increased the 
discriminatory capacity.  
The strength of our study lies in the multiple groups design and the replication of the results 
between two essentially different technologies for molecular assessment in exhaled air. 
Nevertheless, we acknowledge our study has important limitations. First of all, the low 
number of included participants restricts its application in the whole population. However, 
our results are in line with previous research and stresses its potential as screening tool. 
Secondly, our patients and controls were not matched for age and a trend in difference in 
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smoking status was found. This can be due to the long latency period between first asbestos-
exposure and MPM diagnosis, delaying diagnosis to late stages in more elderly people. 
Furthermore, it is hard to find healthy controls without substantial comorbidities at matched 
age. The difference in smoking status can originate from the fact that asbestos workers were 
blue-collar workers; an industry known to have an increased incidence of smokers [29]. 
Nevertheless, since MPM development is independent of smoking, the impact of smoking 
status on our results is expected to be minimal and smoking-associated VOCs (benzene, 2,5-
dimethylfuran, and toluene) were not selected in either model, underlining the independency. 
Thirdly, although an inspiratory VOC-filter was used, it is possible that exogenous compounds 
could have contaminated the breath since inhaled VOCs can be stored for a long time in the 
body’s fat compartments [30], and the sampling and analysis materials used can also release 
compounds. Finally, despite a cross-sectional, case-control design, our study was not blinded 
and we took breath samples from participants with known diagnosis. The next step should be 
to perform a blinded, prospective, case-control, cohort study to assess the diagnostic features 
of the breath test. 
Despite these limitations, we found MPM patients to be discriminated from the at risk groups 
with clinically relevant accuracy by both GC-MS and eNose analysis. The large sensitivity and 
NPV allows breath analysis to be used as screening tool for exclusion of disease in at risk 
persons and to enrich the fraction of individuals at risk for further screening. By doing so, not 
every asbestos-exposed person is subjected to repeated chest imaging procedures, which will 
help the monitoring of asbestos-exposed individuals to be more cost-effective and reduce the 
associated radiation exposure [31]. Future research should focus on the next step: validating 
our results in an independent, large, multicentre series with blinding of the investigator for 
the underlying disease, monitoring AEx persons over time and see how breath analysis can be 
used to screen for MPM. In addition, the VOCs should be linked with the pathophysiology of 
MPM by comparing the VOCs in breath with those in the headspace of mesothelioma cell lines 
and pleural fluid. This will ultimately improve the specificity.  
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CONCLUSION 
GC-MS and eNose analysis allowed to discriminate MPM persons from asymptomatic, former 
asbestos-exposed persons at risk for MPM with great accuracy. The VOCs diethyl ether, 
methylcyclopentane, nonanal, limonene, cyclohexane, VOC IK 1287 and 
isothiocyanatocyclohexane were identified as promising biomarkers for MPM. These data 
provide the proof-of-principle for future screening of persons at risk for MPM as a step-up 
tool in its diagnosis, making it less-invasive for the patient. 
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Supplementary Figures 
 
 
Figure S1: Boxplots of important selected VOCs by lasso regression. AEx: asymptomatic former 
asbestos-exposed controls. ARD: patients with benign asbestos related diseases. HC: healthy controls. 
IK: Kováts retention index. MPM: malignant pleural mesothelioma. VOC: volatile organic compound. 
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Figure S2: Mass spectrum of VOC IK 1287. 
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CHAPTER 1 
GENERAL DISCUSSION 
 
An early detection of malignant pleural mesothelioma is hampered due to non-specific 
symptoms, which do not always manifest, and non-specific imaging techniques. MPM is 
formally diagnosed only after histopathological examination of a biopsy obtained through 
invasive thoracoscopy. Every asymptomatic person at risk with a suspected mesothelioma 
momentarily undergoes this procedure, leading to many false positives, increased morbidity 
from diagnostic delay or mistreatment, psychological stress, and unnecessary healthcare costs 
and procedures. Therefore, a screening tool which can help enrich the population at risk for 
further follow-up is urgently needed. It is essential such tools are accurate, associated with 
disease, and finally lead to an improved patient outcome by affecting the clinical decision 
making [1-5]. Important for diagnosis and screening is the accuracy of the diagnostic test 
which is determined by its sensitivity, NPV, specificity, and PPV [5, 6]. Considering the use for 
screening asbestos-exposed individuals at risk for mesothelioma, the breath test should have 
a high sensitivity and NPV to ensure that no patients will be missed and to rule out disease in 
the true negative population without the disease. Hence, maximizing sensitivity and NPV 
should be key for breathomics research regarding screening for mesothelioma. For diagnosing 
mesothelioma, the test should have a high specificity and PPV that allows to rule in diagnosis 
in the true positive patient population. However, when in this case a patient is false negative, 
the impact on the outcome is expected to be worse than when being false positive in a 
screening procedure, accompanying with an increased associated psychological stress and 
effects on quality of life.  
Imaging screening studies have not been proven to be effective in identifying early 
mesothelioma in pleural tissue [7]. For blood biomarkers like SMRP, a meta-analysis showed 
that mesothelin hampers sensitivity to be used for the early diagnosis of mesothelioma [8], 
which is also seen in other independent studies [9]. However, SMRP could be useful as 
prognostic marker or for follow–up after mesothelioma diagnosis has been made [10, 11]. No 
single blood biomarker was found to be accurate enough for diagnosis of screening for 
mesothelioma. A biomarker panel combining two or more blood markers increases the 
potential, suggesting an important role for biomarker panels for screening and diagnosis [12-
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14]. Since mesothelioma carcinogenesis is related to an increased oxidative stress [15, 16], we 
hypothesized that volatile organic compounds in breath could be of interest as biomarkers for 
screening. Therefore, this thesis aimed to elucidate the role of breath analysis for the 
screening and diagnosis of pleural mesothelioma and to initiate the first steps in biomarker 
development. 
 
In our first study, we performed the first step in this process and aimed to explore the 
possibility to use breath analysis for mesothelioma diagnosis or screening and to identify 
discriminatory VOCs. We have demonstrated the feasibility of a standardised breath test using 
MCC/IMS and discriminated MPM patients from healthy asymptomatic persons with and 
without historical asbestos exposure with a clinically acceptable specificity and negative 
predictive value. Considering the rather low number of samples but high number of 
parameters, we opted to use a least absolute shrinkage and selection operator (lasso) 
regression method. Another aspect of why we chose to use this method is because of its ability 
to select a subset of important variables, which decreases the complexity of the final 
regression model and improves the interpretability, which is clinically useful [17]. From the 
inclusion of 89 VOCs in the lasso regression, we could identify the compounds P3, P5, P50, P71 
and P87 as being the most important discriminators between patients and controls. 
 
Our second study assessed the analytical validity of the test where we repeated the first study 
using the same protocol and analysing scheme. We initiated a cross-sectional, case-control 
study including more patients and controls and including groups that are important for the 
differential diagnosis of MPM and could confound the results, such as lung cancer patients 
and patients with benign asbestos-related and non-asbestos-related diseases. A total of 330 
individuals were included (Part II, Table 4, page 85), which is believed to be the largest study 
assessing breath analysis for mesothelioma detection. In this study, MPM patients were 
discriminated from at risk groups with a large clinically relevant accuracy (82%-88%). The large 
sensitivity (87%-94%) and negative predictive value (83%-96%) allows breath analysis to be 
used as step-up screening tool in the diagnostic workflow for MPM. In this study, we analysed 
250 VOCs instead of 89 in the first study. Again, we opted to use a lasso regression. The 
compounds selected by the lasso regression as the most discriminative were the VOCs P1, P3, 
P7, P9, P15, P21, and P26. It is interesting to see that P3 was retained from our previous proof-
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of-principle study. Several factors can explain the modest discrepancies between the studies. 
First of all, a larger number of participants is included, increasing the power of the study to 
improve the differentiation of the groups. Furthermore, 250 VOCs were allowed to be selected 
in the model. This gives the opportunity to make clinical differentiations based upon a larger 
pool of possible variables, and explains the fact that some other compounds were selected as 
important discriminators. However, since P3 remained selected, this strongly suggests a 
possible role in MPM pathogenesis. Considering the discrimination between lung cancer and 
mesothelioma patients, only a modest discrimination was achieved (72% accuracy). Sensitivity 
(73%) and specificity (71%) were inadequate for clinical use, increasing the possibility that the 
discriminatory VOCs we found are rather compounds for general tumour detection instead of 
being specific for mesothelioma. Nevertheless, since we did obtain a modest discrimination, 
some of these VOCs must possess some kind of specificity for mesothelioma. Above of this, 
VOC P3 was not selected in the discrimination between MPM and lung cancer patients, 
stressing its potential use as MPM marker. Future research should focus on detecting these 
compounds (see Part IV, Chapter 2, page 163) and determine the clinical validity. One way to 
achieve this is by performing in vitro studies. The fact we obtained comparable accuracies 
compared to our previous study, confirms the analytical validity of breath analysis. 
Furthermore, we opted to perform a manual selection, optimization and analysis of the 
MCC/IMS VOC peaks, since it was shown to generate better results than automated peak 
selection and therefore is referred to as the gold standard [18]. However, since breath analysis 
yield huge amounts of data, future research should weigh the trade-off between a slightly 
higher accuracy when selecting peaks manually and a huge increase in processing speed when 
automated procedures are chosen. 
 
The final study was performed in order to proof analytical validity and to identify VOCs 
important for the discrimination, since we only obtained a “pseudo-identification” from the 
MCC/IMS library. Therefore, we set up a cross-sectional, case-control study and used the gold 
standard (GC-MS) to differentiate MPM patients from the at risk control groups. Using GC-MS, 
mesothelioma patients were discriminated with 97% accuracy from persons previously 
exposed to asbestos, reaching a sensitivity and specificity of more than 90%. Even a 
combination with patients with benign asbestos-related diseases into a general group with 
asbestos-exposure improved the screening capabilities with a sensitivity and negative 
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predictive value of both 100%. The most important discriminatory VOCs were nonanal, diethyl 
ether, limonene, methylcyclopentane, cyclohexane, a VOC with Kováts retention index 1287, 
and isothiocyanatocyclohexane.  
Despite the satisfying results from our studies, there are some critical points that need to be 
considered. First, for GC-MS analysis, only 113 VOCs were analysed from the plethora of VOCs 
that are already found in human breath, albeit not unequivocally identified [19, 20]. Second, 
because of the labour-intense effort in finding and optimizing the peaks, we selected only 
those compounds with a signal-to-noise ratio above 10 (S/N>10) and hence, are above the 
limit of quantification (LOQ). However, VOCs with a S/N between 3 and 10 (above the limit of 
detection; LOD), could also potentially be interesting to investigate. Subsequently, we cannot 
say with certainty that the VOCs we found with GC-MS are the ones found with MCC/IMS and 
vice versa. Therefore, a direct comparison between MCC/IMS and GC-MS samples is 
advocated in future research [21]. Furthermore, as with MCC/IMS measurements, it would be 
interesting to develop an automated peak finding algorithm that allows to select all optimized 
peaks with a S/N above the LOD in the GC-MS chromatogram [22]. This would lead to a faster 
and efficient peak selecting procedure which is less labour-intense and increases the number 
of potentially discriminatory VOCs. However, one has to cope with possible co-eluting 
compounds and has to select and integrate the compounds in an equal way. Lastly, for some 
of our VOCs found with GC-MS, we do not have a definite identification after cross-checking 
with the mass spectral library of the National Institute of Standards and Technology (NIST). 
These VOCs are reported by their Kováts retention index, which allows pseudo-identification, 
and further steps are needed to allow their final identification. VOC identification is also 
tentative since we cannot exclude that the VOCs we identified as important are co-eluting 
compounds if they have the same mass-to-charge (m/z) ratio and spectral pattern (for 
instance, because these are isomers) [23]. To exclude potential co-eluting compounds, the use 
of special software [24], or extra measurements with GCxGC-MS (2D-GC-MS) or separations 
even up to four dimensions can solve this issue [25-27]. However, this will be accompanied 
with an increased research cost. 
The strength of our study lies also in the fact that we took parallel breath samples from some 
patients to validate our GC-MS findings with sensor technology, which are essentially different 
technologies for molecular assessment in exhaled air. This was the analytical validity of the 
test and generated in-line results, albeit with lower discriminatory characteristics. This is due 
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to the lower number of samples and the fact that electronic noses generate a breathprint 
using the bulk of the breath instead of looking at specific compounds. This underlines the fact 
that by being more specific and focussing on specific compounds (as with GC-MS), you can 
increase the discriminatory capacity. As with SMRP in blood, no single VOC biomarker was 
selected as being important and all studies had an acceptable discrimination due to the 
combination of VOCs. This stresses the importance of biomarker panels instead of single 
markers for disease detection and screening, certainly in a heterogeneous disease like MPM. 
 
In general, there are some characteristics that we need to account for when dealing with 
breath analysis. Despite our studies are being matched for gender, and the gender balance is 
comparable to what is reported for mesothelioma, and several studies found gender not to 
influence VOCs [28-31], others did find an effect of gender on the VOC levels [32, 33]. 
Therefore, we cannot fully exclude gender-specific variations. Next to this, we were not able 
to match for age since it is hard to find matched healthy controls without comorbidities at that 
age. Several studies have shown some VOCs to be associated with increasing age [33, 34], 
while others did not find any association between VOCs and ageing [31, 35-37]. Therefore, we 
cannot fully exclude the possibility that certain VOCs are linked with this age difference. 
Furthermore, given the fact that physical exercise increases the cardiac output and 
metabolism, we can expect differences in VOC depending on the exercise level. Several studies 
focused on the effect of exercise on the VOC composition of breath, especially isoprene and 
acetone [38-42], or showed that exercise could change the breathprint of healthy subjects 
[43]. Next to this, it has been shown that the expiratory flow rate, breath holding manoeuvres 
or including the dead space in the analysis induced significant changes in the breathprints of 
healthy volunteers [44, 45]. Therefore, we opted to sample alveolar air, with the patient being 
in a relaxed state, sitting upright after a resting period and breathing normally without 
performing any forced breathing manoeuvres. Furthermore, a numerous amount of 
compounds can be derived from inspired air or from food intake [46-48]. For inspired air, 
several studies used inspiratory VOC filters to exclude environmental VOCs. However, this is 
not straightforward because exogenous compounds can be stored in the body tissues for a 
long time [49, 50] or can undergo metabolic changes before exhalation [51]. Next, there is no 
consensus on how to deal with background contamination. We decided to take a background 
sample for every participant and chose to calculate the alveolar gradient of the compounds. 
Chapter 1 – General Discussion 
162 | Part IV 
By doing so, we try not to be stringent by ignoring every VOC that is present in the 
environment in the breath sample and try to account for VOCs that are stored in the body. 
Furthermore, this allowed us to further reduce the noise by compensating for contamination 
coming from the used sampling materials. As mentioned, the diet could also induce a change 
in VOCs [52-55]. After eating, the food is being metabolized and could ameliorate VOC 
changes. After an inspection of the literature, we used a fasting period of 2 hours, which was 
applied the most in breath research. However, it still needs to be elucidated if this time frame 
is large enough. 
Another important source of exhaled VOCs are the gut microbiome or respiratory microbial 
infections [56-59]. These VOCs could help to identify respiratory infections but their effect in 
mesothelioma is expected to be minimal. However, these compounds could potentially help 
in differentiating pneumonia from other diseases. Considering all of the above-mentioned 
pitfalls in breath analysis, the International Association on Breath Research (IABR) founded an 
international consortium to address the issues concerning the sampling, storage and analysis 
of breath samples [60, 61], and progress in these different aspects of breath analysis can be 
expected in the upcoming years.  
 
In conclusion, we can say that with MCC/IMS, we were able to discriminate MPM patients 
from the population at risk for mesothelioma with a clinically high sensitivity and negative 
predictive value (Part III, Chapters 1 and 2), making it optimal to rule out disease in those 
asymptomatic persons at risk and enrich the population for further screening methods or 
biopsy, for instance with CT and thoracoscopy. This was validated with GC-MS (Part III, Chapter 
3). Considering MPM versus asymptomatic persons exposed to asbestos fibres, we obtained 
93% sensitivity and 95% NPV. Above of this, the specificity and PPV were 100%, also allowing 
the tool to be used for diagnostic purposes. With an eNose, we generated in-line results but 
the low specificity suggests to use the breath test as screening tool rather than for diagnosing 
MPM. Future research should focus on these aspects and continue the pipeline in biomarker 
development. This is discussed in the next chapter. 
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CHAPTER 2 
FUTURE PERSPECTIVES 
 
This thesis comprises the first steps in biomarker development: the discovery of biomarkers 
for MPM screening and determination of the analytical validity of breath sampling (Part I, 
Chapter 6). However, several steps have to be taken before a biomarker can be implemented 
into the clinic. The next step in biomarker discovery is to find biological evidence for the 
presence of the VOCs in breath. Therefore, we have initiated a third phase of the MesoBreath 
series in which we will analyse the headspace of different mesothelioma and lung cancer cell 
lines. This in vitro study is necessary as it will form the translational bridge between the breath 
test and the tumour’s metabolism or associated inflammation. This will lead to the 
identification of key compounds that are related to the tumour’s metabolism and assess the 
clinical validity of breath analysis for MPM.  
However, in our in vivo research, MPM patients had only a moderate separation from lung 
cancer patients, probably due to a common tumour metabolism. By looking which compounds 
differ between MPM and lung cancer cell lines, we can focus only on these and by confirming 
their presence in breath, it will ultimately improve the specificity of the breath test [62]. Above 
of this, the in vitro cell lines could potentially be subjected to hypoxic conditions that imitates 
the in vivo situation. Furthermore, the next step also includes to explore a xenograft 
mesothelioma mouse model since this translational model mimics the tumour in its natural 
environment. By sampling xenograft mice with mesothelioma, VOCs in early stage 
mesothelioma could potentially be identified. 
When several compounds are selected as being key in discriminating MPM from the at risk 
population, specific sensors for these compounds could be built and combined into a hand-
held eNose specifically for MPM. This than should again be tested in the population to assess 
its clinical utility. In order to do so, a large, prospective, case-control cohort study should be 
initiated that allows to follow an at risk population over time. By taking breath samples over 
time at certain time intervals, VOCs can be followed and their kinetics studied. This test should 
also be compared with the current diagnostic work-up, resulting in a direct comparison with 
a CT scan and biopsy. Furthermore, since our research did not suggest a role of breath analysis 
for diagnosing, but rather for screening, the place of breath analysis in the mesothelioma 
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diagnostic workflow has to be determined. The prospective study should assess the clinical 
utility of breath analysis before any other diagnostic work-up and see if it allows us to enrich 
the patients at risk for further screening. When the test result is negative for a specific test 
person, he or she should not be considered for further screening. On the other hand, it could 
also be used after CT-scan when there is doubt about the presence of a tumour. In that way, 
only patients positive for the breath test could be referred for biopsy or patients with a 
negative test can be excluded for further biopsy. 
Another element to investigate is the combination of biomarkers into biomarker panels. In 
the prospective study, blood samples could be taken to measure the SMRP levels in parallel 
to a breath sample. Combining breath VOCs with SMRP could complement each other and 
increase the detection characteristics. In the end, a high sensitivity and negative predictive 
value for the test would allow to rule out disease in the true negative population, thereby 
excluding these from an invasive diagnostic course. This will ultimately help the diagnosis for 
MPM to be more efficient which results in a more cost-effective screening and decrease the 
burden of radiation for the patient. 
 
  
References for Part IV 
Part IV | 165 
REFERENCES FOR PART IV 
 
[1] Lyman GH, Moses HL. Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking 
Precision Medicine. N Engl J Med. 2016;375(1):4-6. 
[2] Lyman GH, Moses HL. Biomarker Tests for Molecularly Targeted Therapies: Laying the 
Foundation and Fulfilling the Dream. J Clin Oncol. 2016;34(17):2061-6. 
[3] Deverka P, Messner DA, McCormack R, et al. Generating and evaluating evidence of the clinical 
utility of molecular diagnostic tests in oncology. Genet Med. 2016;18(8):780-7. 
[4] Parkinson DR, McCormack RT, Keating SM, et al. Evidence of clinical utility: an unmet need in 
molecular diagnostics for patients with cancer. Clin Cancer Res. 2014;20(6):1428-44. 
[5] Bossuyt PMM. Defining Biomarker Performance and Clinical Validity. J Med Biochem. 
2011;30(3):193-200. 
[6] Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ. 
2002;324(7335):477-80. 
[7] Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin 
Thorac Cardiovasc Surg. 2009;21(2):97-104. 
[8] Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural 
mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541-9. 
[9] Smolkova P, Nakladalova M, Zapletalova J, et al. Validity of mesothelin in occupational medicine 
practice. Int J Occup Med Environ Health. 2016;29(3):395-404. 
[10] Linch M, Gennatas S, Kazikin S, et al. A serum mesothelin level is a prognostic indicator for 
patients with malignant mesothelioma in routine clinical practice. BMC Cancer. 2014;14(1):674. 
[11] Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble 
mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison 
with benign asbestosis and lung cancer. J Thorac Oncol. 2008;3(11):1317-24. 
[12] Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination improves 
the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol. 2012;7(5):883-9. 
[13] Muley T, Dienemann H, Herth FJ, et al. Combination of mesothelin and CEA significantly 
improves the differentiation between malignant pleural mesothelioma, benign asbestos 
disease, and lung cancer. J Thorac Oncol. 2013;8(7):947-51. 
[14] Mundt F, Nilsonne G, Arslan S, et al. Hyaluronan and N-ERC/mesothelin as key biomarkers in a 
specific two-step model to predict pleural malignant mesothelioma. PLoS One. 
2013;8(8):e72030. 
[15] Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial 
cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl 
Acad Sci U S A. 2010;107(28):12611-6. 
[16] Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a 
NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc 
Natl Acad Sci U S A. 2006;103(27):10397-402. 
References for Part IV 
166 | Part IV 
[17] Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: Data Mining, Inference, 
and Prediction. 2nd ed. New York: Springer Science; 2009. 745 p. 
[18] Hauschild AC, Kopczynski D, D’Addario M, et al. Peak Detection Method Evaluation for Ion 
Mobility Spectrometry by Using Machine Learning Approaches. Metabolites. 2013;3:277-93. 
[19] Amann A, Costello Bde L, Miekisch W, et al. The human volatilome: volatile organic compounds 
(VOCs) in exhaled breath, skin emanations, urine, feces and saliva. J Breath Res. 
2014;8(3):034001. 
[20] de Lacy Costello B, Amann A, Al-Kateb H, et al. A review of the volatiles from the healthy human 
body. J Breath Res. 2014;8(1):014001. 
[21] Maurer F, Hauschild AC, Eisinger K, et al. MIMA—a software for analyte identification in 
MCC/IMS chromatograms by mapping accompanying GC/MS measurements. Int J Ion Mobil 
Spec. 2014;17(2):95-101. 
[22] Baranska A, Smolinska A, Boots AW, Dallinga JW, van Schooten FJ. Dynamic collection and 
analysis of volatile organic compounds from the headspace of cell cultures. J Breath Res. 
2015;9(4):047102. 
[23] Phillips M, Bauer TL, Cataneo RN, et al. Blinded Validation of Breath Biomarkers of Lung Cancer, 
a Potential Ancillary to Chest CT Screening. PLoS One. 2015;10(12):e0142484. 
[24] van der Schee MP, Fens N, Brinkman P, et al. Effect of transportation and storage using sorbent 
tubes of exhaled breath samples on diagnostic accuracy of electronic nose analysis. J Breath Res. 
2013;7(1):016002. 
[25] Stephan S, Jakob C, Hippler J, Schmitz OJ. A novel four-dimensional analytical approach for 
analysis of complex samples. Anal Bioanal Chem. 2016;408(14):3751-9. 
[26] Gruber B, Keller S, Groeger T, et al. Breath gas monitoring during a glucose challenge by a 
combined PTR-QMS/GCxGC-TOFMS approach for the verification of potential volatile 
biomarkers. J Breath Res. 2016;10(3):036003. 
[27] Phillips M, Cataneo RN, Chaturvedi A, et al. Detection of an extended human volatome with 
comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry. PLoS 
One. 2013;8(9):e75274. 
[28] Dragonieri S, Quaranta VN, Carratu P, Ranieri T, Resta O. Influence of age and gender on the 
profile of exhaled volatile organic compounds analyzed by an electronic nose. J Bras Pneumol. 
2016;42(2):143-5. 
[29] Schwarz K, Pizzini A, Arendacka B, et al. Breath acetone-aspects of normal physiology related to 
age and gender as determined in a PTR-MS study. J Breath Res. 2009;3(2):027003. 
[30] Kushch I, Arendacka B, Stolc S, et al. Breath isoprene--aspects of normal physiology related to 
age, gender and cholesterol profile as determined in a proton transfer reaction mass 
spectrometry study. Clin Chem Lab Med. 2008;46(7):1011-8. 
[31] Turner C, Spanel P, Smith D. A longitudinal study of breath isoprene in healthy volunteers using 
selected ion flow tube mass spectrometry (SIFT-MS). Physiol Meas. 2006;27(1):13-22. 
[32] Das MK, Bishwal SC, Das A, et al. Investigation of gender-specific exhaled breath volatome in 
humans by GCxGC-TOF-MS. Anal Chem. 2014;86(2):1229-37. 
References for Part IV 
Part IV | 167 
 [33] Lechner M, Moser B, Niederseer D, et al. Gender and age specific differences in exhaled isoprene 
levels. Respir Physiol Neurobiol. 2006;154(3):478-83. 
[34] Mazzatenta A, Pokorski M, Di Giulio C. Real time analysis of volatile organic compounds (VOCs) 
in centenarians. Respir Physiol Neurobiol. 2015;209:47-51. 
[35] Peng G, Hakim M, Broza YY, et al. Detection of lung, breast, colorectal, and prostate cancers 
from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103(4):542-51. 
[36] Poli D, Goldoni M, Corradi M, et al. Determination of aldehydes in exhaled breath of patients 
with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. J Chromatogr B Analyt 
Technol Biomed Life Sci. 2010;878(27):2643-51. 
[37] Mazzone PJ, Hammel J, Dweik R, et al. Diagnosis of lung cancer by the analysis of exhaled breath 
with a colorimetric sensor array. Thorax. 2007;62(7):565-8. 
[38] Smith D, Chippendale TWE, Dryahina K, Spanel P. SIFT-MS Analysis of Nose-Exhaled Breath; 
Mouth Contamination and the Influence of Exercise. Curr Anal Chem. 2013;9(4):565-75. 
[39] Szabo A, Ruzsanyi V, Unterkofler K, et al. Exhaled methane concentration profiles during exercise 
on an ergometer. J Breath Res. 2015;9(1):016009. 
[40] Greenwald R, Ferdinands JM, Teague WG. Ionic determinants of exhaled breath condensate pH 
before and after exercise in adolescent athletes. Pediatr Pulmonol. 2009;44(8):768-77. 
[41] King J, Kupferthaler A, Unterkofler K, et al. Isoprene and acetone concentration profiles during 
exercise on an ergometer. J Breath Res. 2009;3(2):027006. 
[42] Sukul P, Trefz P, Kamysek S, Schubert JK, Miekisch W. Instant effects of changing body positions 
on compositions of exhaled breath. J Breath Res. 2015;9(4):047105. 
[43] Bikov A, Lazar Z, Schandl K, et al. Exercise changes volatiles in exhaled breath assessed by an 
electronic nose. Acta Physiol Hung. 2011;98(3):321-8. 
[44] Bikov A, Hernadi M, Korosi BZ, et al. Expiratory flow rate, breath hold and anatomic dead space 
influence electronic nose ability to detect lung cancer. BMC Pulm Med. 2014;14:202. 
[45] Thekedar B, Oeh U, Szymczak W, Hoeschen C, Paretzke HG. Influences of mixed expiratory 
sampling parameters on exhaled volatile organic compound concentrations. J Breath Res. 
2011;5(1):016001. 
[46] Beauchamp J. Inhaled today, not gone tomorrow: pharmacokinetics and environmental 
exposure of volatiles in exhaled breath. J Breath Res. 2011;5(3):037103. 
[47] Beauchamp JD, Pleil JD. Simply breath-taking? Developing a strategy for consistent breath 
sampling. J Breath Res. 2013;7(4):042001. 
[48] Tarnoki DL, Bikov A, Tarnoki AD, et al. Lack of heritability of exhaled volatile compound pattern: 
an electronic nose twin study. J Breath Res. 2014;8(1):016001. 
[49] Amann A, Mochalski P, Ruzsanyi V, Broza YY, Haick H. Assessment of the exhalation kinetics of 
volatile cancer biomarkers based on their physicochemical properties. J Breath Res. 
2014;8(1):016003. 
[50] Jia C, Yu X, Masiak W. Blood/air distribution of volatile organic compounds (VOCs) in a nationally 
representative sample. Sci Total Environ. 2012;419:225-32. 
References for Part IV 
168 | Part IV 
[51] Pleil JD, Stiegel MA, Risby TH. Clinical breath analysis: discriminating between human 
endogenous compounds and exogenous (environmental) chemical confounders. J Breath Res. 
2013;7(1):017107. 
[52] Bikov A, Paschalaki K, Logan-Sinclair R, et al. Standardised exhaled breath collection for the 
measurement of exhaled volatile organic compounds by proton transfer reaction mass 
spectrometry. BMC Pulm Med. 2013;13(1):43. 
[53] Lindinger W, Taucher J, Jordan A, Hansel A, Vogel W. Endogenous production of methanol after 
the consumption of fruit. Alcohol Clin Exp Res. 1997;21(5):939-43. 
[54] Smith D, Spanel P, Davies S. Trace gases in breath of healthy volunteers when fasting and after 
a protein-calorie meal: a preliminary study. J Appl Physiol (1985). 1999;87(5):1584-8. 
[55] Baranska A, Tigchelaar E, Smolinska A, et al. Profile of volatile organic compounds in exhaled 
breath changes as a result of gluten-free diet. J Breath Res. 2013;7(3):037104. 
[56] Bos LD, Sterk PJ, Schultz MJ. Volatile metabolites of pathogens: a systematic review. PLoS 
Pathog. 2013;9(5):e1003311. 
[57] Filipiak W, Sponring A, Baur MM, et al. Molecular analysis of volatile metabolites released 
specifically by Staphylococcus aureus and Pseudomonas aeruginosa. BMC Microbiol. 
2012;12:113. 
[58] Lemfack MC, Nickel J, Dunkel M, Preissner R, Piechulla B. mVOC: a database of microbial 
volatiles. Nucleic Acids Res. 2014;42(Database issue):D744-8. 
[59] Boots AW, Smolinska A, van Berkel JJ, et al. Identification of microorganisms based on headspace 
analysis of volatile organic compounds by gas chromatography-mass spectrometry. J Breath Res. 
2014;8(2):027106. 
[60] Herbig J, Beauchamp J. Towards standardization in the analysis of breath gas volatiles. J Breath 
Res. 2014;8(3):037101. 
[61] Beauchamp J. Current sampling and analysis techniques in breath research--results of a task 
force poll. J Breath Res. 2015;9(4):047107. 
[62] Filipiak W, Filipiak A, Sponring A, et al. Comparative analyses of volatile organic compounds 
(VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived 
breath markers. J Breath Res. 2014;8(2):027111. 
 
 169 
 
 
 
 
SUMMARY 
SAMENVATTING 
 
  
 170 
 
Summary 
171 
SUMMARY 
 
Malignant pleural mesothelioma (MPM) is an aggressive malignancy originating from the layer 
that covers the thoracic cavity and the lung and is causally associated with previous asbestos 
exposure. Despite a ban on asbestos use in the entire European Union in 2005, asbestos is still 
being produced and consumed in several countries in need for industrial growth. Together 
with a long average latency period of 40 to 50 years between first asbestos exposure and MPM 
diagnosis, this indicates that MPM incidence will further increase. The mean age at diagnosis 
is 69 years. There are worldwide differences in incidence ranging from 40 per million 
inhabitants in Australia to 9 per million in the US. Europe has in incidence rate of 20 per million 
inhabitants with large intercountry differences. For Belgium, the cancer registry estimated an 
incidence rate of 39 per million male inhabitants in 2008, one of the highest worldwide due 
to the large asbestos consumption in the past. With a 5-year survival rate below 5%, prognosis 
remains poor, stressing the need for an earlier diagnosis by screening. Clinical symptoms 
(dyspnoea, chest pain) and imaging techniques are not specific enough and are therefore not 
advocated as screening tools. Serum biomarkers, like serum mesothelin-related peptide 
(SMRP), were not optimal for use as a stand-alone diagnostic marker with sensitivities ranging 
from 19% to 68% and specificities ranging from 88% to 100%, Presently, any screening for 
mesothelioma in asbestos-exposed individuals is considered futile and hence not 
recommended. MPM is only diagnosed after examination of a biopsy obtained after 
thoracoscopy. 
The quest for simple, non-invasive diagnostic tests in respiratory medicine has recently shifted 
to the analysis of exhaled breath. Breath contains volatile organic compounds (VOCs) in pico-
molar concentrations which arise from the body’s (patho)physiological processes, enter the 
bloodstream and enter the lung alveoli by gas exchange mechanisms. VOCs have already 
demonstrated to be useful in the detection of asthma, COPD, and several tumours like breast 
cancer. There are over 3000 different VOCs detected in human breath. Since the first 
identification of VOCs in 1971, the field of breath analysis evolved into a high-throughput 
breathomics field, focusing on sampling and statistical procedures to translate breath analysis 
to the clinic. 
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This research work focusses on the role of breath analysis for mesothelioma diagnosis and 
screening. Before this study was initiated, several studies provided the proof-of-principle 
wherein the breath of groups with small sample sizes was analysed and wherein MPM patients 
could be separated from controls using gas chromatography – mass spectrometry (GC-MS) 
and pattern recognition tools as electronic noses (eNoses). However, we wanted to take the 
next step in biomarker development and use multicapillary column-ion mobility spectrometry 
(MCC-IMS) as breath analysing tool because it allows a (pseudo)identification of VOCs, can be 
used at the patients’ bedside or in the spirometry laboratory and is less costly than GC-MS, 
the gold standard. In order to obtain a large and relevant patient population, we set up a 
Belgian multicentre, case-control study. This allowed us to evaluate breath analysis in one of 
the largest studies concerning breath analysis for MPM. We included 52 mesothelioma 
patients and 278 control subjects consisting of healthy controls with and without historical 
asbestos exposure, patients with benign asbestos-related diseases, patients with benign 
respiratory diseases unrelated to asbestos exposure and lung cancer patients. 
We first looked whether MCC/IMS was able to discriminate MPM patients from healthy 
controls with and without historical occupational asbestos exposure. The diagnostic 
accuracies were satisfying and several VOCs were selected as being important discriminators, 
allowing us to proceed our research.  
The next step was to see if our results could be replicated in larger samples and by including 
other control groups. This gives us the analytical validity of the test and ultimately helps 
identifying important VOCs. The results of this study confirm our previous findings. We 
discriminated mesothelioma patients from asymptomatic persons with historical asbestos 
exposure with 88% accuracy. When adding patients with benign asbestos-related diseases to 
the at risk control population, the sensitivity and specificity of the breath test were 94% and 
96%, respectively, indicating the use of breath analysis as screening tool. Nevertheless, MPM 
patients were only moderately discriminated from lung cancer patients (77% accuracy), 
suggesting a more common tumour metabolism. This study provided the analytical validity of 
the MCC/IMS breath test. 
Since we only obtained a pseudo-identification of the VOCs, we performed another cross-
sectional, case-control study in which we analysed the breath of a subset of patients with two 
different technologies for the molecular assessment of breath. By using GC-MS, the gold 
standard in breath analysis, we discriminated MPM patients from both control groups with 
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known asbestos exposure with 94% accuracy and 100% sensitivity and negative predictive 
value. We have identified the compounds diethyl ether, methylcyclopentane, nonanal, 
limonene, cyclohexane, isothiocyanatocyclohexane and a VOC with Kováts retention index 
1287 as important discriminators. Above-of-this, we took parallel samples in these patients 
for eNose analysis to validate the findings. This generated in-line results, underlining the 
potential to use handheld sensor technology for future screening of persons exposed to 
asbestos. 
 
In conclusion, we have shown that breath analysis by MCC/IMS was able to discriminate MPM 
patients from subjects at risk and its analytical validity was assessed. Furthermore, by GC-MS 
analysis and eNose validation, we identified important discriminators and showed the 
potential use of sensors for screening. We found that the use of breath analysis for early MPM 
diagnosis is limited due to the lower specificity of the tests. However, its potential for 
screening has been identified considering the large sensitivity and negative predictive value. 
This allows to rule out disease in true negative subjects and enrich the population at risk for 
further screening with conventional methods. This should allow screening to be more cost-
effective, limiting unnecessary procedures and associated radiation exposure in all persons at 
risk. Future research should address this in a prospective, multicentre, cohort study and 
following subjects with past asbestos exposure over time. 
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SAMENVATTING 
 
Kwaadaardig pleuraal mesothelioom, ook wel longvlieskanker genoemd, is een zeer 
agressieve tumor dat ontstaat uit het mesotheel, een vlies dat de binnenkant van de 
borstholte bedekt en zich rond de longen bevindt. Het ontstaat na blootstelling aan 
asbestvezels. Dit type kanker wordt gekenmerkt door een lange latentieperiode tussen de 
blootstelling aan asbestvezels en de diagnose van gemiddeld 40 à 50 jaar. In de westerse 
landen situeert de gemiddelde leeftijd bij diagnose zich dan ook rond 69 jaar. Desondanks een 
verbod op het gebruik van asbest in meer dan 55 landen waaronder alle landen van de 
Europese Unie, wordt het toch nog gewonnen en verwerkt in gebieden met laag inkomen 
waar de nood aan industriële groei het grootst is. Dit zorgt er voor dat het aantal gevallen met 
longvlieskanker nog zal stijgen in de toekomst. Er zijn wereldwijd duidelijke verschillen in de 
gerapporteerde incidentie van mesothelioom. In Australië worden er jaarlijks 40 per miljoen 
inwoners getroffen door mesothelioom terwijl dit in de Verenigde Staten 9 per miljoen is. In 
Europa ligt de incidentie rond 20 per miljoen inwoners met grote verschillen tussen de landen. 
Het Belgisch kankerregister meldt voor 2008 een incidentieratio van 39 per miljoen mannelijke 
inwoners, één van de hoogste wereldwijd. Dit is een gevolg van ons hoge asbestgebruik in het 
verleden. 
Longvlieskanker heeft een slechte prognose: de mediane overleving van onbehandelde 
patiënten is 6-9 maand en minder dan 5% van de patiënten is nog in leven na 5 jaar. De 
klinische symptomen van mesothelioom (kortademigheid, pijn in de borstkas, hoest) zijn 
meestal niet-specifiek en bedrieglijk. Ze kunnen dan ook niet gebruikt worden als enige 
diagnostische criterium, ook niet in het geval van voorafgaande asbestblootstelling. 
Beeldvorming kan suggestief zijn voor mesothelioom, maar kan ook niet aangewend worden 
voor de eigenlijke diagnose. Om met zekerheid de diagnose van longvlieskanker te stellen is 
een thoracoscopie aangewezen waarbij weefsel wordt weggehaald voor analyse. De 
aspecifieke en laattijdig zichtbare ziekteverschijnselen alsook de diagnostische moeilijkheden 
belemmeren een vroegtijdige diagnose en bijgevolg ook een mogelijks efficiënte behandeling. 
Vorig onderzoek naar diagnostische biomerkers in het bloed, zoals het serum mesotheline-
gerelateerd peptide (SMRP), heeft aangetoond dat deze op zichzelf niet bruikbaar is voor de 
diagnose van longvlieskanker door een te lage gevoeligheid (19-68%). Om diezelfde reden is 
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screening voor longvlieskanker in asbest-blootgestelde personen daarom ook niet 
aangewezen. 
De zoektocht naar een eenvoudige, niet-invasieve diagnostische biomerker leidde recent naar 
het veld van de ademanalyse. De menselijke adem bevat een groot aantal vluchtige organische 
componenten (VOCs) in pico-molaire concentraties die kunnen dienen als diagnostische 
merkers. VOCs komen voort uit endogene biochemische processen die gerelateerd kunnen 
zijn aan ziekte-specifieke mechanismen. Deze worden vrijgesteld in het bloed en naar de 
longen vervoerd waarna ze door de gas uitwisselingsmechanismen in de adem terechtkomen. 
Dit vernieuwend type biomerker heeft reeds zijn rol bewezen in verschillende pulmonale 
aandoeningen, zoals astma, chronisch obstructief longlijden en andere tumoren zoals 
borstkanker.  
Met de voorliggende studie willen we een ademtest ontwikkelen en valideren voor 
vroegtijdige diagnose van mesothelioom. Voorafgaand aan dit onderzoek hebben 
verschillende kleinschalige studies aangetoond dat ademanalyse wel kan werken, waarbij 
patiënten met longvlieskanker konden worden onderscheiden van een risicopopulatie met gas 
chromatografie – massa spectrometrie (GC-MS) en het gebruik van patroonherkenning zoals 
een elektronische neus (eNose). Met dit onderzoek willen we een stap verder gaan in de 
ontwikkeling van een ademtest voor longvlieskanker en nagaan of multi-capillaire kolom/ion 
mobiliteit spectrometrie (MCC/IMS) eveneens bruikbaar is als analysemethode omwille van 
het feit dat deze een (pseudo)identificatie toelaat van de VOCs, gemakkelijk te transporteren 
is naar de patiënt en goedkoper is dan GC-MS analyse, de gouden standaard. Om een zo groot 
mogelijke patiëntenpopulatie te verkrijgen hebben we een multicenter, patiënt-controle 
studie opgezet. Dit laat ons toe om ademanalyse voor de diagnose en screening van 
mesothelioom te evalueren in een van de grootste studies in het veld van de ademanalyse. 
We hebben 52 mesothelioompatiënten en 278 controle personen geïncludeerd bestaande uit 
gezonde personen met en zonder voorafgaande asbestblootstelling, patiënten met 
goedaardige asbest-gerelateerde en niet asbest-gerelateerde aandoeningen en 
longkankerpatiënten. 
In een eerste fase hebben we nagegaan of MCC/IMS bruikbaar is om mesothelioompatiënten 
te onderscheiden van controlepersonen met verhoogd risico. De accuraatheid van de 
discriminatie was tevredenstellend en bepaalde VOCs werden aangeduid als zijnde belangrijk 
in dit onderscheid. 
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Hierna hebben we nagegaan of we dezelfde resultaten verkregen als we de studie herhalen in 
een groter aantal patiënten en als we groepen includeren die een differentiaaldiagnose 
bemoeilijken. Dit geeft ons de analytische validiteit van de test en zal ons helpen om bepaalde 
VOCs aan te duiden als belangrijke discriminatoren. Deze studie bevestigde ons voorgaand 
onderzoek: we konden mesothelioompatiënten onderscheiden van asymptomatische 
personen met voorafgaande asbestblootstelling met 88% accuraatheid. Wanneer personen 
met een goedaardige asbest-gerelateerde aandoening aan de controlegroep werden 
toegevoegd waren de gevoeligheid en specificiteit respectievelijk 94% en 96%. Dit benadrukt 
het gebruik van ademanalyse voor het screenen van mesothelioom in een risicopopulatie. 
Mesothelioompatiënten konden echter maar matig worden onderscheiden van longkanker 
patiënten (77% accuraatheid), wat op een gemeenschappelijk tumormetabolisme kan wijzen. 
Gezien we tot nu toe enkel een “pseudo-identificatie” van de VOCs verkregen, hebben we 
finaal een nieuwe cross-sectionele, patiënt-controle studie opgezet. De opzet was om adem 
te analyseren met twee totaal verschillende types technologie dat toelaat om de moleculaire 
samenstelling van de adem te onderzoeken, met name GC-MS en eNose. GC-MS, de gouden 
standaard in ademonderzoek, liet ons toe om mesothelioompatiënten te onderscheiden van 
beide controlegroepen met gekende asbestblootstelling met 94% accuraatheid en 100% 
gevoeligheid en negatief voorspellende waarde. We hebben de componenten diethyl ether, 
methylcyclopentaan, nonanal, limoneen, cyclohexaan, isothiocyanatocyclohexaan en een 
VOC met een Kováts retentie index 1287 geïdentificeerd als zijnde belangrijk. Hiernaast 
hebben we ademstalen in parallel afgenomen voor analyse met een eNose. Dit resulteerde in 
vergelijkbare resultaten en benadrukt de mogelijkheid om kleine sensoren te gebruiken in een 
toekomstig screeningsprogramma. 
 
Samengevat hebben we aangetoond dat ademanalyse met behulp van MCC/IMS toelaat om 
mesothelioompatiënten te onderscheiden van personen met een risico op de tumor en 
hebben we de analytische validiteit van de methode aangetoond. Vervolgens hebben we de 
resultaten gevalideerd met GC-MS en eNose analyses en hebben we belangrijke 
discriminatoren voor het onderscheid tussen deze groepen aangeduid als mogelijke adem 
biomerkers. We vonden dat het gebruik van ademanalyse voor de diagnose van mesothelioom 
eerder gelimiteerd is door een lagere specificiteit, maar dat het potentieel voor screening is 
bewezen gezien een grote gevoeligheid en negatief voorspellende waarde. Dit laat toe om de 
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ziekte uit te sluiten in de echte personen zonder ziekte en op die manier de risicopopulatie 
aan te rijken voor verder onderzoek met de conventionele methoden. Dit zou moeten 
toelaten om op een meer kosteneffectieve manier te screenen, waarbij risicopersonen geen 
onnodige onderzoeken krijgen en een mindere blootstelling aan de straling afkomstig van de 
beeldvormingstechnieken. Verder onderzoek moet dit nagaan in een prospectieve, 
multicenter, cohort studie waarbij personen met een gekende asbestblootstelling worden 
gevolgd over de tijd. 
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Great things are done by a series of small things brought together. (Vincent Van Gogh) 
Deze uitspraak geldt niet alleen voor het ademonderzoek maar benadrukt eveneens dat de 
‘adembenemende’ reis van een doctoraat niet mogelijk zou geweest zijn zonder de 
samenwerking met en steun van verschillende mensen. Elk had hun eigen rol in het tot stand 
komen van deze thesis en ik wil hun hiervoor daarom uitvoerig bedanken. 
Ten eerste wil ik mijn promotor, prof. dr. Jan van Meerbeeck, bedanken. U hebt U vanaf dag 
één over mij ontfermd en mij stap per stap wegwijs gemaakt in de wereld van de 
multicentrische, klinische studie. Uw uitgebreide kennis van thoraxoncologie was inspirerend 
en de vele “wist-je-datjes” tijdens de diners op congressen waren een welkome afleiding. Uw 
gedrevenheid en enthousiasme werken aanstekelijk en waren een oppepper in tijden van 
moeilijkheden. U leerde mij papers te schrijven, succesvol beurzen en projecten binnen te 
halen en niet op te geven. U leerde mij ook te zoeken naar “laaghangend fruit” en kort op de 
bal te spelen als er zich een unieke kans voordeed, mede door uw zeer snelle feedback. 
Bedankt om mij te begeleiden in het zelfstandig uitvoeren van onderzoek en bij te sturen waar 
nodig om dit werk tot een goed einde te brengen. 
Zonder financiële steun is ook geen onderzoek mogelijk. Ik wil dan ook de Stichting tegen 
Kanker en de Vlaamse Liga tegen Kanker hartelijk bedanken voor hun vertrouwen en steun 
voor deze MesoBreath studie via hun respectievelijke grants STK 2010-205, STK 2012-223 en 
Emmanuel van der Schueren. 
Prof. dr. Guy Joos, diensthoofd afdeling Longziekten, bedankt dat ik op Uw dienst dit klinisch 
onderzoek mocht uitvoeren. 
Graag bedank ik de leden van de lees- en examencommissie: prof. dr. Joris Delanghe, prof. dr. 
Frederik-Jan van Schooten, prof. dr. Arnaud Scherpereel, prof. dr. Evelien Smits, prof. dr. 
Lutgart Braeckman, prof. dr. Veerle Surmont en prof. dr. Eric Derom. Bedankt om deze thesis 
kritisch na te lezen en te beoordelen. Jullie opmerkingen en commentaren hebben dit werk 
naar een hoger niveau getild. Prof. dr. Joris Delanghe, bedankt om als voorzitter alles in goede 
banen te leiden. 
Verder wil ik alle patiënten en deelnemers aan de studie bedanken. Zonder jullie was dit niet 
mogelijk. 
Mijn dank gaat ook uit naar Kevin en Sylvie, die de aanzet hebben gegeven tot de MesoBreath 
studie.  
Voor het includeren te UZ Gent kon ik beroep doen op de assistenten longziekten, prof. dr. 
Veerle Surmont, prof. dr. Karim Vermaelen, prof. Dr. Eric Derom, prof. dr. Kurt Tournoy, dr. 
Fré Bauters, dr. Eva Van Braeckel en dr. Thomas Malfait. Hartelijk dank voor jullie hulp, 
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suggesties en informatie als ik vragen had en voor jullie bijzondere interesse in het 
onderzoeksgebied. Thomas, het feit dat we bij een patiënt thuis een zetel zijn gaan 
kapotsnijden om stalen te nemen om naar de afkomst van VOCs te zoeken, zal me altijd 
bijblijven en dit veldwerk herinnert me eraan dat wetenschappelijk onderzoek soms tot 
onverwachte dingen kan leiden. 
Groot is mijn dank voor de datamanagers: Frauke, Stephanie, Bénédicte, Anja en Tasja in het 
bijzonder. Telkens weer stond ik bij jullie als er weer een centrum aan de studie diende te 
worden toegevoegd of als er nogmaals amendementen aan de studie dienden te worden 
aangebracht. Zonder jullie hulp, opvolging en raad in het kluwen van de wetgeving en de 
regels van het Ethisch Comité was er van de MesoBreath studie niets in huis gekomen, laat 
staan van de vervolgstudies en zijprojecten. Hartelijk bedankt! 
Sven, Lucy, Leen, An, Philippe, Kristoffel en Heleen van het longfunctielabo: bedankt om mij 
testen te laten afnemen in het lab en om zelf bij de patiënten testen af te nemen als ik 
verhinderd was. 
Leen, Kelly, Heidi en Latha: bedankt om de studiepersonen tussen te nemen als ik weer eens 
kwam vragen om enkele tubes bloed ondanks jullie overvolle agenda. 
Een grote dank gaat uit naar Bart “de boekhouder”, Chantal, Annie, Ingrid en Daisy van het 
secretariaat. Bedankt om de administratie van de studie op te volgen en in orde te houden, 
congressen te plannen en er voor te zorgen dat de studierekening klopt. Jullie snelle service 
als ik weer eens kwam opdraven om iets te bestellen heeft de studie zeker vooruit geholpen. 
Om een voldoende aantal patiënten te includeren was een samenwerking tussen 
verschillende universitaire ziekenhuizen onontbeerlijk. Mijn uiterste dank gaat dan ook uit 
naar prof. dr. Kristiaan Nackaerts van UZ Leuven. U was zeer gedreven bij de inclusie van de 
patiënten en had altijd constructieve feedback op de papers. Bedankt voor uw tijd en inzet bij 
de studie. Prof. dr. Geert Verleden, bedankt dat ik op uw dienst de studie mocht uitvoeren. 
Ook Geert Celis en zijn team van de longfunctie UZ Leuven wens ik te bedanken om mij op 
jullie dienst te ontvangen en voor de hulp met de staalafname bij de patiënten. Lies Peeters, 
bedankt om in Leuven als datamanager de studie mee te helpen opstarten. 
Verder dank ik prof. dr. Wilfried Debacker dat ik op zijn dienst in het UZA mijn studie mocht 
uitvoeren. Bedankt dr. Birgitta Hiddinga, dr. Annelies Janssens, dr. Svetlana Tarasevych en dr. 
Carolien De Tollenaere voor de hulp met de inclusie van de patiënten. Grote dank naar Hilde 
Vaerenberg en haar team van het longfunctielabo en Sisca Kohl voor de hulp met de 
staalafname bij de patiënten. Bedankt ook Ann Coene en Sara Gorrebeeck om alles in orde te 
brengen betreffende het Ethisch Comité. 
Bedankt dr. Joris Van Cleemput (Eternit NV) voor de inclusie van onze controles en het 
rondsturen van de brieven hiervoor, hierdoor zijn een groot aantal belangrijke controles 
geïncludeerd. Bedankt om de medische dienst zo te structureren dat ze ten volle benut werd 
voor het wetenschappelijk onderzoek. Daarbij bedank ik ook graag Chris, Veerle en Mark van 
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de medische dienst voor het nemen van de thoraxfoto’s, hulp bij het invullen van de 
vragenlijsten evenals de bloedafname bij de controles. In het bijzonder een extra bedanking 
voor Mark voor het ophalen en rondbrengen van de mesothelioompatiënten naar de andere 
onderzoekscentra om toch een zo maximaal mogelijk aantal patiënten te includeren, zonder 
dit transport hadden we een groot aantal patiënten gemist. 
Bedankt prof. Olivier Thas en Matthijs voor de statistische hulp en leerrijke discussies. 
Matthijs, bedankt om telkens op korte termijn tijd vrij te maken als ‘R’ weer eens niet wilde 
draaien. Prof. Herman Van Langenhove en Lore, bedankt voor jullie inbreng en suggesties in 
het GC-MS gedeelte van de studie. Prof. Peter Sterk en Paul, bedankt voor jullie hulp bij de 
eNose analyses en om mij wegwijs te maken in de wereld van de elektronische neuzen. 
Bedankt ook aan alle collega’s van het translationeel lab die in de loop van mijn doctoraat mijn 
pad hebben gekruist: prof. Ken Bracke, prof. Tania Maes, Sharen, Fien, Lisa, Ellen, Smitha, 
Leen, Griet, Katrien, Elise en Evy. Bedankt dat jullie altijd zijn komen luisteren naar mijn 
praatjes op de research staff en voor de discussies en suggesties achteraf. Hierbij wil ik ook 
van de gelegenheid gebruik maken om prof. dr. Guy Brusselle te bedanken voor zijn suggesties 
om het onderzoek te verbeteren en voor de grondige informatie rond klinisch onderzoek. 
Bedankt aan de collega’s van het tumour immunology lab om de eerste stappen van de 
vervolgstudie te helpen opzetten. Prof. dr. Karim Vermaelen, bedankt voor je kritische vragen 
en hulp bij het plannen van het volgend translationeel onderzoek. Sabrina, succes met de 
verderzetting van het MesoBreath project. Je gedrevenheid en inzet zal leiden tot een 
geslaagd doctoraat. 
Een welgemeende dank gaat uit naar de bureau-collega’s: Bihiyga, Lies en Lotte. Bibi, je bracht 
mij heel wat nieuwe woordenschat bij in “De Gêntsche toale” en je uitbundigheid, 
gedrevenheid en werklust werkten inspirerend. Bedankt voor de wijze woorden en raad bij 
het uitvoeren van het onderzoek. Lies, ook tussen je vele vergaderingen, calls, revisies, papers, 
analyses en naast de nodige aandacht van je twee jonge kinderen heb je toch altijd de tijd 
gevonden voor een babbel en om mij bij te staan met statistisch advies als ik weer eens 
vastzat. Bedankt! Lotte, als spring-int-veld straal je veel energie uit en dat werkt aanstekelijk, 
al kan dat ook van al die koppen koffie zijn. Succes met je onderzoek; ik weet zeker dat een 
mooi doctoraat binnenkort zal volgen. Allen bedankt voor de fijne babbels en lunches, de 
interessante discussies en het minder stil maken van de “stille ruimte”. 
Verder dien ik ook nog mijn persoonlijke omgeving te bedanken voor al de steun die ze hebben 
geboden en voor de interesse in het onderzoek. Een heel speciale dank gaat hierbij uit naar 
mijn ouders. Ma en pa, jullie hebben mij van kinds af aan gesteund en gemotiveerd om te 
doen wat ik wilde doen en om mijn dromen waar te maken. Bedankt voor de bezoekjes, 
etentjes en jullie warmte. Kimberly, zus, bedankt voor de leuke humoristische momenten, een 
welkome afwisseling in de doctoraatsdrukte. Eveneens een grote dank aan de ouders van mijn 
vriendin, waar ik een tweede thuis heb gevonden, voor hun interesse in mijn onderzoek. 
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Alle vrienden, studiegenoten, familie en kennissen: de bezoekjes, feesten en weekendjes weg 
zorgden voor een fijne en welgekomen afleiding tijdens het doctoraat. Bedankt! 
Tot slot wil ik de persoon bedanken die het hele doctoraatsproces het dichtst heeft 
meegemaakt en die er ook waarschijnlijk het hardst heeft van afgezien. Ann-Sophie, al 13 jaar 
ben je mijn steun en toeverlaat en hebben we lief en leed gedeeld. Tijdens het doctoraat 
hebben we een huis gekocht, zijn we gaan samenwonen en zijn we stilletjes aan alles aan het 
inrichten. Hoewel ik altijd probeerde een evenwicht te zoeken tussen werk en privé, heb je 
toch moeten ondervinden dat een doctoraat soms wat meer vraagt, heel veel zelfs. 
Desondanks dit alles had je begrip en steunde je mij wanneer nodig en was je een luisterend 
oor, iets wat ik enorm heb geapprecieerd. De laatste jaren lag de nadruk op mijn doctoraat, 
nu is het tijd dat mijn aandacht weer naar jou gaat. Bedankt voor al je warmte en je liefde. We 
gaan nog een mooie toekomst tegemoet. Dit werk draag ik op aan jou! 
 
Bedankt, allemaal! 
Kevin, Januari 2017 
 
